128item 9acontrols and procedures128item 9bother information129   part iii 130item 10directors executive officers and corporate governance130item 11executive compensation130item 12security ownership of certain beneficial owners and management and related stockholder matters130item 13certain relationships and related transactions and director independence130item 14principal accounting fees and services130   part iv 130item 15exhibits financial statement schedules131   signatures142  2table of contentspart iitem 1 businessthe companyboston scientific corporation is a worldwide developer manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties our mission is to transform lives through innovative medical solutions that improve the health of patients around the world when used in this report the terms we us our and the company mean boston scientific corporation and its divisions and subsidiariesour history began in the late 1960s when our cofounder john abele acquired an equity interest in meditech inc a research and development company focused on developing alternatives to surgery in 1969 meditech introduced a family of steerable catheters used in some of the first lessinvasive procedures performed in 1979 john abele joined with pete nicholas to form boston scientific corporation which indirectly acquired meditech this acquisition began a period of active and focused marketing new product development and organizational growth since then we have advanced the practice of lessinvasive medicine by helping physicians and other medical professionals treat a variety of diseases and conditions and improve patients quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the bodyour net sales have increased substantially since our formation over thirty years ago our growth has been fueled in part by strategic acquisitions designed to improve our ability to take advantage of growth opportunities in the medical device industry our strategic acquisitions have helped us to add promising new technologies to our pipeline and to offer one of the broadest product portfolios in the world for use in lessinvasive procedures we believe that the depth and breadth of our product portfolio has also enabled us to compete more effectively in the current healthcare environment of cost containment managed care large buying groups government contracting hospital consolidation and international expansion and will generally assist us in navigating through the complexities of the global healthcare market including healthcare reformbusiness strategythe following are our five strategic imperativesstrengthen execution to grow sharewe believe that our success will be driven by our ability to consistently deliver initiatives that grow profitability and market share we are focused on improving the speed and performance of our business units by adding new capabilities processes and innovative technologiesexpand into high growth adjacencieswe seek to diversify our product portfolio by realigning our research and development spend and focusing our business development investment toward higher growth opportunities we are focused on executing on our committed growth adjacencies while increasing our access to developing technologies through this diversification we expect to increase our opportunity for growth in areas that complement our core businesses drive global expansionwe are focused on expanding into the emerging markets by expanding our global commercial presence we seek to increase revenue and market share and strengthen our relationships with leading physicians and their clinical research programs we are focused on building new capabilities in countries whose economies and healthcare sectors are growing rapidly we have local leadership teams with extensive incountry experience to help strengthen our position in these fast growing regions fund the journey to fuel growthwe are driving continuous improvement to expand our profitability optimizing our manufacturing cost structure reducing our corporate infrastructure and reallocating spending to support our growth initiatives 3table of contentsdevelop key capabilitieswe intend to develop key capabilities by providing economic and customer focused solutions so that our product portfolio is aligned to the needs of the market place and by developing core internal skills to better manage our business in a dynamic and evolving environment we are globally focused on building a culture of empowerment and engagement while improving our diversitywe believe that our execution of these strategic imperatives will drive innovation accelerate profitable revenue growth and increase stockholder valueproductsduring 2012 our products were offered for sale by seven core businesses  interventional cardiology cardiac rhythm management crm endoscopy peripheral interventions urologywomens health neuromodulation and electrophysiology in january 2011 we closed the sale of our neurovascular business to stryker corporation we continue to generate sales from the neurovascular business pursuant to our supply and distribution agreements with stryker however these sales are at significantly lower levels and at reduced gross profit margins as compared to periods prior to the divestiture during 2012 we derived 30 percent of our sales from our interventional cardiology business 26 percent of our sales from our crm business 17 percent of our sales from our endoscopy business 11 percent of our sales from our peripheral interventions business seven percent of our sales from our urologywomens health business five percent of our sales from our neuromodulation business and two percent of our sales from our electrophysiology business approximately two percent of our 2012 sales were derived from the neurovascular business that we sold to stryker corporation the following section describes certain of our product offeringsendoscopygastroenterologywe market a broad range of products to diagnose treat and ease a variety of digestive diseases including those affecting the esophagus stomach liver pancreas duodenum and colon common disease states include esophagitis portal hypertension peptic ulcers as well as esophageal biliary pancreatic and colonic cancer we offer the radial jaw 4 singleuse biopsy forceps which are designed to enable collection of large highquality tissue specimens without the need to use large channel therapeutic endoscopes our exclusive line of rx biliary system devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts such as removing gallstones opening obstructed bile ducts and obtaining biopsies in suspected tumors we also market the spyglass direct visualization system for direct imaging of the pancreaticobiliary system the spyglass system is the first singleoperator cholangioscopy device that offers clinicians a direct visualization of the pancreaticobiliary system and includes supporting devices for tissue acquisition stone management and lithotripsy our products also include the wallflex family of stents in particular the wallflex biliary line and wallflex esophageal line and in 2012 we launched our wallflex biliary transheptic stent system for treatment of biliary strictures in addition we continue to see growth of our hemostasis franchise on the continued adoption and utilization of our resolution clip device for gastrointestinal bleeding in december of 2012 the first patient enrolled in our study comparing the wallflex biliary rx fully covered selfexpanding metal stent sems to plastic stents for the treatment of benign bile duct strictures caused by chronic pancreatitis sems which have a significantly larger diameter than plastic biliary stents have long been the standard of care for palliation of malignant biliary strictures this study is evaluating the benefits of using a sems in benign biliary strictures with an objective to demonstrate stricture resolution in fewer procedures 4table of contentsinterventional bronchoscopywe market devices to diagnose treat and ease pulmonary disease systems within the airway and lungs our products are designed to help perform biopsies retrieve foreign bodies from the airway open narrowings of an airway stop internal bleeding and ease symptoms of some types of airway cancers our product line includes pulmonary biopsy forceps transbronchial aspiration needles cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management in october 2010 we completed our acquisition of asthmatx inc which adds to our endoscopy portfolio a lessinvasive catheterbased bronchial thermoplasty procedure for the treatment of severe persistent asthma the alair bronchial thermoplasty system developed by asthmatx has both conformite europeenne ce mark and us food and drug administration fda approval and is the first devicebased asthma treatment approved by the fda in the third quarter of 2012 the america medical association ama current procedural terminology cpt editorial panel assigned category i cpt codes specifically for bronchial thermoplasty beginning january 1 2013 once recognized the category i cpt procedure codes will be available for all public and private health insurance payers in the united states which will allow physicians and hospitals to seek reimbursement for bronchial thermoplasty procedures we believe these codes will provide greater access to treatment for patients with poorly controlled severe asthma help facilitate claims processing and help private payers approve coverage for this form of treatment we continue to focus on driving commercialization and increased awareness of the alair system peripheral interventions piwe sell various products designed to treat patients with peripheral disease disease which appears in blood vessels other than in the heart and in the biliary tree including a broad line of medical devices used in percutaneous transluminal angioplasty pta and peripheral vascular stenting our peripheral product offerings include stents balloon catheters wires peripheral embolization devices and vena cava filters we launched three new peripheral angioplasty balloons in 2011 including our nextgeneration mustang percutaneous transluminal angioplasty balloon our coyote balloon catheter a highly deliverable and ultralow profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures and our charger pta balloon catheter a 0035 percutaneous transluminal angioplasty balloon catheter designed for poststent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries with our coyote mustang and charger devices we offer balloons across all size platforms in 2012 we launched our epic selfexpanding nitinol stent system in the us and certain international markets the carotid wallstent stent system in japan and innova selfexpanding bare metal stent system in europe and certain international markets in february 2011 we announced the acquisitions of si therapies and revascular therapeutics inc which added to our pi portfolio a reentry catheter and intraluminal chronic total occlusion cto crossing device enabling endovascular treatment in cases that typically cannot be treated with standard endovascular devices in 2011 we commenced a limited market release of our offroad reentry catheter system in certain international markets and in february 2012 we launched our truepath intraluminal cto device in the us emea and other international markets we believe that offering these devices will enhance our position in assisting physicians in addressing the challenges of treating complex peripheral lesions in the fourth quarter of 2012 we acquired vessix vascular inc a developer of catheterbased renal denervation systems for the treatment of uncontrolled hypertension we expect to launch this platform commercially in europe and other international markets in 2013we also sell products designed to treat patients with nonvascular disease disease that appears outside the blood system our nonvascular suite of products includes biliary stents drainage catheters and micropuncture sets designed to treat diagnose and ease various forms of benign and malignant tumors we continue to market our extensive line of interventional oncology product solutions including the recently launched renegade hiflo fathom microcatheter and guidewire system and interlock  35 fibered idc occlusion system for peripheral embolizationneuromodulationwithin our neuromodulation business we market the precision spinal cord stimulation scs system used for the management of chronic pain this system delivers pain management by applying an electrical signal to mask pain signals traveling from the spinal cord to the brain in addition during the fourth quarter of 2012 we received ce mark approval for the precision spectra spinal cord stimulator system and began a european market launch of this technology the precision spectra system is the worlds first and only scs system with 32 contacts and 32 dedicated power sources and is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain in 2011 we launched our clik anchor for our precision plus scs system the worlds first rechargeable scs device for chronic pain management in the fourth quarter of 2011 we received fda approval for and launched the infinion 16 percutaneous lead the worlds first and only 16contact percutaneous lead we also market the linear 34 and linear 36 percutaneous leads for use with our scs systems which are designed to provide physicians more treatment options for their chronic pain patients these leads provide the broadest range of percutaneous lead configurations in the industry 5table of contentswe believe that we continue to have a technology advantage compared to our competitors with proprietary features such as multiple independent current control which is intended to allow the physician to target specific areas of pain more precisely we are looking to strengthen the clinical evidence with spinal cord stimulation and are committed to studies designed to demonstrate cost effectiveness or demonstrate the value of proprietary features in our scs system in january 2011 we completed the acquisition of intelect medical inc a developmentstage company developing advanced visualization and programming for the vercise system we believe this acquisition leverages the core architecture of our vercise platform and will advance our technology in the field of deepbrain stimulation during the third quarter of 2012 we received ce mark approval for the use of our vercise deep brain stimulation dbs system for the treatment of parkinsons disease in europe we believe we have an exciting opportunity in dbs with our ability to customize the field designed to precisely stimulate the target without extraneous stimulation of adjacent areas that may cause unwanted side effects urologywomens healthour urologywomens health division develops manufactures and sells devices to treat various urological and gynecological disorders within our urology business we sell a variety of products designed to treat patients with urinary stone disease and benign prostatic hyperplasia bph we offer a full line of stone management products including ureteral stents wires lithotripsy devices stone retrieval devices sheaths balloons and catheters within our womens health business we market a range of devices for the treatment of conditions such as female urinary incontinence pelvic floor reconstruction rebuilding of the anatomy to its original state and menorrhagia excessive menstrual bleeding we offer a full breadth of midurethral sling products sling materials graft materials pelvic floor reconstruction kits and suturing devices we market our genesys hydro thermablator hta system a nextgeneration endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia the genesys hta system features a smaller and lighter console simplified setup requirements and an enhanced graphic user interface and is designed to improve operating performanceelectrophysiologywithin our electrophysiology business we develop lessinvasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart included in our product offerings are radio frequency rf generators steerable rf ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories our leading products include the blazer and blazer prime line of temperature ablation catheters designed to deliver enhanced performance responsiveness and durability our cooled ablation portfolio includes the only closedloop irrigated catheter on the market the chilli ii cooled ablation catheter and the newly launched blazer openirrigated ablation catheter with a unique total tip cooling design in 2012 we received health canada and ce mark approval of the blazer openirrigated catheter our latest radiofrequency ablation rfa catheter designed to treat a variety of arrhythmias such as atrial fibrillation atrial flutter ventricular tachycardia and other supraventricular tachycardias additionally on october 9 2012 we acquired rhythmia medical inc a developer of nextgeneration mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures including atrial fibrillation and atrial flutter we believe that this acquisition as well as the recent and expected product launches will help to position us to competitively participate in the fastgrowing electrophysiology market cardiac rhythm managementwe develop manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities including implantable cardioverter defibrillator icd systems used to detect and treat abnormally fast heart rhythms tachycardia that could result in sudden cardiac death including the worlds first and only commercially available subcutaneous implantable cardioverter defibrillator  the sicd system and implantable cardiac resynchronization therapy defibrillator crtd systems used to treat heart failure andimplantable pacemaker systems used to manage slow or irregular heart rhythms bradycardia including implantable cardiac resynchronization therapy pacemaker crtp systems used to treat heart failure a key component of many of our implantable device systems is our remote latitude patient management system which enables physicians to monitor device performance remotely while patients are in their homes allowing for more frequent monitoring in order to guide treatment decisions 6table of contentsin the first half of 2012 we launched our ingenio family of pacemaker systems in the us and emea and in the third quarter of 2012 we received ce mark approval for use of our ingenio and advantio pacemakers in patients in need of a magnetic resonance imaging mri scan which we believe represents a significant advancement to our family of pacemaker devices in the second quarter of 2012 we received fda approval for our invive cardiac resynchronization therapy pacemakers crtps invive is built on the same platform as our high voltage cardiac resynchronization therapy defibrillator crtds is enabled for remote patient monitoring and includes features that promote ease of use also during the first half of 2012 we completed the acquisition of cameron health inc cameron cameron developed the worlds first and only commercially available subcutaneous implantable cardioverter defibrillator  the sicd system which we believe is a differentiated technology that will provide us the opportunity to both increase our market share in the existing icd market and expand that market over time the sicd system has ce mark approval and is available in emea in addition during the third quarter of 2012 we received fda approval for the sicd system and commenced a limited commercial launch in the us with this approval we are now able to offer our us physician customers an entirely new option to treat their patients who are at risk for sudden cardiac arrest we believe the recent product developments noted above will help to better position us within the crm marketinterventional cardiologycoronary stent systemsour broad innovative product offerings have enabled us to become a leader in the interventional cardiology market this leadership is due in large part to our coronary stent product offerings coronary stents are tiny mesh tubes used in the treatment of coronary artery disease which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart we believe we have further enhanced the outcomes associated with the use of coronary stents particularly the processes that lead to restenosis the growth of neointimal tissue within an artery after angioplasty and stenting through dedicated internal and external product development strategic alliances and scientific research of drugeluting stent systems we market our internallydeveloped and selfmanufactured promus element everolimuseluting stent platform in all major markets worldwide as well as our taxus paclitaxeleluting stent line including our thirdgeneration taxus element stent system we are the only company in the industry to offer a twodrug platform strategy with our paclitaxeleluting and everolimuseluting stent system offerings and we offer a broad range of stent sizes in addition during the fourth quarter of 2012 we received ce mark approval for the synergy everolimuseluting platinum chromium coronary stent system featuring an ultrathin abluminal outer bioabsorbable polymer coating the synergy stent is unique in that its proprietary polymer and everolimus drug coating dissipate by three months this innovation has the potential to improve postimplant vessel healing and will eliminate longterm polymer exposure a possible cause of late adverse events in the first quarter of 2013 we also received ce mark approval and launched our nextgeneration promus premier everolimuseluting platinum chromium coronary stent system in europe and other select geographiescore coronary technologywe market a broad line of products used to treat patients with atherosclerosis a principal cause of coronary artery obstructive disease which is characterized by a thickening of the walls of the coronary arteries and a narrowing of arterial openings caused by the progressive development of deposits of plaque our product offerings include balloon catheters rotational atherectomy systems guide wires guide catheters embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty ptca procedures as well as intravascular ultrasound ivus imaging system in addition in october 2012 we completed the acquisition of bridgepoint medical inc a developer of proprietary catheterbased systems to treat coronary chronic total occlusions ctos through this acquisition we expect to augment our current portfolio of interventional cardiology products which we believe will enable us to be a singlesource supplier for complex pci procedures during 2012 we received fda clearance for our emerge percutaneous transluminal coronary angioplasty ptca balloon dilatation catheter and began marketing the device in the united states the emerge catheter is a nextgeneration predilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary arteries both the monorail and overthewire otw options are available the emerge catheter has been commercially available in ce mark countries since the second quarter of 2012 intraluminal ultrasound imagingwe market a family of intraluminal catheterdirected ultrasound imaging catheters and systems for use in coronary arteries and heart chambers as well as certain peripheral vessels the ilab ultrasound imaging system continues as our flagship console and is compatible with our full line of imaging catheters this system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders further ilab systems have been placed in cardiology labs worldwide which provide an installed base through which we expect to launch new products including an improved line of coronary intravascular vessel imaging catheters and an integrated fractional flow reserve ffr device following regulatory approval these imaging products would provide our cardiology sales force with a differentiated product offering in one of the fastest growing segments of interventional cardiology 7table of contentsstructural heart therapyin january 2011 we completed the acquisition of sadra medical inc sadra through the acquisition of sadra we are developing a fully repositionable and retrievable device for transcatheter aortic valve replacement tavr to treat through patients with severe aortic stenosis the lotus valve system consists of a stentmounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve the lowprofile delivery system and introducer sheath are designed to enable accurate positioning repositioning and retrieval at any time prior to release of the aortic valve implant we believe tavr is one of the fastest growing medical device marketsin march 2011 we completed the acquisition of atritech inc atritech atritech developed a novel device designed to close the left atrial appendage in patients with atrial fibrillation af who are at risk for ischemic stroke the watchman left atrial appendage closure technology watchman laa developed by atritech is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs and is approved for use in ce mark countries additionally in august 2012 european regulators approved an expanded indication for the watchman laa closure device the new indication offers patients with af and a contraindication to warfarin and the newer oral anticoagulants a new treatment option for stroke reduction innovationour approach to innovation combines internallydeveloped products and technologies with those we may obtain externally through strategic acquisitions and alliances our research and development efforts are focused largely on the development of nextgeneration and novel technology offerings across multiple programs and divisions in addition we have undertaken strategic acquisitions to help enable us to continue to be a leader in the medical device industry we expect to continue to invest in our core franchises and also investigate opportunities to further expand our presence in and diversify into strategic growth adjacencies we have closed several acquisitions targeting many of these areas in 2011 we completed the acquisitions of sadra medical inc intelect medical inc and atritech inc and in 2012 we completed the acquisitions of cameron health inc bridgepoint medical inc rhythmia medical inc and vessix vascular inc all discussed above there can be no assurance that technologies developed internally or acquired through acquisitions and alliances will achieve technological feasibility obtain regulatory approvals or gain market acceptance and any delay in the development or approval of these technologies may adversely impact our ability to drive future growthresearch and developmentour investment in research and development is critical to driving our future growth we expended 886 million on research and development in 2012 895 million in 2011 and 939 million in 2010 representing approximately 12 percent of our net sales each year our investment in research and development reflectsregulatory compliance clinical science and internal research and development programs as well as other programs obtained through our strategic acquisitions and alliances andengineering efforts which incorporate customer feedback into continuous improvement efforts for currently marketed and nextgeneration productswe have directed our development efforts toward regulatory compliance and innovative technologies designed to expand current markets or enter adjacent markets we are transforming the way we conduct research and development and are scrutinizing our cost structure which we expect will enhance our overall efficiency and effectiveness our approach to new product design and development is through focused crossfunctional teams we believe that our formal process for technology and product development aids in our ability to offer innovative and manufacturable products in a consistent and timely manner involvement of the research and development clinical quality regulatory manufacturing and marketing teams early in the process is the cornerstone of our product development cycle this collaboration allows these teams to concentrate resources on the most viable and clinically relevant new products and technologies and focus on bringing them to market in a timely and costeffective manner in addition to internal development we work with hundreds of leading research institutions universities and clinicians around the world to develop evaluate and clinically test our products we believe our future success will depend upon the strength of these development efforts8table of contentsmarketing and salesduring 2012 we marketed our products to over 13000 hospitals clinics outpatient facilities and medical offices in nearly 100 countries worldwide the majority of our net sales are derived from countries in which we have direct sales organizations we also have a network of distributors and dealers who offer our products in certain countries and markets which accounts for our remaining sales we expect to continue to leverage our infrastructure in markets where commercially appropriate and use third parties in those markets where it is not economical or strategic to establish or maintain a direct presence we are not dependent on any single institution and no single institution accounted for more than ten percent of our net sales in 2012 or 2011 however large group purchasing organizations hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our us net sales we have a dedicated corporate sales organization in the us focused principally on selling to major buying groups and integrated healthcare networks we consistently strive to understand and exceed the expectations of our customers each of our businesses maintains dedicated sales forces and marketing teams focusing on physicians who specialize in the diagnosis and treatment of different medical conditions we believe that this focused disease state management enables us to develop highly knowledgeable and dedicated sales representatives and to foster collaborative relationships with physicians we believe that we have positive working relationships with physicians and others in the medical industry which enable us to gain a detailed understanding of new therapeutic and diagnostic alternatives and to respond quickly to the changing needs of physicians and their patients international operationsinternational net sales accounted for approximately 50 percent of our net sales in 2012 net sales and operating income attributable to our 2012 geographic regions are presented in note o  segment reporting to our 2012 consolidated financial statements included in item 8 of this annual report incorporated by reference herein our international structure operates through three international business units emea consisting of europe the middle east and africa japan and intercontinental consisting of our asia pacific and the americas reporting units maintaining and expanding our international presence is an important component of our longterm growth plan through our international presence we seek to increase net sales and market share leverage our relationships with leading physicians and their clinical research programs accelerate the time to bring new products to market and gain access to worldwide technological developments that we can implement across our product lines we are investing in infrastructure in emerging markets in order to introduce new products and strengthen our sales capabilities in these countries a discussion of the risks associated with our international operations is included in item 1a of this annual reportas of december 31 2012 we had six international manufacturing facilities including three in ireland two in costa rica and one in puerto rico approximately 59 percent of our products sold worldwide during 2012 were manufactured at these facilities additionally we maintain international research and development capabilities in ireland as well as physician training centers in france and japanmanufacturing and raw materialswe are focused on continuously improving our supply chain effectiveness strengthening our manufacturing processes and increasing operational efficiencies within our organization by shifting global manufacturing along product lines we are able to leverage our existing resources and concentrate on the development and commercial launch of new products and the enhancement of existing products we continue to implement new systems designed to provide improved quality and reliability service greater efficiency and lower supply chain costs and have substantially increased our focus on process controls and validations supplier controls distribution controls and providing our operations teams with the training and tools necessary to drive continuous improvement in product quality in addition we remain focused on examining our operations and general business activities to identify costimprovement opportunities in order to enhance our operational effectivenessour products are designed and manufactured in technology centers around the world either by us or third parties in most cases the manufacturing of our products is concentrated in one or a few locations we consistently monitor our inventory levels manufacturing and distribution capabilities and maintain recovery plans to address potential disruptions that we may encounter however significant interruptions in our manufacture of products for an extended duration may result in loss of market share which could adversely affect our results of operations and financial conditionmany components used in the manufacture of our products are readily fabricated from commonly available raw materials or offtheshelf items available from multiple supply sources however certain items are custom made to meet our specifications we believe that in most cases redundant capacity exists at our suppliers and that alternative sources of supply are available or could be developed within a reasonable period of time we also have an ongoing program to identify singlesource components and to develop alternative backup supplies and we regularly readdress the adequacy and abilities of our suppliers to meet our needs 9table of contentsin certain cases we may not be able to quickly establish additional or replacement suppliers for specific materials components or products largely due to the regulatory approval system and the complex nature of our manufacturing processes and those of our suppliers a reduction or interruption in supply an inability to develop and validate alternative sources if required or a significant increase in the price of raw materials components or products could adversely affect our operations and financial condition particularly materials or components related to our crm products and drugeluting stent systems in addition our products require sterilization prior to sale and we utilize a mix of internal resources and thirdparty vendors to perform this service we believe we have capabilities sufficient to sterilize our products however to the extent we or our thirdparty sterilizers are unable to sterilize our products whether due to capacity regulatory or other constraints we may be unable to transition to other providers in a timely manner which could have an adverse impact on our operationspursuant to the doddfrank wall street reform and consumer protection act the securities and exchange commission sec promulgated final rules regarding disclosure of the use of certain minerals known as conflict minerals which are mined from the democratic republic of the congo and adjoining countries these rules may impose additional costs on us including for diligence as to the sources of any conflict minerals used in our products as well as for any resulting changes we make to products processes or sources of supply in addition these rules could have an adverse effect on the sourcing supply and pricing of materials used in our productsquality assurancewe are committed to providing high quality products to our customers to meet this commitment we have implemented updated quality systems and concepts throughout our organization our quality system starts with the initial product specification and continues through the design of the product component specification process and the manufacturing sale and servicing of the product our quality system is intended to build in quality and process control and to utilize continuous improvement concepts throughout the product life these systems are designed to enable us to satisfy the various international quality system regulations including those of the fda with respect to products sold in the us all of our manufacturing facilities including our us and european distribution centers are certified under the iso13485 quality system standard established by the international standards organization for medical devices which requires among other items an implemented quality system that applies to component quality supplier control product design and manufacturing operations this certification can be obtained only after a complete audit of a companys quality system by an independent outside auditor maintenance of the certification requires that these facilities undergo periodic reexaminationin addition we maintain an ongoing initiative to seek iso14001 certification at our plants around the world iso14001 is a globally recognized standard for environmental management systems established by the international standards organization which provides a voluntary framework to identify key environmental aspects associated with our business we engage in continuous environmental performance improvement efforts and at present as it relates to our major manufacturing and tier 1 distribution facilities 13 of our 14 facilities have attained iso14001 certification we are committed to achieving iso14001 certification at all of our major manufacturing facilities and tier i distribution centers worldwidecompetitionwe encounter significant competition across our product lines and in each market in which we sell our products from various companies some of which may have greater financial and marketing resources than we do our primary competitors include abbott laboratories medtronic inc and st jude medical inc as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment we also face competition from nonmedical device companies such as pharmaceutical companies which may offer alternative therapies for disease states intended to be treated using our productswe believe that our products compete primarily on their ability to safely and effectively perform diagnostic and therapeutic procedures in a lessinvasive manner as well as clinical outcomes ease of use comparative effectiveness reliability and physician familiarity in the current environment of managed care economicallymotivated buyers consolidation among healthcare providers increased competition and declining reimbursement rates we have been increasingly required to compete on the basis of price value reliability and efficiency we believe the current global economic conditions and healthcare reform measures could put additional competitive pressure on us including on our average selling prices overall procedure rates and market sizes we recognize that our continued competitive success will depend upon our ability to offer products with differentiated clinical outcomes create or acquire innovative scientifically advanced technology apply our technology costeffectively and with superior quality across product lines and markets develop or acquire proprietary products attract and retain skilled personnel obtain patent or other protection for our products obtain required regulatory and reimbursement approvals continually enhance our quality systems manufacture and successfully market our products either directly or through outside parties and supply sufficient inventory to meet customer demand10table of contentsregulatory environmentthe medical devices that we manufacture and market are subject to regulation by numerous worldwide regulatory bodies including the fda and comparable international regulatory agencies these agencies require manufacturers of medical devices to comply with applicable laws and regulations governing the development testing manufacturing labeling marketing and distribution of medical devices devices are generally subject to varying levels of regulatory control based on the risk level of the device in the us authorization to commercially distribute a new device generally can be met in one of three ways the first process requires that a premarket notification 510k be made to the fda to demonstrate that the device is as safe and effective as or substantially equivalent to a legally marketed device the predicate device applicants must submit performance data to establish substantial equivalence in some instances data from human clinical trials must also be submitted in support of a 510k premarket notification if so these data must be collected in a manner that conforms to the applicable investigational device exemption ide regulations the fda must issue a decision finding substantial equivalence before commercial distribution can occur changes to cleared devices that could not significantly affect the safety or effectiveness of the device can generally be made without additional 510k premarket notifications otherwise a new 510k is requiredthe second process requires the submission of a premarket approval pma application to the fda to demonstrate that the device is safe and effective for its intended use this approval process applies to most class iii devices and generally requires clinical data to support the safety and effectiveness of the device obtained in adherence with ide requirements the fda will approve the pma application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose and that the proposed manufacturing is in compliance with the quality system regulation qsr this process is generally more detailed lengthier and more expensive than the 510k processthe third process requires that an application for a humanitarian device exemption hde be made to the fda for the use of a humanitarian use device hud an hud is intended to benefit patients by treating or diagnosing a disease or condition that affects or is manifested in fewer than 4000 individuals in the us per year the application submitted to the fda for an hde is similar in both form and content to a pma application but is exempt from the effectiveness requirements of a pma the hud provision of the regulation provides an incentive for the development of devices for use in the treatment or diagnosis of diseases affecting smaller patient populationsin the european union we are required to comply with applicable medical device directives including the medical devices directive and the active implantable medical devices directive and obtain ce mark certification in order to market medical devices the ce mark is applied following approval from an independent notified body or declaration of conformity it is an international symbol of adherence to quality assurance standards and compliance with applicable european medical devices directives we are also required to comply with the regulations of each other country where we commercialize products such as the requirement that we obtain approval from the japanese ministry of health labor and welfare mhlw before we can launch new products in japan the fda and other worldwide regulatory agencies actively monitor compliance to local laws and regulations through review and inspection of design and manufacturing practices record keeping reporting of adverse events labeling and promotional practices the fda can ban certain medical devices detain or seize adulterated or misbranded medical devices order repair replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health the fda may also enjoin and restrain a company for certain violations of the food drug and cosmetic act and the safe medical devices act pertaining to medical devices or initiate action for criminal prosecution of such violations international sales of medical devices manufactured in the us that are not approved by the fda for use in the us or that are banned or deviate from lawful performance standards are subject to fda export requirements exported devices are subject to the regulatory requirements of each country to which the device is exported some countries do not have medical device regulations but in most foreign countries medical devices are regulated frequently regulatory approval may first be obtained in a foreign country prior to application in the us due to differing regulatory requirements however other countries such as china for example require approval in the country of origin first most countries outside of the us require that product approvals be recertified on a regular basis generally every five years the recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance where recertification applications are required they must be approved in order to continue selling our products in those countriesour global regulatory environment is becoming increasingly stringent and unpredictable which could increase the time cost and complexity of obtaining regulatory approvals for our products several countries that did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded on existing regulations certain regulators are exhibiting less flexibility and are requiring local data in addition to global data 11table of contentswhile harmonization of global regulations has been pursued requirements continue to differ significantly among countries we expect this global regulatory environment will continue to evolve which could impact our ability to obtain future approvals for our products or could increase the cost and time to obtain such approvals in the futurewe are also subject to various environmental laws directives and regulations both in the us and abroad our operations like those of other medical device companies involve the use of substances regulated under environmental laws primarily in manufacturing and sterilization processes we do not believe that compliance with environmental laws will have a material impact on our capital expenditures earnings or competitive position however given the scope and nature of these laws there can be no assurance that environmental laws will not have a material impact on our results of operations we assess potential environmental contingent liabilities on a regular basis at present we are not aware of any such liabilities that would have a material impact on our businesswe believe that sound environmental health and safety performance contributes to our competitive strength while benefiting our customers shareholders and employees we are committed to continuous improvement in these areas by reducing pollution the depletion of natural resources and our overall environmental footprint specifically we are working to optimize energy and resource usage ultimately reducing greenhouse gas emissions and waste we are certified to the ftse4good corporate social responsibility index managed by the financial times and the london stock exchange which measures the performance of companies that meet globally recognized standards of corporate responsibility this certification recognizes our dedication to those standards and it places us in a select group of companies with a demonstrated commitment to responsible business practices and sound environmental policiesgovernment affairswe maintain a global government affairs presence headquartered in washington dc to actively monitor and advocate on a myriad of legislation and policies impacting us both on a domestic and an international front the government affairs office works closely with members of congress and committee staff the white house and administration office state legislatures and regulatory agencies and governments overseas on issues affecting our business our proactive approach and depth of political and policy expertise are aimed at having our positions heard by federal state and global decisionmakers while also advancing our business objectives by educating policymakers on our positions key priorities and the value of our technologies the government affairs office also manages our political action committee and works closely with trade groups on issues affecting our industry and healthcare in generalhealthcare reform political economic and regulatory influences are subjecting the healthcare industry to potential fundamental changes that could substantially affect our results of operations government and private sector initiatives related to limiting the growth of healthcare costs including price regulation competitive pricing coverage and payment policies comparative effectiveness of therapies technology assessments and health care delivery structure reforms are continuing in many countries where we do business including the us these changes are causing the marketplace to put increased emphasis on the delivery of more costeffective treatments although we believe our lessinvasive products and technologies generate favorable clinical outcomes value and cost efficiency the resources necessary to demonstrate value to our customers patients payors and other stakeholders may be significant in addition uncertainty remains regarding the continued implementation of the patient protection and affordable care act aca and its impact to our businessfurther the federal government as part of the aca and certain state governments have enacted laws aimed at increasing transparency in relationships between medical device biologics and pharmaceutical companies and healthcare professionals hcps as a result we are required by law to report many types of payments made and items of value provided to hcps licensed by certain states on the federal level we are required to begin tracking financial relationships in august 2013 and reporting by the end of the first quarter of 2014 we have devoted substantial time and financial resources in order to develop and implement enhanced structure policies systems and processes in order to comply with these us federal and state legal and regulatory requirements in addition certain foreign jurisdictions are currently acting to implement similar laws failure to adhere to our policies comply with required laws or implement adequate policies and practices to address changes to legal and regulatory requirements could have a negative impact on our results of operations additionally new legislation imposes a 23 percent excise tax on medical device manufacturers on us sales of class i ii and iii medical devices beginning in january 2013 thirdparty coverage and reimbursementour products are purchased principally by hospitals physicians and other healthcare providers around the world that typically bill various thirdparty payors including governmental programs eg medicare and medicaid in the united states private insurance plans and managed care programs for the healthcare services provided to their patients12table of contentswe expect that pricing of medical devices will remain under pressure as alternative payment models such as bundling valuebased purchasing and accountable care organizations acos begin to take shape in the united states initiatives to limit the growth of healthcare costs including price regulation are also underway in many countries in which we do business implementation of cost containment initiatives and healthcare reforms in significant markets such as the us japan europe and other markets may limit the price of or the level at which reimbursement is provided for our products and may influence a physicians selection of products used to treat patientsin addition patients and clinicians are becoming more informed on the risks and benefits of alternative treatments as comparative effectiveness research findings are beginning to be disseminated therefore we believe that compelling clinical and economic data will become increasingly important to demonstrate efficacy and justify the economic benefits of technology purchasesthirdparty payors and governments may provide or deny coverage for certain technologies and associated procedures based on independently determined assessment criteria reimbursement by payors for these services is based on a wide range of methodologies that may reflect the services assessed resource costs clinical outcomes and economic value these reimbursement methodologies confer different and sometimes conflicting levels of financial risk and incentives to healthcare providers and patients and these methodologies are subject to frequent refinements thirdparty payors are also increasingly adjusting reimbursement rates often downwards and challenging the prices charged for medical products and services there can be no assurance that our products will be automatically covered by thirdparty payors that reimbursement will be available or if available that the thirdparty payors coverage policies will not adversely affect our ability to sell our products profitablyproprietary rights and patent litigationwe rely on a combination of patents trademarks trade secrets and nondisclosure agreements to protect our intellectual property we generally file patent applications in the us and foreign countries where patent protection for our technology is appropriate and available as of december 31 2012 we held more than 15000 patents and had approximately 7300 patent applications pending worldwide that cover various aspects of our technology in addition we hold exclusive and nonexclusive licenses to a variety of thirdparty technologies covered by patents and patent applications there can be no assurance that pending patent applications will result in the issuance of patents that patents issued to or licensed by us will not be challenged or circumvented by competitors or that these patents will be found to be valid or sufficiently broad to protect our technology or to provide us with a competitive advantage in the aggregate these intellectual property assets and licenses are of material importance to our business however we believe that no single patent technology trademark intellectual property asset or license except for those relating to our drugeluting coronary stent systems is material in relation to our business as a wholewe rely on nondisclosure and noncompetition agreements with employees consultants and other parties to protect in part trade secrets and other proprietary technology there can be no assurance that these agreements will not be breached that we will have adequate remedies for any breach that others will not independently develop equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets and proprietary knowledgethere has been substantial litigation regarding patent and other intellectual property rights in the medical device industry particularly in the areas in which we compete we continue to defend ourselves against claims and legal actions alleging infringement of the patent rights of others adverse determinations in any patent litigation could subject us to significant liabilities to third parties require us to seek licenses from third parties and if licenses are not available prevent us from manufacturing selling or using certain of our products which could have a material adverse effect on our business additionally we may find it necessary to initiate litigation to enforce our patent rights to protect our trade secrets or knowhow and to determine the scope and validity of the proprietary rights of others patent litigation can be costly and timeconsuming and there can be no assurance that our litigation expenses will not be significant in the future or that the outcome of litigation will be favorable to us accordingly we may seek to settle some or all of our pending litigation particularly to manage risk over time settlement may include cross licensing of the patents that are the subject of the litigation as well as our other intellectual property and may involve monetary payments to or from third parties 13table of contentswe maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims or adverse decisions see item 3 and note k  commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual report for a discussion of intellectual property and other litigation and proceedings in which we are involved in managements opinion we are not currently involved in any legal proceeding other than those specifically identified in note k which individually or in the aggregate could have a material effect on our financial condition operations andor cash flowsrisk managementwe have an enterprise risk management erm program in which we provide coordinated oversight control and continuous improvement of processes and tools used to identify and manage business risk on an annual basis we reassess our risks based on the committee of sponsoring organizations of the treadway commission coso erm framework in the areas of strategic risk financial risk external risk operational risk and compliance risk with the goal of achieving our business strategies and objectives this assessment which engages key individuals from our board of directors and management provides increased visibility into the risks we face highlights risk interdependencies and seeks to improve overall risk management effectiveness current economic climateour results of operations could be substantially affected by global economic factors and local operating and economic conditions our customers may experience financial difficulties or be unable to borrow money to fund their operations which may adversely impact their ability or decision to purchase our products particularly capital equipment or to pay for our products they do purchase on a timely basis if at all we cannot predict to what extent global economic conditions including the increased focus on healthcare systems and costs in the us and abroad may negatively impact our average selling prices our net sales and profit margins procedural volumes and reimbursement rates from thirdparty payorsemployeesas of december 31 2012 we had approximately 24000 employees including approximately 12000 in operations 6000 in selling marketing and distribution 4000 in clinical regulatory and research and development and 2000 in administration of these employees we employed approximately 10000 outside the us approximately 7000 of whom are in the manufacturing operations function we believe that the continued success of our business will depend in part on our ability to attract and retain qualified personnel and we are committed to developing our people and providing them with opportunities to contribute to our growth and successcommunity outreachwe are committed to making more possible in the communities where we live and work we bring this commitment to life by supporting global national and local health and education initiatives striving to improve patient advocacy adhering to strong ethical standards that deliver on our commitments and minimizing our impact on the environment a prominent example of our ongoing commitment to patients is our close the gap program which aims to eliminate cardiovascular care disparities by helping to ensure all patients  regardless of age gender race ethnicity or primary language  receive access to optimal cardiac care to achieve this goal close the gap provides awareness to the community about cardiovascular risk factors teaches healthcare providers about cultural beliefs and barriers to treatment and advocates for measures that help ensure all patients receive the cardiovascular care they need by sponsoring programs and working via partnerships in the community our close the gap program has helped these messages reach over one million peoplethrough the boston scientific foundation established in 2001 we fund nonprofit organizations in our local communities community grants focus on increasing access to quality healthcare and improving educational opportunities particularly with regards to science technology engineering and math stem education boston scientific has committed to contributing 15 million to our close the gap program and stem education14table of contentsseasonalityour worldwide sales do not reflect any significant degree of seasonality however customer purchases have historically been lighter in the third quarter of the year as compared to other quarters this reflects among other factors lower demand during summer months in the northern hemisphere particularly in european countriesavailable informationcopies of our annual report on form 10k quarterly reports on form 10q current reports on form 8k and amendments to those reports filed or furnished pursuant to section 13a or 15d of the securities exchange act of 1934 as amended are available free of charge on our website wwwbostonscientificcom as soon as reasonably practicable after we electronically file the material with or furnish it to the us securities and exchange commission sec printed copies of these posted materials are also available free of charge to shareholders who request them in writing from investor relations one boston scientific place natick ma 017601537 information on our website or linked to our website is not incorporated by reference into this annual reportsafe harbor for forwardlooking statementscertain statements that we may make from time to time including statements contained in this annual report and information incorporated by reference into this annual report constitute forwardlooking statements within the meaning of section 27a of the securities act of 1933 as amended and section 21e of the securities exchange act of 1934 as amended forwardlooking statements may be identified by words like anticipate expect project believe plan may estimate intend and similar words these forwardlooking statements are based on our beliefs assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance these forwardlooking statements include among other things statements regarding our financial performance our business and results of operations our business strategy and related financial returns our growth initiatives including our emerging markets strategy and investments acquisitions and related payments and the integration and impact of acquired businesses and technologies finalizing the separation of our neurovascular business the timing and impact of our restructuring and plant network optimization initiatives including expected costs and cost savings our intention not to pay dividends use of our cash flow our outstanding accounts receivable in europe our estimates for the us and worldwide crm markets our estimates for the worldwide coronary stent market changes in the market and our market share for our other businesses procedural volumes and pricing pressures competitive pressures facing our businesses our royalty and other expenses clinical trials including timing and results our product portfolio product development and iterations new and existing product launches including their timing and acceptance and their impact on the market and our business competitive product launches product performance and our ability to gain a competitive advantage the strength of our technologies and pipeline timing of regulatory approvals our regulatory and quality compliance expected research and development efforts and the allocation of research and development expenditures our sales and marketing strategy reimbursement practices the ability of our suppliers and sterilizers to meet our requirements our ability to meet customer demand goodwill and other intangible asset impairment analysis and charges the effect of new accounting pronouncements on our financial results the impact of healthcare reform legislation including compliance with the affordable care act the effect of new and proposed tax laws including the medical devise excise tax the outcome and timing of matters before taxing authorities our tax position and income tax reserves and our ability to realize all our deferred tax assets the outcome and impact of intellectual property qui tam actions governmental investigations and proceedings and litigation matters adequacy of our reserves the drivers and impact of our investment ratings anticipated expenses and capital expenditures and our ability to finance them and our ability to meet the financial covenants required by our credit facilities or to renegotiate the terms of or obtain waivers for compliance with those covenants if our underlying assumptions turn out to be incorrect or if certain risks or uncertainties materialize actual results could vary materially from the expectations and projections expressed or implied by our forwardlooking statements as a result readers are cautioned not to place undue reliance on any of our forwardlooking statements except as required by law we do not intend to update any forwardlooking statements even if new information becomes available or other events occur in the futurethe forwardlooking statements in this annual report are based on certain risks and uncertainties including the risk factors described in item 1a under the heading risk factors and the specific risk factors discussed below and in connection with forwardlooking statements throughout this annual report which could cause actual results to vary materially from the expectations and projections expressed or implied by our forwardlooking statements these factors in some cases have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forwardlooking statements these additional factors include among other things future political economic competitive reimbursement and regulatory conditions new product introductions demographic trends intellectual property litigation and governmental investigations financial market conditions and future business decisions made by us and our competitors all of which are difficult or impossible to predict accurately and many of which are beyond our control we caution each reader of this annual report to consider carefully these factors 15table of contentsthe following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forwardlooking statements for further discussion of these and other risk factors see item 1a  risk factors our businessesour ability to increase crm net sales including for both new and replacement units expand the market and capture market sharethe volatility of the coronary stent market and our ability to increase our drugeluting stent systems net sales including with respect to our synergy promus element and promus premier stent systems and capture market sharethe ongoing impact on our business including crm and coronary stent businesses of physician alignment to hospitals governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed including with respect to the drugeluting coronary stent market the average number of stents used per procedure and average selling pricescompetitive offerings and related declines in average selling prices for our products particularly our drugeluting coronary stent systems and our crm products the performance of and physician and patient confidence in our products and technologies including our coronary drugeluting stent systems and crm products or those of our competitors the impact and outcome of ongoing and future clinical trials including coronary stent and crm clinical trials and market studies undertaken by us our competitors or other third parties  our ability to timely and successfully launch new or nextgeneration products and technology features worldwide and across our businesses in line with our commercialization strategies including our sicd system the effect of consolidation and competition in the markets in which we do business or plan to do business disruption in the manufacture or supply of certain components materials or products or the failure to timely secure alternative manufacturing or additional or replacement components materials or productsour ability to retain and attract key personnel including in our cardiology and crm sales force and other key cardiology and crm personnelthe impact of enhanced requirements to obtain regulatory approval in the us and around the world including the associated timing and cost of product approval andthe impact of increased pressure on the availability and rate of thirdparty reimbursement for our products and procedures in the us and around the world including with respect to the timing and costs of creating and expanding markets for new products and technologies 16table of contentsregulatory compliance and litigationthe impact of healthcare policy changes and legislative or regulatory efforts in the us and around the world to modify product approval or reimbursement processes including a trend toward demonstrating clinical outcomes comparative effectiveness and cost efficiency as well as the impact of other healthcare reform legislationrisks associated with our regulatory compliance and quality systems and activities in the us and around the world including meeting regulatory standards applicable to manufacturing and quality processesour ability to minimize or avoid future field actions or fda warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to medical devicesthe impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes as well as economic pressuresthe effect of our litigation and risk management practices including selfinsurance and compliance activities on our loss contingencies legal provision and cash flowsthe impact of diversion of management attention as a result of and costs to cooperate with litigate andor resolve governmental investigations and our class action product liability contract and other legal proceedings andrisks associated with a failure to protect our intellectual property rights and the outcome of patent litigationinnovation and certain growth initiativesthe timing size and nature of our strategic growth initiatives and market opportunities including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunitiesour ability to complete planned clinical trials successfully obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates including the successful completion of inprocess projects from purchased research and developmentour ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable revenue growth opportunities as well as to keep them in line with the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologiesour ability to successfully develop manufacture and market new products and technologies in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsoletethe impact of our failure to succeed at or our decision to discontinue writedown or reduce the funding of any of our research and development projects including inprocess projects from purchased research and development in our growth adjacencies or otherwise dependence on acquisitions alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions alliances and investments andthe failure to successfully integrate and realize the expected benefits from the strategic acquisitions alliances and investments we have consummated or may consummate in the future17table of contentsinternational marketsour dependency on international net sales to achieve growth including in emerging marketsthe impact of changes in our international structure and leadershiprisks associated with international operations and investments including political and economic conditions protection of our intellectual property compliance with established and developing local legal and regulatory requirements as well as changes in reimbursement practices and policiesour ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete including through investments in product diversification and emerging markets such as brazil russia india and chinaour ability to execute and realize anticipated benefits from our investments in emerging markets andthe potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales expenses and resulting margins liquidityour ability to generate sufficient cash flow to fund operations capital expenditures global expansion initiatives litigation settlements share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and covenant complianceour ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to usthe unfavorable resolution of open tax matters exposure to additional tax liabilities and the impact of changes in us and international tax laws  the impact of examinations and assessments by domestic and international taxing authorities on our tax provision financial condition or results of operationsthe impact of goodwill and other intangible asset impairment charges including on our results of operations andthe impact of the european sovereign debt crisis on our ability to collect outstanding and future receivables andor sell receivables under our factoring programs cost reduction and optimization initiativesrisks associated with significant changes made or expected to be made to our organizational and operational structure pursuant to our 2011 restructuring plan as expanded and as a result of our 2010 restructuring plan and plant network optimization program andbusiness disruption and employee distraction as we execute our global compliance program restructuring plans and divestitures of assets or businesses and implementing strategic and restructuring initiatives18table of contentsitem 1a risk factors in addition to the other information contained in this annual report and the exhibits hereto the following risk factors should be considered carefully in evaluating our business our business financial condition cash flows or results of operations could be materially adversely affected by any of these risks this section contains forwardlooking statements you should refer to the explanation of the qualifications and limitations on forwardlooking statements set forth at the end of item 1 of this annual report additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business financial condition cash flows or results of operationsdeclines in average selling prices for our products particularly our drugeluting coronary stent systems may materially adversely affect our results of operationswe have experienced pricing pressures across many of our businesses due to competitive activity increased market power of our customers as the healthcare industry consolidates economic pressures experienced by our customers and the impact of managed care organizations and other thirdparty payors competitive pricing pressures have particularly affected our drugeluting coronary stent system offerings we estimate that the average selling price of our drugeluting stent systems in the us decreased seven percent in 2012 as compared to the prior year continued declines in average selling prices of our products due to pricing pressures may have an adverse impact on our results of operations we derive a significant portion of our net sales from the sale of drugeluting coronary stent systems and crm products declines in market size average selling prices procedural volumes and our share of the markets in which we compete increased competition market perceptions of studies published by third parties or product launch delays may materially adversely affect our results of operations and financial condition including potential future writeoffs of our goodwill and other intangible assets balancesnet sales from drugeluting coronary stent systems represented approximately 18 percent of our consolidated net sales during 2012 in 2012 lower average selling prices driven by competitive and other pricing pressures and declines in procedural volumes resulted in a decline in our share of the us drugeluting stent market as well as an overall decrease in the size of the market there can be no assurance that these and other factors will not further impact our share of the us or worldwide drugeluting stent markets that we will regain or gain share of the us or worldwide drugeluting stent markets or that the size of the us drugeluting stent market will reach previous levels or will not decline further all of which could materially adversely affect our results of operations or financial condition in addition a delay in the timing of the launch of nextgeneration products the overall performance of and continued physician confidence in those products may result in a further decline in our market share and have an adverse impact on our results of operationsnet sales from our crm group represented approximately 26 percent of our consolidated net sales in 2012 our crm net sales declined in 2012 primarily due to the impact of average selling price pressures driven by governmental competitive and other pricing pressures and lower procedural volumes as a result of continued contraction in the us icd market further physician reaction to study results published by the journal of the american medical association regarding evidencebased guidelines for icd implants the us department of justice investigation into hospitals icd implant practices the expansion of medicare recovery audits and ongoing physician alignment to hospitals have had and may continue to have a negative impact on the size of the crm market our us icd sales represented approximately 45 percent of our worldwide crm net sales in 2012 and any changes in this market could have a material adverse effect on our financial condition or results of operations there can be no assurance that the size of the crm market will increase above existing levels or that we will be able to increase crm market share or increase net sales in a timely manner if at all decreases in market size or our share of the crm market and decreases in net sales from our crm products could have a significant impact on our financial condition or results of operations in addition our inability to increase our worldwide crm net sales could result in future goodwill and other intangible asset impairment charges further variability in the timing of the launch of nextgeneration products may result in excess or expired inventory positions and future inventory charges or may result in a loss of market share and adversely impact our results of operationsconsolidation in the healthcare industry could lead to increased demands for price concessions or the exclusion of some suppliers from certain of our significant market segments which could have an adverse effect on our business financial condition or results of operationsthe cost of healthcare has risen significantly over the past decade and numerous initiatives and reforms by legislators regulators and thirdparty payors to curb these costs have resulted in a consolidation trend in the healthcare industry including hospitals 19table of contentsthis consolidation has resulted in greater pricing pressures decreased average selling prices and the exclusion of certain suppliers from important market segments as group purchasing organizations independent delivery networks and large single accounts continue to consolidate purchasing decisions for some of our hospital customers there can be no assurance that measures we may take to address these trends will succeed we expect that market demand government regulation thirdparty reimbursement policies government contracting requirements and societal pressures will continue to change the worldwide healthcare industry resulting in further business consolidations and alliances among our customers and competitors which may continue to exert further downward pressure on the prices of our products and adversely impact our business financial condition or results of operationswe face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry which could have an adverse effect on our business financial condition or results of operationsthe medical device markets in which we primarily participate are highly competitive we encounter significant competition across our product lines and in each market in which our products are sold from various medical device companies some of which may have greater financial and marketing resources than we do our primary competitors include abbott laboratories medtronic inc and st jude medical inc as well as a wide range of medical device companies that sell a single or limited number of competitive products or which participate in only a specific market segment we also face competition from nonmedical device companies including pharmaceutical companies which may offer alternative therapies for disease states intended to be treated using our productsadditionally the medical device markets in which we primarily participate are characterized by extensive research and development and rapid technological change developments by other companies of new or improved products processes or technologies may make our products or proposed products obsolete or less competitive and may negatively impact our net sales we are required to devote continued efforts and financial resources to develop or acquire scientifically advanced technologies and products apply our technologies costeffectively across product lines and markets obtain patent and other protection for our technologies and products obtain required regulatory and reimbursement approvals and successfully manufacture and market our products consistent with our quality standards if we fail to develop new products or enhance existing products it could have a material adverse effect on our business financial condition or results of operationsbecause we derive a significant amount of our net sales from international operations and a significant percentage of our future growth is expected to come from international operations including from emerging markets changes in international economic or regulatory conditions could have a material impact on our business financial condition or results of operationssales outside the us accounted for approximately 50 percent of our net sales in 2012 additionally a significant percentage of our future growth is expected to come from international operations including from our increased sales presence and other investments in emerging markets such as brazil russia china and india we recently created a new asiapacific regional organization under new leadership to further increase our capabilities and strengthen our position in this fast growing region sales practices in certain international markets however may be inconsistent with our desired business practices and us legal requirements which may impact our ability to expand as planned in addition we continue to invest in infrastructure in brazil china and india including the development of a world class training center for healthcare providers and invest in local research and development and clinical studies however risks and uncertainties related to political and economic conditions in these regions traditional business practices foreign currency fluctuations interest rate fluctuations regulatory and reimbursement approvals competitive offerings infrastructure development complications and intellectual property protection may adversely impact our ability to implement our business strategy in these markets and as a result our sales growth and operating profits from our international operations may be adversely affected further international markets are increasingly being affected by economic pressure to contain reimbursement levels and healthcare costs and certain international markets may also be impacted by foreign government efforts to understand healthcare practices and pricing in other countries which could result in increased pricing transparency across geographies and pressure to harmonize reimbursement and ultimately reduce the selling prices of our products most international jurisdictions have regulatory approval and periodic renewal requirements for medical devices and countries that previously did not have regulatory requirements for medical devices may adopt such requirements we must comply with these requirements in order to market our products in these jurisdictions in addition the trend in countries around the world toward more stringent regulatory requirements for product clearance changing reimbursement models and more rigorous inspection and enforcement activities has generally caused or may cause us and other medical device manufacturers to experience more uncertainty delay risk and expense we expect the international regulatory environment will continue to evolve which could impact our ability to obtain approvals for our products in those jurisdictions which may have a material impact on our business20table of contentsfurther any significant changes in the competitive political legal regulatory reimbursement or economic environment where we conduct international operations may have a material impact on our business financial condition or results of operations if we are unable to manage our debt levels maintain investment grade credit ratings at the three ratings agencies or experience a disruption in our cash flows it could have an adverse effect on our cost of borrowing financial condition or results of operationsas part of our strategy to maximize stockholder value we use financial leverage to reduce our cost of capital our outstanding debt balance was at 4256 billion as of december 31 2012 and 4261 billion as of december 31 2011 in february 2012 moodys investors service upgraded our corporate credit rating to baa3 an investmentgrade rating and in july 2011 fitch ratings upgraded our corporate credit rating to bbb an investmentgrade rating in addition standard amp poors ratings services has maintained an investmentgrade corporate credit rating for us since 2009 we believe these ratings reflect the strength of our product portfolio and cash flows the reduction of our debt and our improved financial fundamentals our inability to maintain investment grade credit ratings at the three ratings agencies however could increase our cost of borrowing funds in the future delays in our product development and new product launches disruption in our cash flow or our ability to continue to effectively manage our debt levels could have an adverse effect on our cost of borrowing financial condition or results of operations in addition our credit facilities contain financial covenants that require us to maintain specified financial ratios if we are unable to satisfy these covenants we may be required to obtain waivers from our lenders and no assurance can be made that our lenders would grant such waivers on favorable terms or at all and we could be required to repay any borrowings on demandwe may record future goodwill impairment charges or other asset impairment charges related to one or more of our business or regional reporting units which could materially adversely impact our results of operations we test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist we assess goodwill for impairment at the reporting unit level and in evaluating the potential for impairment of goodwill we make assumptions regarding estimated revenue projections growth rates cash flows and discount rates as a result of revised estimates developed during our annual strategic planning process and analysis performed in conjunction with our annual goodwill impairment test in the second quarter of 2012 we concluded that the revenue growth rates projected for our europe middle east and africa emea reporting unit would be slightly lower than our previous estimates primarily driven by macroeconomic factors and our performance in the european market we concluded that the goodwill within the emea reporting unit was impaired and recorded a noncash 3602 billion 3579 billion aftertax charge in the second quarter of 2012 in the third quarter of 2012 we performed an interim goodwill impairment test and recorded a noncash 748 million pre and aftertax charge associated with our us cardiac rhythm management us crm reporting unit primarily driven by the reduction in the estimated size of the us crm market related adjustments to our business and other competitive factors which led to lower projected us crm results compared to prior forecasts we continue to identify three reporting units with goodwill that is at higher risk of potential failure of the first step of the goodwill impairment test in future reporting periods these reporting units include our us crm reporting unit which holds 216 million of remaining allocated goodwill our us cardiovascular reporting unit which holds 2380 billion of allocated goodwill and our us neuromodulation reporting unit which holds 1266 billion of allocated goodwill each as of december 31 2012 as of december 31 2012 the level of excess fair value over carrying value for these reporting units identified as being at higher risk with the exception of the us crm reporting unit whose carrying value continues to exceed its fair value was approximately seven  to 11 percent during the fourth quarter of 2012 the level of excess fair value over carrying value of our us cardiovascular reporting unit declined as a result of our performance declines in our market share due to competitive launches and continued average selling price declines in the us drugeluting stent des market as a result of continued competitive pressures and declines in procedural volumes based on the remaining book value of our us crm reporting unit following the goodwill impairment charge recorded during the third quarter of 2012 the carrying value of our us crm reporting unit continues to exceed its fair value due primarily to the value of amortizable intangible assets allocated to this reporting unit the remaining book value of the amortizable intangible assets allocated to the us crm reporting unit was approximately 3303 billion as of december 31 2012 in accordance with asc topic 350 we tested the amortizable intangible assets as of september 30 2012 in conjunction with the interim goodwill impairment test of our us crm reporting unit we performed the impairment analysis of the amortizable intangible assets on an undiscounted cash flow basis and concluded that these assets were not impaired however following the recent declines in our crm projections the recoverability of our crmrelated amortizable intangibles 4636 billion globally as of december 31 2012 are sensitive to changes in future cash flow assumptions and our crm business performance the 4636 billion of crmrelated amortizable intangibles are at higher risk of potential failure of the first step of the amortizable intangible recoverability test in future reporting periods an impairment of a material portion of our crmrelated amortizable intangibles carrying value would occur if the second step of the amortizable intangible test is required in a future reporting period21table of contentson a quarterly basis we monitor the key drivers of fair value for our reporting units to detect events or other changes that would warrant an interim impairment test of our goodwill we also monitor quarterly for events or other potential indicators of impairment that would warrant an interim impairment test of our intangible assets for each of these assets relatively small declines in the future performance and cash flows of the reporting unit or asset group changes in our reporting units or in the structure of our business as a result of future reorganizations or divestitures of assets or businesses or small changes in other key assumptions may result in the recognition of significant asset impairment charges which could have a material adverse impact on our results of operations failure to integrate acquired businesses into our operations successfully or effectively manage the separation activities relating to the divestiture of our neurovascular business could adversely affect our business financial condition and operating resultsas part of our strategy to realign our business portfolio we completed several acquisitions in 2012 and 2011 in our strategic growth areas and may pursue additional acquisitions in the future our integration of the operations of acquired businesses requires significant efforts including the coordination of information technologies research and development sales and marketing operations manufacturing and finance these efforts result in additional expenses and involve significant amounts of managements time some of the factors that could affect the success of our acquisitions include among others the strength of the acquired companies underlying technology and ability to execute results of clinical trials regulatory approvals and reimbursement levels of the acquired products and related procedures our ability to adequately fund acquired inprocess research and development projects and retain key employees and our ability to achieve synergies with our acquired companies such as increasing sales of our products achieving cost savings and effectively combining technologies to develop new products our failure to manage successfully and coordinate the growth of the combined acquired companies could have an adverse impact on our business and our future growth in addition we cannot be certain that the businesses we acquire will become profitable or remain so and if our acquisitions are not successful we may record related asset impairment charges in the futurein addition we closed the sale of our neurovascular business to stryker corporation in january 2011 the divestiture of this business continues to involve a number of risks including the diversion of management and employee attention and unexpected costs and delays including with respect to the transfer of certain manufacturing facilities that we expect to occur during 2013 in addition we are providing postclosing services through a transition services agreement and are also manufacturing and supplying products to stryker these transition services and supply arrangements are expected to end in 2013 our inability to effectively manage the separation activities and events could adversely affect our business financial condition and results of operationswe may not be successful in our strategy relating to future strategic acquisitions of investments in or alliances with other companies and businesses which have been a significant source of historical growth for us and will be key to our diversification into new markets and technologiesour strategic acquisitions investments and alliances are intended to further expand our ability to offer customers effective high quality medical devices that satisfy their interventional needs if we are unsuccessful in our acquisitions investments and alliances we may be unable to grow our business these acquisitions investments and alliances have been a significant source of our growth the success of our strategy relating to future acquisitions investments or alliances will depend on a number of factors includingour ability to identify suitable opportunities for acquisition investment or alliance if at allour ability to finance any future acquisition investment or alliance on terms acceptable to us if at allwhether we are able to complete an acquisition investment or alliance on terms that are satisfactory to us if at all andintellectual property and litigation related to newly acquired technologies any potential future acquisitions we consummate may be dilutive to our earnings and may require additional debt or equity financing depending on their size or naturewe may not realize the expected benefits from our restructuring and optimization initiatives our longterm expense reduction programs may result in an increase in shortterm expense and our efforts may lead to additional unintended consequencesin january 2013 we announced an expansion of our 2011 restructuring plan the expansion which is intended to further strengthen our operational effectiveness and efficiencies and support new investments which we expect to increase stockholder value key activities under the expansion include further initiatives to standardize and automate certain processes and activities relocate select administrative and functional activities rationalize organizational reporting structures expand shared services and align expenses to revenues within certain divisions and geographic regions in addition they include further efforts to streamline various corporate functions eliminate bureaucracy increase productivity and better align corporate resources to our key business strategies 22table of contentsfurther in february 2010 we announced a 2010 restructuring plan designed to strengthen and position us for longterm success key activities under the 2010 restructuring plan included the integration of our cardiovascular and crm businesses as well as the restructuring of certain other businesses and corporate functions the realignment of our international structure and the reprioritization and diversification of our product portfolio additionally in january 2009 we announced our plant network optimization program aimed at simplifying our plant network reducing our manufacturing costs and improving gross margins activities under our 2010 restructuring plan were completed in 2012 and our plant network optimization program was substantially completed in 2012 cost reduction initiatives under these collective plans include various cost and efficiency improvement measures which may include headcount reductions the relocation of certain resources as well as administrative and functional activities the closure of certain facilities the transfer of certain production lines the sale of certain nonstrategic assets and other efforts to streamline our business among other actions these measures could yield unintended consequences such as distraction of our management and employees business disruption attrition beyond our planned reduction in workforce and reduced employee productivity we may be unable to attract or retain key personnel attrition beyond our planned reduction in workforce or a material decrease in employee morale or productivity could negatively affect our business sales financial condition and results of operations in addition headcount reductions may subject us to the risk of litigation which could result in substantial cost moreover our expense reduction programs result in charges and expenses that impact our operating results we cannot guarantee that these measures or other expense reduction measures we take in the future will result in the expected cost savingscurrent domestic and international economic conditions could adversely affect our results of operationsthe continued global financial uncertainty including the european sovereign debt crisis has caused disruption in the financial markets including diminished liquidity and credit availability there can be no assurance that there will not be further deterioration in the global economy and the strength and timing of economic recovery remains uncertain we cannot predict to what extent the global economic slowdown and european sovereign debt crisis may negatively impact our average selling prices our net sales and profit margins procedural volumes and reimbursement rates from third party payors in addition current economic conditions may adversely affect our suppliers leading them to experience financial difficulties or to be unable to borrow money to fund their operations which could cause disruptions in our ability to produce our products further our customers may experience financial difficulties or be unable to borrow money to fund their operations which may adversely impact their ability or decision to purchase our products particularly capital equipment or to pay for our products they do purchase on a timely basis if at all for example our net sales have been adversely impacted by reductions in procedural volumes due to unemployment levels and other economic factors and these reductions may continue in addition the european sovereign debt crisis may impact our future ability to transfer receivables to third parties in certain southern european countries third parties such as banks offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt this could result in terminations of or changes to the costs or credit limits of our existing factoring programs such terminations or changes could have a negative impact on our cash flow and days sales outstanding within italy spain and portugal the number of days our receivables are outstanding has increased above historical levels while we are pursuing alternative factoring providers and financing arrangements to mitigate our credit exposure to receivables in this region there can be no assurances that we will be able to mitigate our risk of further reductions in cash flow in this region in addition conditions in the financial markets and other factors beyond our control may also adversely affect our ability to borrow money in the credit markets and to obtain financing for acquisitions or other general corporate and commercial purposes healthcare policy changes including recently passed healthcare reform legislation may have a material adverse effect on our business financial condition results of operations and cash flowspolitical economic and regulatory influences are subjecting the healthcare industry to potential fundamental changes that could substantially affect our results of operations government and private sector initiatives to limit the growth of healthcare costs including price regulation competitive pricing coverage and payment policies comparative effectiveness of therapies technology assessments and alternative payment models are continuing in many countries where we do business including the us these changes are causing the marketplace to put increased emphasis on the delivery of more costeffective treatments our strategic initiatives include measures to address this trend however there can be no assurance that any of our strategic measures will successfully address this trendthe patient protection and affordable care act and health care and education affordability reconciliation act of 2010 were enacted into law in the us in march 2010 as a us headquartered company with significant sales in the us this healthcare reform law will materially impact us certain provisions of the law will not be effective until 2014 and 2015 and there are many programs and requirements for which the details have not yet been fully established or consequences not fully understood however on june 28 2012 the united states supreme court upheld the constitutionality of the laws mandate requiring individuals to purchase health insurance but rejected specific provisions that would have penalized states that did not expand their current medicaid programs as a result of this ruling and other factors we expect implementation of most of the major provisions of the law to continue as currently enacted the law imposes on medical device manufacturers a 23 percent excise tax on us sales of 23table of contentsclass i ii and iii medical devices beginning in 2013 us net sales represented approximately 50 percent of our worldwide net sales in 2012 and therefore this tax burden may have a material negative impact on our results of operations and our cash flows other provisions of this law as currently enacted including comparative effectiveness research an independent payment advisory board and pilot programs to evaluate alternative payment methodologies could meaningfully change the way healthcare is developed and delivered and may adversely affect our business and results of operations further we cannot predict what healthcare programs and regulations will be ultimately implemented at the federal or state level or the effect of any future legislation or regulation in the us or internationally however any changes that lower reimbursements for our products reduce medical procedure volumes or increase cost containment pressures on us or other participants in the healthcare industry could adversely affect our business and results of operationshealthcare cost containment pressures and legislative or administrative reforms resulting in restrictive reimbursement practices of thirdparty payors or preferences for alternate therapies could decrease the demand for our products the prices which customers are willing to pay for those products and the number of procedures performed using our devices which could have an adverse effect on our business financial condition or results of operationsour products are purchased principally by hospitals physicians and other healthcare providers around the world that typically bill various thirdparty payors including governmental programs eg medicare and medicaid private insurance plans and managed care programs for the healthcare services provided to their patients the ability of customers to obtain appropriate reimbursement for their products and services from private and governmental thirdparty payors is critical to the success of medical technology companies the availability of reimbursement affects which products customers purchase and the prices they are willing to pay reimbursement varies from country to country and can significantly impact the acceptance of new products and services even if we develop a promising new product we may find limited demand for the product unless reimbursement approval is obtained from private and governmental thirdparty payors further legislative or administrative reforms to the reimbursement systems in the us japan or other international countries in a manner that significantly reduces reimbursement for procedures using our medical devices or denies coverage for those procedures including price regulation competitive pricing coverage and payment policies comparative effectiveness of therapies technology assessments and managedcare arrangements could have a material adverse effect on our business financial condition or results of operationsmajor thirdparty payors for hospital services in the us and abroad continue to work to contain healthcare costs the introduction of cost containment incentives combined with closer scrutiny of healthcare expenditures by both private health insurers and employers has resulted in increased discounts and contractual adjustments to hospital charges for services performed has led to increased physician employment by hospitals in the us and has shifted services between inpatient and outpatient settings initiatives to limit the increase of healthcare costs including price regulation are also underway in several countries in which we do business hospitals or physicians may respond to these costcontainment pressures by substituting lower cost products or other therapies for our productswe are subject to extensive and dynamic medical device regulation which may impede or hinder the approval or sale of our products and in some cases may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved productsour products marketing sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the fda pursuant to the federal food drug and cosmetic act fdc act by comparable agencies in foreign countries and by other regulatory agencies and governing bodies under the fdc act medical devices must receive fda clearance or approval before they can be commercially marketed in the us in the european union we are required to comply with applicable medical device directives including the medical devices directive and the active implantable medical devices directive and obtain ce mark certification in order to market medical devices the ce mark is applied following approval from an independent notified body or declaration of conformity the process of obtaining marketing approval or clearance from the fda or by comparable agencies in foreign countries for new products or with respect to enhancements or modifications to existing products couldtake a significant period of timerequire the expenditure of substantial resourcesinvolve rigorous preclinical and clinical testing as well as increased postmarket surveillancerequire changes to products andresult in limitations on the indicated uses of products24table of contents in addition exported devices are subject to the regulatory requirements of each country to which the device is exported some countries do not have medical device regulations but in most foreign countries medical devices are regulated frequently regulatory approval may first be obtained in a foreign country prior to application in the us due to differing regulatory requirements however other countries such as china for example require approval in the country of origin first most countries outside of the us require that product approvals be recertified on a regular basis generally every five years the recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance where recertification applications are required they must be approved in order to continue selling our products in those countries there can be no assurance that we will receive the required approvals for new products recertifications or modifications to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive postmarket study requirementsour global regulatory environment is becoming increasingly stringent and unpredictable which could increase the time cost and complexity of obtaining regulatory approvals for our products as well as the clinical and regulatory costs of supporting those approvals several countries that did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded on existing regulations certain regulators are exhibiting less flexibility and are requiring local data in addition to global data while harmonization of global regulations has been pursued requirements continue to differ significantly among countries we expect this global regulatory environment will continue to evolve which could impact our ability to obtain future approvals for our products or could increase the cost and time to obtain such approvals in the futurethe fda and other worldwide regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing practices recordkeeping reporting of adverse events labeling and promotional practices the fda can ban certain medical devices detain or seize adulterated or misbranded medical devices order repair replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health the fda may also enjoin and restrain a company for certain violations of the fdc act and the safe medical devices act pertaining to medical devices or initiate action for criminal prosecution of such violations international sales of medical devices manufactured in the us that are not approved by the fda for use in the us or that are banned or deviate from lawful performance standards are subject to fda export requirements regulations regarding the development manufacture and sale of medical devices are evolving and subject to future change we cannot predict what impact if any those changes might have on our business failure to comply with regulatory requirements could have a material adverse effect on our business financial condition and results of operations later discovery of previously unknown problems with a product or manufacturer could result in fines delays or suspensions of regulatory clearances seizures or recalls of products physician advisories or other field actions operating restrictions andor criminal prosecution we may also initiate field actions as a result of a failure to strictly comply with our internal quality policies the failure to receive product approval clearance on a timely basis suspensions of regulatory clearances seizures or recalls of products physician advisories or other field actions or the withdrawal of product approval by the fda or by comparable agencies in foreign countries could have a material adverse effect on our business financial condition or results of operationsour products including those of our cardiovascular businesses are continually subject to clinical trials conducted by us our competitors or other third parties the results of which may be unfavorable or perceived as unfavorable by the market and could have a material adverse effect on our business financial condition or results of operationsas a part of the regulatory process of obtaining marketing clearance for new products we conduct and participate in numerous clinical trials with a variety of study designs patient populations and trial endpoints unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us by our competitors or by third parties or the markets perception of this clinical data may adversely impact our ability to obtain product approvals our position in and share of the markets in which we participate and our business financial condition results of operations or future prospectsour future growth is dependent upon the development of new products which requires significant research and development clinical trials and regulatory approvals all of which are very expensive and timeconsuming and may not result in commercially viable productsin order to develop new products and improve current product offerings we focus our research and development programs largely on the development of nextgeneration and novel technology offerings across multiple programs and businesses if we are unable to develop and launch products as anticipated our ability to maintain or expand our market position in the markets in which we participate may be materially adversely impacted further we are continuing to investigate and have completed several acquisitions involving opportunities to further expand our presence in and diversify into priority growth areas expanding our focus beyond our current businesses is expensive and timeconsuming further there can be no assurance that we will be able to access these 25table of contentstechnologies on terms favorable to us or that these technologies will achieve commercial feasibility obtain regulatory approval or gain market acceptance a delay in the development or approval of these technologies or our decision to reduce our investments may adversely impact the contribution of these technologies to our future growththe medical device industry is experiencing greater scrutiny and regulation by governmental authorities and is the subject of numerous investigations often involving marketing and other business practices these investigations could result in the commencement of civil and criminal proceedings substantial fines penalties and administrative remedies divert the attention of our management impose administrative costs and have an adverse effect on our financial condition results of operations and liquidity and may lead to greater governmental regulation in the futurethe medical devices we design develop manufacture and market are subject to rigorous regulation by the fda and numerous other federal state and foreign governmental authorities these authorities have been increasing their scrutiny of our industry we have received subpoenas and other requests for information from congress and other state and federal governmental agencies including among others the us department of justice doj the office of inspector general of the department of health and human services hhs and the department of defense we have also received subpoenas and other requests for information from comparable international governmental agencies these investigations relate primarily to financial arrangements with healthcare providers regulatory compliance and product promotional practices we have cooperated with these investigations and responded to these requests and expect to continue to do so in the future we cannot predict when the investigations will be resolved the outcome of these investigations or their impact on us and cooperation may involve significant costs including document production costs an adverse outcome in one or more of these investigations could include the commencement of civil and criminal proceedings substantial fines penalties and administrative remedies including exclusion from government reimbursement programs entry into corporate integrity agreements cias with governmental agencies and amendments to existing cias in addition resolution of any of these matters could involve the imposition of additional and costly compliance obligations for example in 2009 we entered into a civil settlement with the doj regarding the dojs investigation relating to certain postmarket surveys conducted by guidant corporation before we acquired guidant in 2006 as part of the settlement we entered into a cia with the office of inspector general for hhs the cia requires enhancements to certain compliance procedures related to financial arrangements with healthcare providers the obligations imposed upon us by the cia and cooperation with ongoing investigations involve employee resource costs and diversion of employee focus we may incur additional future costs to fulfill the obligations imposed upon us by the cia further the cia and if any of the ongoing investigations continue over a long period of time could further divert the attention of management from the daytoday operations of our business and impose significant additional administrative burdens on us these potential consequences as well as any adverse outcome from these investigations could have a material adverse effect on our financial condition results of operations and liquidityin addition certain state governments including that of massachusetts where we are headquartered and the federal government have enacted legislation aimed at increasing transparency of our interactions with healthcare providers as a result we are required by law to disclose payments and other transfers for value to healthcare providers licensed by certain states and starting with payments or other transfers of value made on or after august 1 2013 to all us physicians and us teaching hospitals at the federal level any failure to comply with these legal and regulatory requirements could impact our business in addition we have and may continue to devote substantial additional time and financial resources to further develop and implement enhanced structure policies systems and processes to comply with enhanced legal and regulatory requirements which may also impact our businessfurther supreme court case law has clarified that the fdas authority over medical devices preempts certain state tort laws but recently federal appeals courts have determined that some state tort law claims remain and legislation has been introduced at the federal level to allow state intervention all of which could lead to increased and inconsistent regulation at the state levelchanges in tax laws unfavorable resolution of tax contingencies or exposure to additional income tax liabilities could have a material impact on our financial condition results of operations andor liquidity we are subject to income taxes as well as nonincome based taxes in both the us and various foreign jurisdictions we are subject to ongoing tax audits in various jurisdictions tax authorities may disagree with certain positions we have taken and assess additional taxes we regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision and have established contingency reserves for material known tax exposures including potential tax audit adjustments related to transfer pricing methodology disputes we have received notices of deficiency from the irs reflecting proposed audit adjustments for guidant corporation for its 2001 through 2006 tax years and boston scientific corporation for its 2006 and 2007 tax years we have filed or will timely file petitions with the us tax court contesting the notices of deficiency for the tax years in challenge there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these audits could have a material impact on our results of operations or financial condition additionally changes in tax laws or tax rulings could materially impact our effective tax rate for example new legislation imposes on medical device 26table of contentsmanufacturers a 23 percent excise tax on us sales of class i ii and iii medical devices beginning in january 2013 proposals for fundamental us corporate tax reform if enacted could have a significant adverse impact on our future results of operations we may not effectively be able to protect our intellectual property or other sensitive company data which could have a material adverse effect on our business financial condition or results of operationsthe medical device market in which we primarily participate is largely technology driven physician customers particularly in interventional cardiology have historically moved quickly to new products and new technologies as a result intellectual property rights particularly patents and trade secrets play a significant role in product development and differentiation however intellectual property litigation is inherently complex and unpredictable and appellate courts can overturn lower court patent decisions furthermore as our business increasingly relies on technology systems and infrastructure our intellectual property other proprietary technology and other sensitive company data is potentially vulnerable to loss damage or misappropriationcompeting parties in our industry frequently file multiple suits to leverage patent portfolios across product lines technologies and geographies and to balance risk and exposure between the parties in some cases several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices these forces frequently drive settlement not only of individual cases but also of a series of pending and potentially related and unrelated cases in addition although monetary and injunctive relief is typically sought remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal accordingly the outcomes of individual cases are difficult to time predict or quantify and are often dependent upon the outcomes of other cases in other geographiesseveral third parties have asserted that our current and former product offerings infringe patents owned or licensed by them we have similarly asserted that products sold by our competitors infringe patents owned or licensed by us adverse outcomes in one or more of the proceedings against us could limit our ability to sell certain products in certain jurisdictions or reduce our operating margin on the sale of these products and could have a material adverse effect on our financial condition results of operations or liquiditypatents and other proprietary rights are and will continue to be essential to our business and our ability to compete effectively with other companies will be dependent upon the proprietary nature of our technologies we rely upon trade secrets knowhow continuing technological innovations strategic alliances and licensing opportunities to develop maintain and strengthen our competitive position we pursue a policy of generally obtaining patent protection in both the us and abroad for patentable subject matter in our proprietary devices and attempt to review thirdparty patents and patent applications to the extent publicly available in order to develop an effective patent strategy avoid infringement of thirdparty patents identify licensing opportunities and monitor the patent claims of others we currently own numerous us and foreign patents and have numerous patent applications pending we also are party to various license agreements pursuant to which patent rights have been obtained or granted in consideration for cash crosslicensing rights or royalty payments no assurance can be made that any pending or future patent applications will result in the issuance of patents that any current or future patents issued to or licensed by us will not be challenged or circumvented by our competitors or that our patents will not be found invalid in addition we may have to take legal action in the future to protect our patents trade secrets or knowhow or to assert them against claimed infringement by others any legal action of that type could be costly and time consuming and no assurances can be made that any lawsuit will be successful we are generally involved as both a plaintiff and a defendant in a number of patent infringement and other intellectual propertyrelated actions the invalidation of key patents or proprietary rights that we own or an unsuccessful outcome in lawsuits to protect our intellectual property could have a material adverse effect on our business financial condition or results of operationsin addition the laws of certain countries in which we market and plan on manufacturing in the near future some of our products do not protect our intellectual property rights to the same extent as the laws of the united states if we are unable to protect our intellectual property in these countries it could have a material adverse effect on our business financial condition or results of operationsfurthermore our intellectual property other proprietary technology and other sensitive company data is potentially vulnerable to loss damage or misappropriation from system malfunction computer viruses unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events while we have invested to protect our intellectual property and other data and continue to work diligently in this area there can be no assurance that our precautionary measures will prevent breakdowns breaches cyberattacks or other events such events could have a material adverse effect on our reputation business financial condition or results of operations27table of contentspending and future intellectual property litigation could be costly and disruptive to uswe operate in an industry that is susceptible to significant intellectual property litigation and in recent years it has been common for companies in the medical device field to aggressively challenge the patent rights of other companies in order to prevent the marketing of new devices we are currently the subject of various patent litigation proceedings and other proceedings described in more detail under item 3 legal proceedings and note k commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual report intellectual property litigation is expensive complex and lengthy and its outcome is difficult to predict adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins financial condition results of operation or liquidity pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel in the event that our right to market any of our products is successfully challenged we may be required to obtain a license on terms which may not be favorable to us if at all if we fail to obtain a required license or are unable to design around a patent our business financial condition or results of operations could be materially adversely affectedpending and future product liability claims and other litigation including private securities litigation shareholder derivative suits and contract litigation may adversely affect our business reputation and ability to attract and retain customersthe design manufacture and marketing of medical devices of the types that we produce entail an inherent risk of product liability claims many of the medical devices that we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely a number of factors could result in an unsafe condition or injury to or death of a patient with respect to these or other products that we manufacture or sell including physician technique and experience in performing the surgical procedure component failures manufacturing flaws design defects or inadequate disclosure of productrelated risks or productrelated information these factors could result in product liability claims a recall of one or more of our products or a safety alert relating to one or more of our products product liability claims may be brought by individuals or by groups seeking to represent a class we are currently the subject of product liability litigation proceedings and other proceedings described in more detail under item 3 legal proceedings and note k commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual report the outcome of litigation particularly class action lawsuits is difficult to assess or quantify plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts including not only actual damages but also punitive damages the magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time in addition the cost to defend against any future litigation may be significant further we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims and adverse decisions product liability claims securities and commercial litigation and other litigation in the future regardless of the outcome could have a material adverse effect on our financial condition results of operations or liquidityany failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business financial condition and results of operationsas a medical device manufacturer we are required to register with the fda and are subject to periodic inspection by the fda for compliance with its quality system regulation requirements which require manufacturers of medical devices to adhere to certain regulations including testing quality control and documentation procedures in addition the federal medical device reporting regulations require us to provide information to the fda whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or if a malfunction were to occur could cause or contribute to a death or serious injury compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the fda which may result in observations on form 483 and in some cases warning letters that require corrective action in the european community we are required to maintain certain international standards organization iso certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications if we or our manufacturers fail to adhere to quality system regulations or iso requirements this could delay production of our products and lead to fines difficulties in obtaining regulatory clearances recalls enforcement actions including injunctive relief or consent decrees or other consequences which could in turn have a material adverse effect on our financial condition or results of operations28table of contentsinterruption of our manufacturing operations could adversely affect our results of operations and financial conditionour products are designed and manufactured in technology centers around the world either by us or third parties in most cases the manufacturing of our products is concentrated in one or a few locations factors such as a failure to follow specific internal protocols and procedures equipment malfunction environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products in the event of an interruption in manufacturing we may be unable to quickly move to alternate means of producing affected products or to meet customer demand in some instances for example if the interruption is a result of a failure to follow regulatory protocols and procedures we may experience delays in resuming production of affected products due primarily to needs for regulatory approvals as a result we may experience loss of market share which we may be unable to recapture and harm to our reputation which could adversely affect our results of operations and financial conditionwe rely on external manufacturers to supply us with certain materials components and products any disruption in our sources of supply or the price of inventory supplied to us could adversely impact our production efforts and could materially adversely affect our business financial condition or results of operationswe purchase many of the materials and components used in manufacturing our products some of which are custom made from thirdparty vendors certain supplies are purchased from singlesources due to quality considerations expertise costs or constraints resulting from regulatory requirements in the event of a disruption in supply we may not be able to establish additional or replacement suppliers for certain components materials or products in a timely manner largely due to the complex nature of our and many of our suppliers manufacturing processes in addition our products require sterilization prior to sale and we rely on a mix of internal resources and thirdparty vendors to perform this service production issues including capacity constraint the inability to sterilize our products quality issues affecting us or our suppliers an inability to develop and validate alternative sources if required or a significant increase in the price of materials or components could adversely affect our results of operations and financial conditionour share price will fluctuate and accordingly the value of an investment in our common stock may also fluctuatestock markets in general and our common stock in particular have experienced significant price and volume volatility over recent years the market price and trading volume of our common stock may continue to be subject to significant fluctuations due not only to general stock market conditions but also to variability in the prevailing sentiment regarding our operations or business prospects as well as among other things changing investment priorities of our shareholders if we are unable to attract retain and focus key personnel it could have an adverse effect on our business financial condition and results from operations  we constantly monitor the dynamics of the economy the healthcare industry and the markets in which we compete and we continue to assess opportunities to improve operational effectiveness and better align expenses with revenues while preserving our ability to make needed investments research and development projects capital and our people that we believe are essential to our longterm success in our industry there is substantial competition for key personnel in the regions in which we operate and we may face increased competition for such employees particularly in emerging markets as the trend toward globalization continues if we are unable to attract key personnel in a timely manner including key sales and other personnel who have critical industry experience and relationships in the regions in which we operate including in emerging markets such as brazil russia india and china it may have an adverse effect on our business and our ability to drive growth including through execution of our strategic initiatives furthermore some of the key personnel for whom we compete have postemployment arrangements with their current or former employer that may impact our ability to hire them or expose us and them to claims in addition if we are unable to retain and focus our existing key personnel it may have an adverse effect on our business financial condition and results from operations moreover we recently completed changes in our senior management structure which may lead to inefficiencies and have an adverse effect on our business and results of operations29table of contentsitem 1b unresolved staff commentsnoneitem 2 propertiesour world headquarters are located in natick massachusetts with additional support provided from regional headquarters located in singapore and paris france on november 8 2012 we announced that we are consolidating our natick massachusetts headquarters into our marlborough massachusetts location where we expect to establish a new global headquarters campus as of december 31 2012 our principal manufacturing and technology centers were located in minnesota california and indiana within the us as well as internationally in ireland costa rica and puerto rico our products are distributed worldwide from customer fulfillment centers in massachusetts the netherlands and japan as of december 31 2012 we maintained 12 major manufacturing facilities including six in the us three in ireland two in costa rica and one in puerto rico as well as various distribution and technology centers around the world many of these facilities produce and manufacture products for more than one of our divisions and include research facilities the following is a summary of our facilities as of december 31 2012 in approximate square feet  owned leased totalus 4739000 1329000 6068000international 1512000 1227000 2739000  6251000 2556000 8807000we regularly evaluate the condition and capacity of our facilities to ensure they are suitable for the development manufacturing and marketing of our products and provide adequate capacity for current and expected future needsitem 3 legal proceedingssee note k  commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual report and incorporated herein by referenceitem 4 mine safety disclosuresnone30table of contentspart iiitem 5 market for registrants common equity related stockholder matters and issuer purchases of equity securitiesmarket informationour common stock is traded on the new york stock exchange nyse under the symbol bsx the following table provides the market range for the closing price of our common stock for each of the last eight quarters based on reported sales prices on the nyse2012 high lowfirst quarter 636 530second quarter 631 551third quarter 582 497fourth quarter 582 507     2011    first quarter 778 685second quarter 779 657third quarter 728 562fourth quarter 590 509holdersthe closing price of our common stock on february 15 2013 was 754 as of february 15 2013 there were 14707 holders of record of our common stockdividendswe did not pay a cash dividend in 2012 or 2011 we currently do not intend to pay dividends and intend to retain all of our earnings to invest in the continued growth of our business and return value to shareholders by buying back shares of our common stock pursuant to our share repurchase authorizations we may consider declaring and paying a dividend in the future however there can be no assurance that we will do sosecurities authorized for issuance under equity compensation plansplease see item 12 security ownership of certain beneficial owners and management and related stockholder matters under part iii of this annual report for information on where to find information required by item 201d of regulation sk31table of contentspurchases of equity securities by the issuer and affiliated purchasesduring 2012 we used 600 million of cash generated from operations to repurchase approximately 105 million shares of our common stock pursuant to our share repurchase authorizations and in 2011 we used 492 million of cash generated from operations to repurchase approximately 82 million shares of our common stock pursuant to our share repurchase authorizations discussed in note l  stockholders equity to our 2012 consolidated financial statements contained in item 8 of this annual reportthe following table provides information with respect to purchases by boston scientific corporation of equity securities that are registered by us pursuant to section 12 of the securities exchange act of 1934 during the fourth quarter of 2012periodtotal number of shares purchasedaverage price paid per sharetotal number of shares purchased as part of publicly announced plans or programs approximate dollar value of shares that may yet be purchased under the plans or programs 100112  103112 110112  1130121793791555517937915 120112  123112  total1793791555517937915119551196      on july 28 2011 we announced that our board of directors had approved a program authorizing the repurchase of up to 10 billion of our common stock and reapproved approximately 37 million shares remaining under our previous share repurchase program the approximate aggregate dollar value of the remaining shares that may yet be purchased under the plans and programs in the table above was calculated using a stock price of 573 for the approximately 21 million shares authorized under our previous share repurchase program which was the closing stock price of our common stock on december 31 2012 as reported on the new york stock exchange as of december 31 2012 we had no remaining authorization available under our 2011 share repurchase programon january 25 2013 our board of directors approved a new program authorizing the repurchase up to 10 billion of our common stocksale of unregistered securitiesduring the three years ended december 31 2012 fewer than 20 employees purchased approximately 3150 shares of our common stock the issuance of such shares was pursuant to an exemption from the registration requirements of the securities act of 1933 as amended securities act pursuant to section 42 of the securities act32table of contentsstock performance graphthe graph below compares the fiveyear total return to stockholders on our common stock with the return of the standard amp poors sampp 500 stock index and the sampp health care equipment index the graph assumes 100 was invested in our common stock and in each of the named indices on december 31 2007 and that all dividends were reinvested33table of contentsitem 6 selected financial datafiveyear selected financial datain millions except per share dataoperating datayear ended december 31 2012 2011 2010 2009 2008net sales 7249 7622 7806 8188 8050gross profit 4900 4963 5207 5612 5581total operating expenses 8768 4059 5863 6506 7086operating income loss 3868 904 656 894 1505income loss before income taxes 4107 642 1063 1308 2031net income loss 4068 441 1065 1025 2036net income loss per common share          basic 289 029 070 068 136assuming dilution 289 029 070 068 136balance sheet dataas of december 31 2012 2011 2010 2009 2008cash cash equivalents and marketable securities 207 267 213 864 1641working capital 1 1250 1298 1006 1577 2219total assets 17154 21290 22128 25177 27139borrowings longterm and shortterm 4256 4261 5438 5918 6745stockholders equity 6870 11353 11296 12301 13174book value per common share 507 784 743 814 8771 in 2010 we reclassified certain assets to the assets held for sale caption in our consolidated balance sheets these assets are labeled as current in our 2010 consolidated balance sheet to give effect to the short term nature of those assets that were divested in the first quarter of 2011 in connection with the sale of our neurovascular business and other assets that were expected to be sold in 2011 we reclassified 2009 balances for comparative purposes in the working capital metric above we have not restated working capital for these items in years prior to 2009 see also note c  divestitures and assets held for sale to our 2012 consolidated financial statements included in item 8 of this annual report34table of contentsitem 7 managements discussion and analysis of financial condition and results of operationsthe following discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying notes included in item 8 of this annual reportexecutive summaryfinancial highlights and trendsin 2012 we generated net sales of 7249 billion as compared to 7622 billion in 2011 a decrease of 373 million or five percent our net sales were unfavorably impacted by 123 million from foreign currency fluctuations in 2012 as compared to 2011 and sales related to our divested neurovascular business declined 19 million in 2012 refer to note c  divestitures and assets held for sale included in item 8 of this annual report for additional information on the neurovascular divestiture excluding the impact of foreign currency and sales from divested businesses our net sales decreased 232 million or three percent as compared to the prior year this decrease was due primarily to constant currency declines in net sales from our interventional cardiology business of 266 million and cardiac rhythm management crm business of 145 million these decreases were partially offset by constant currency increases in net sales from our endoscopy business of 84 million from our peripheral interventions business of 56 million and net sales from our neuromodulation business of 32 million as compared to the same period in the prior year1 refer to the business and market overview section for further discussion of our sales resultsour reported net loss in 2012 was 4068 billion or 289 per share our reported results for 2012 included goodwill and intangible asset impairment charges acquisition and divestiturerelated net credits restructuring and litigationrelated charges discrete tax items and amortization expense aftertax of 5001 billion or 355 per share excluding these items net income for 2012 was 933 million or 066 per share1our reported net income in 2011 was 441 million or 029 per share our reported results for 2011 included goodwill and intangible asset impairment charges acquisition divestiture restructuring and litigationrelated charges and credits discrete tax items and amortization expense aftertax of 577 million or 038 per share excluding these items net income for 2011 was 1018 billion or 067 per share1  the following is a reconciliation of our results of operations prepared in accordance with us gaap to those adjusted results considered by management refer to results of operations for a discussion of each reconciling item  year ended december 31 2012    tax   impact perin millions except per share data pretax impact aftertax sharegaap results 4107 39 4068 289nongaap adjustments        goodwill and other intangible asset impairment charges 4492 46 4446 315acquisition and divestiturerelated net credits 50 14 36 002restructuringrelated charges 160 38 122 009litigationrelated charges 192 74 118 008discrete tax items   2 2 amortization expense 395 46 349 025adjusted results 1082 149 933 0661 sales growth rates that exclude the impact of changes in foreign currency exchange rates and net income and net income per share excluding certain items required by gaap are not prepared in accordance with generally accepted accounting principles in the united states us gaap refer to additional information in this item 7 for a discussion of managements use of these nongaap financial measures35table of contents  year ended december 31 2011    tax   impact perin millions except per share data pretax impact aftertax sharegaap results 642 201 441 029nongaap adjustments        goodwill and other intangible asset impairment charges 718 5 713 047acquisition and divestiturerelated net credits 798 229 569 037restructuringrelated charges 129 39 90 006litigationrelated charges 48 18 30 002discrete tax items   27 27 002amortization expense 421 81 340 022adjusted results 1160 142 1018 0671 sales growth rates that exclude the impact of changes in foreign currency exchange rates and net income and net income per share excluding certain items required by gaap are not prepared in accordance with generally accepted accounting principles in the united states us gaap refer to additional information in this item 7 for a discussion of managements use of these nongaap financial measurescash generated by operating activities was 1260 billion in 2012 as compared to 1008 billion in 2011 our operating cash flows in 2011 included approximately 300 million of onetime litigationrelated payments our cash generated from operations continues to be a significant source of funds for investing in our growth and returning value to shareholders by buying back shares of our common stock pursuant to our share repurchase authorizations discussed in note l  stockholders equity to our 2012 consolidated financial statements contained in item 8 of this annual report during 2012 we used approximately 600 million of cash generated from operations to repurchase approximately 105 million shares of our common stock as compared to 2011 in which approximately 492 million of cash generated from operations was used to repurchase approximately 82 million shares of our common stock as of december 31 2012 we had total debt of 4256 billion cash and cash equivalents of 207 million and working capital of 1250 billion in february 2012 moodys investors service upgraded our corporate credit rating to baa3 an investmentgrade rating with a stable outlook we now hold investmentgrade ratings with all three major creditrating agencies we believe our investment grade credit profile reflects the size and diversity of our product portfolio our leading share position in several of our served markets our strong cash flow our solid financial fundamentals and our financial strategy36table of contentsbusiness and market overviewendoscopyour endoscopy division develops and manufactures devices to treat a variety of medical conditions including diseases of the digestive and pulmonary systems our worldwide net sales of these products were 1252 billion in 2012 as compared to 1187 billion in the 2011 an increase of 65 million or five percent us net sales of our endoscopy products were 605 million in 2012 as compared to 562 million in the prior year our international net sales were 647 million in 2012 as compared to 625 million in 2011 and included a 19 million negative impact from changes in foreign currency exchange rates excluding the impact of changes in foreign currency exchange rates our worldwide endoscopy net sales increased 84 million or seven percent in 2012 as compared to 2011 this performance was primarily the result of growth across several of our key product franchises including our biopsy business our biliary device franchise driven by continued growth in our expect endoscopic ultrasound aspiration needle our metal stent franchise driven by our industryleading wallflex product family which now includes our wallflex biliary transhepatic stent system for treatment of biliary strictures launched in the first quarter of 2012 and our hemostasis franchise on the continued adoption and utilization of our resolution clip for gastrointestinal bleeding in october 2010 we completed our acquisition of asthmatx inc through asthmatx we design manufacture and market a lessinvasive catheterbased bronchial thermoplasty procedure for the treatment of severe persistent asthma the alair bronchial thermoplasty system developed by asthmatx has both conformite europeenne ce mark and us food and drug administration fda approval and is the first devicebased asthma treatment approved by the fda in the third quarter of 2012 the american medical association ama current procedural terminology cpt editorial panel assigned category i cpt codes specifically for bronchial thermoplasty beginning january 1 2013 the category i cpt procedure codes are recognized by all public and private health insurance payers in the united states which will allow physicians and hospitals to seek reimbursement for bronchial thermoplasty procedures we believe these codes will provide greater access to treatment for patients with poorly controlled severe asthma help facilitate claims processing and help private payers approve coverage for this form of treatment we continue to focus on driving commercialization and increased awareness of the alair system we expect this technology to strengthen our existing offering of pulmonary devices and contribute to future sales growth and diversification of the endoscopy business during 2012 we saw growth in our alair system product line with worldwide net sales of 11 million in 2012 as compared to approximately 4 million in 2011peripheral interventions piour pi product offerings include stents balloon catheters wires peripheral embolization devices and other devices used to diagnose and treat peripheral vascular disease our worldwide net sales of these products were 774 million in 2012 as compared to 731 million in 2011 an increase of 43 million or six percent our us net sales of these products were 340 million in 2012 as compared to 310 million in 2011 our international net sales were 434 million in 2012 as compared to 421 million in 2011 and included a 13 million negative impact from changes in foreign currency exchange rates excluding the impact of changes in foreign currency exchange rates our worldwide pi net sales increased 56 million or eight percent in 2012 as compared to 2011 the yearoveryear increase in worldwide pi net sales was primarily driven by growth in our core pi franchise as the result of new product launches in stents balloons and chronic total occlusions cto devices which we expect to continue to drive our future growth we also recently announced the acquisition of vessix vascular inc a developer of catheterbased renal denervation systems for the treatment of uncontrolled hypertension through the acquisition of vessix we added a second generation highly differentiated technology to our hypertension strategy and we believe this technology will accelerate our entry into the hypertension market we expect to launch this technology commercially in europe and certain other international markets in 2013 we believe that offering these devices will enhance our position in assisting physicians in addressing the challenges of treating complex peripheral lesionsneuromodulationour neuromodulation business offers the precision spinal cord stimulation scs system used for the management of chronic pain our worldwide net sales of neuromodulation products were 367 million in 2012 as compared to 336 million in 2011 an increase of 31 million or nine percent our us net sales of neuromodulation products were 342 million in 2012 as compared to 317 million in the prior year and our international net sales of these products were 25 million in 2012 and 19 million in 2011 excluding the negative impact of changes in foreign currency exchange rates of 1 million our neuromodulation worldwide net sales in 2012 grew nine percent as compared to the prior year the increase was primarily driven by us net sales as a result of strong sales of our infinion 16 percutaneous lead which received fda approval in the fourth quarter of 2011 and continued focus on commercial execution during the third quarter of 2012 we received ce mark approval for use of our vercise deep brain stimulation dbs system for the treatment of parkinsons disease in europe and we expect to begin our us pivotal study for the treatment of parkinsons disease in 2013 we believe we have an exciting opportunity in dbs with our ability to customize 37table of contentsthe field designed to precisely stimulate the target without extraneous stimulation of adjacent areas that may cause unwanted side effects in addition during the fourth quarter of 2012 we received ce mark approval for the precision spectra spinal cord stimulator scs system the precision spectra system is the worlds first and only scs system with 32 contacts and 32 dedicated power sources and is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain urologywomens healthour urologywomens health division develops and manufactures devices to treat various urological and gynecological disorders our worldwide net sales of these products were 500 million in 2012 as compared to 498 million in 2011 an increase of approximately 2 million or less than one percent our us net sales were 355 million in 2012 as compared to 362 million in 2011 our international net sales were 145 million in 2012 as compared to 136 million for the prior year and included a 3 million negative impact from changes in foreign currency exchange rates excluding the impact of changes in foreign currency exchange rates our worldwide urologywomens health net sales increased 5 million or one percent in 2012 as compared to 2011our urology business grew approximately five percent on strong sales execution and continued commercial expansion however our womens health business declined 11 percent primarily due to continued pressures on elective procedures and lower sales levels following the fda release of a public health notice update in july 2011 regarding complications related to the use of urogynecologic surgical mesh for pelvic organ prolapsedespite the recent performance of the urologywomens health division due primarily to the market contraction as a result of the 2011 fda release of a public health notice update we believe that our urologywomens health business has the opportunity for growth as a result of our pipeline of upcoming product launches and our plans to continue expanding the global footprint of this business electrophysiologyour electrophysiology business develops lessinvasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart our leading products include the blazer line of ablation catheters designed to deliver enhanced performance responsiveness and durability our blazer line includes our next generation blazer prime ablation catheter and our blazer openirrigated catheter launched in select european countries worldwide net sales of our electrophysiology products were 147 million in 2012 and 2011 our us net sales of these products were 108 million in 2012 as compared to 107 million in 2011 our international net sales of these products were 39 million in 2012 and 40 million in 2011 and included a negative impact from changes in foreign currency exchange rates of 2 million excluding the impact of changes in foreign currency exchange rates our worldwide electrophysiology net sales increased 2 million or one percent in 2012 as compared to 2011 additionally on october 9 2012 we acquired rhythmia medical inc a developer of nextgeneration mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures including atrial fibrillation and atrial flutter we believe that this acquisition as well as our other expected product launches will help to position us to competitively participate in the fastgrowing electrophysiology market in january 2013 the first patient was enrolled in the zero af clinical trial to evaluate the safety and effectiveness of the blazer openirrigated temperature ablation catheter in patients with symptomatic drug refractory paroxysmal atrial fibrillation the results of the zero af trial are expected to be used to support a fda regulatory submission for a paroxysmal atrial fibrillation indication the blazer openirrigated catheter is our first entry into the openirrigated catheter segment and is approved for use in ce mark countries and canada the blazer openirrigated catheter offers the total tip cooling design engineered to consistently cool the entire tip of the electrode during radiofrequency energy delivery to treat many heart rhythm disorders including paroxysmal atrial fibrillationcardiac rhythm managementour crm division develops manufactures and markets a variety of implantable devices including implantable cardioverter defibrillator icd systems and pacemaker systems that monitor the heart and deliver electricity to treat cardiac abnormalities worldwide net sales of our crm products of 1908 billion represented approximately 26 percent of our consolidated net sales for 2012 our worldwide crm net sales decreased 179 million or nine percent in 2012 as compared to the prior year our us crm net sales decreased 114 million or nine percent in 2012 as compared to 2011 our international crm net sales decreased 65 million or seven percent in 2012 as compared to 2011 and included a 34 million negative impact from changes in foreign currency exchange rates excluding the impact of changes in foreign currency exchange rates our 2012 worldwide crm net sales decreased 145 million or seven percent as compared to 2011 38table of contentsthe following are the components of our worldwide crm net sales  year ended year endedin millions december 31 2012 december 31 2011  us international total us international totalicd systems 858 521 1379 949 569 1518pacemaker systems 256 273 529 279 290 569crm products 1114 794 1908 1228 859 2087the reduction in our crm net sales during 2012 as compared to 2011 is primarily due to the impact of average selling price pressures driven by governmental competitive and other pricing pressures and lower procedural volumes as a result of continued contraction in the us icd market due to a variety of factors including physician reaction to study results published by the journal of the american medical association in prior years regarding evidencebased guidelines for icd implants us department of justice doj investigations into hospitals icd implant practices and the expansion of medicare recovery audits as well as ongoing physician alignment to hospitals in addition our sales levels related to replacement procedures were lower than the prior year due to historical product recalls and subsequent reductions in our denovo first time icd implants following these recalls however we believe that our us denovo icd share increased throughout 2012 as a result of our incepta and energen line of defibrillators launched in the fourth quarter of 2011 and our highlyreliable reliance lead platformin the first half of 2012 we launched our ingenio family of pacemaker systems in the us and emea and in july 2012 we received ce mark approval for use of our ingenio and advantio pacemakers in patients in need of a magnetic resonance imaging mri scan which we believe represents a significant advancement to our family of pacemaker devices in the second quarter of 2012 we received fda approval for our invive cardiac resynchronization therapy pacemakers crtps during the second quarter of 2012 we completed the acquisition of cameron health inc cameron cameron developed the worlds first and only commercially available subcutaneous implantable cardioverter defibrillator  the sicd system which we believe is a differentiated technology that will provide us the opportunity to both increase our market share in the existing icd market and expand that market over time the sicd system has received ce mark approval and is available in emea in september 2012 we received fda approval for the sicd system and commenced a limited commercial launch in the united states we believe these recent product developments will help to better position us within the crm market net sales from our crm products represent a significant source of our overall net sales therefore increases or decreases in our crm net sales could have a significant impact on our results of our consolidated operations variables that may impact the size of the crm market andor our share of that market include but are not limited tothe ongoing impact of physician alignment to hospitals government investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed and average selling pricesour ability to retain and attract key members of our crm sales force and other key crm personnelthe ability of crm manufacturers to maintain the trust and confidence of the implanting physician community the referring physician community and prospective patients in crm technologiesfuture product field actions or new physician advisories issued by us or our competitorsour ability to timely and successfully acquire or develop and launch new or nextgeneration competitive products and technologies worldwide in line with our commercialization strategies including the sicd systemnew product launches by our competitorsvariations in clinical results reliability or product performance of our and our competitors products anddelayed or limited regulatory approvals and unfavorable reimbursement policiesduring the third quarter of 2012 we recorded a goodwill impairment charge primarily driven by the reduction in the estimated size of the us crm market and related adjustments to our business and other competitive factors which led to lower projected us crm results compared to prior forecasts additionally during the second quarter of 2012 we recorded a goodwill impairment charge related to our emea business the emea goodwill impairment charge was primarily driven by our revised projections for revenue growth in emea which were slightly lower than our previous estimates which was primarily due to macroeconomic factors and our performance in the european market refer to results of operations for further details39table of contentsinterventional cardiology coronary stent systemswe offer innovative products in the coronary stent market to treat coronary artery disease we market our internallydeveloped and selfmanufactured promus element everolimuseluting stent platform in all major markets worldwide as well as our taxus paclitaxeleluting stent line including our thirdgeneration taxus element stent system beginning in the first quarter of 2013 we also received ce mark approval and launched our nextgeneration promus premier everolimuseluting platinum chromium coronary stent system in europe and other select geographies we are the only company in the industry to offer a twodrug platform strategy with our paclitaxeleluting and everolimuseluting stent system offerings and we offer a broad range of stent sizes during the fourth quarter of 2012 we received ce mark approval for the synergy everolimuseluting platinum chromium coronary stent system featuring an ultrathin abluminal outer bioabsorbable polymer coating the synergy stent is unique in that its proprietary polymer and everolimus drug coating dissipate by three months this innovation has the potential to improve postimplant vessel healing and will eliminate longterm polymer exposure a possible cause of late adverse events during the fourth quarter of 2012 we also enrolled the first patient in the evolve ii clinical trial which is designed to further assess the safety and effectiveness of the synergy stent system and support us fda and japanese regulatory approvals for this technologyworldwide net sales of our coronary stent systems with the inclusion of baremetal stent systems was 1363 billion or approximately 19 percent of our consolidated net sales in 2012 our worldwide net sales of these products decreased 257 million or 16 percent in 2012 as compared to 2011 excluding the impact of changes in foreign currency exchange rates which had a 33 million negative impact on our coronary stent system net sales in 2012 as compared to the prior year net sales of these products decreased 224 million or 14 percent our us net sales of drugeluting stent systems decreased 193 million or 26 percent in 2012 as compared to 2011 this decrease was primarily related to lower market share due to competitive launches in 2012 continued average selling price declines in the us drugeluting stent des market as a result of continued competitive pressures and declines in procedural volumes our international drugeluting stent system net sales decreased 39 million or five percent in 2012 as compared to the previous year excluding the impact of changes in foreign currency exchange rates our international drugeluting stent system net sales decreased 11 million or two percent due to continued lower market share related to competitive launches during 2012 we substantially completed the conversion of our us and international drugeluting stent system sales to our selfmanufactured promus element and taxus stent systems which has positively impacted our gross profit margins the following are the components of our worldwide coronary stent system sales  year ended year endedin millions december 31 2012 december 31 2011  us international total us international totaldrugeluting 557 720 1277 750 759 1509baremetal 24 62 86 32 79 111  581 782 1363 782 838 1620historically the worldwide coronary stent market has been dynamic and highly competitive with significant market share volatility in addition in the ordinary course of our business we conduct and participate in numerous clinical trials with a variety of study designs patient populations and trial end points unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us our competitors or third parties or the markets perception of these clinical data may adversely impact our position in and share of the drugeluting stent market and may contribute to increased volatility in the marketwe believe that we will continue to maintain a strong position within the worldwide drugeluting stent market for a variety of reasons includingthe performance benefits of our current and future technologythe strength of our pipeline of drugeluting stent products which has shown favorable results in clinical trials to datethe broad and consistent longterm results of our taxus clinical trials and the favorable results of promus element and taxus element ion stent system clinical trials to dateour overall position in the interventional medical device market and our experienced interventional cardiology sales forcethe strength of our clinical selling marketing and manufacturing capabilities andour increased presence and investment in rapidly growing emerging markets including brazil russia india and china40table of contentshowever a decline in net sales from our drugeluting stent systems could have a significant adverse impact on our operating results significant variables that may impact the size of the drugeluting stent market and our position within this market include but are not limited tothe impact of competitive pricing pressure on average selling prices of drugeluting stent systems available in the marketthe impact and outcomes of ongoing and future clinical results involving our or our competitors products including those trials sponsored by our competitors or perceived product performance of our or our competitors productsnew product launches by our competitorsour ability to timely and successfully launch new or nextgeneration products and technologies in line with our commercialization strategiesphysician and patient confidence in our current and nextgeneration technologychanges in the overall number of percutaneous coronary intervention procedures performed drugeluting stent penetration rates and the average number of stents used per proceduredelayed or limited regulatory approvals and unfavorable reimbursement policies andthe outcome of intellectual property litigationinterventional cardiology excluding coronary stent systemsin addition to coronary stent systems our interventional cardiology business markets balloon catheters rotational atherectomy systems guide wires guide catheters embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty ptca procedures as well as intravascular ultrasound ivus imaging systems our worldwide net sales of these products were 816 million in 2012 as compared to 875 million in 2011 a decrease of 59 million or seven percent our us net sales were 311 million in 2012 as compared to 342 million in 2011 our international net sales of these products were 505 million in 2012 as compared to 533 million in 2011 and included a 17 million unfavorable impact from changes in foreign currency exchange rates for 2012 as compared to the prior year excluding the impact of changes in foreign currency exchange rates interventional cardiology excluding coronary stent systems worldwide net sales decreased 42 million or five percent as compared to the prior year primarily due to competitive launches and pricing pressures in april 2012 we received ce mark approval for and launched our emerge ptca dilatation catheter in our emea region and we received fda clearance for this product in september 2012 the emerge catheter is a nextgeneration predilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary arteries in addition in october 2012 we completed the acquisition of bridgepoint medical inc a developer of proprietary catheterbased systems to treat coronary chronic total occlusions ctos through this acquisition we expect to augment our current portfolio of interventional cardiology products which we believe will enable us to be a singlesource supplier for complex percutaneous coronary intervention pci proceduresin january 2011 we completed the acquisition of sadra medical inc through our acquisition of sadra we are developing a fully repositionable and retrievable device for transcatheter aortic valve replacement tavr to treat patients with severe aortic stenosis the lotus valve system consists of a stentmounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve the lowprofile delivery system and introducer sheath are designed to enable accurate positioning repositioning and retrieval at any time prior to release of the aortic valve implant we believe tavr is one of the fastest growing medical device markets in april 2012 we completed enrollment in the reprise i clinical trial designed to evaluate the acute safety of the lotus valve system in october 2012 we enrolled the first patients in the reprise ii clinical trial to evaluate the safety and performance of the lotus valve system the results of the reprise ii trial are expected to be used to support ce mark and other international regulatory approvals which we anticipate receiving in the second half of 2013due to revised expectations of the required effort time and cost involved in completing sadras inprocess research and development projects and bringing the related products to market we recorded an intangible asset impairment charge in the second quarter of 2012 refer to results of operations for further details we continue to believe that the technology associated with the sadra acquisition represents a significant future opportunity for us in the structural heart market in march 2011 we completed the acquisition of atritech inc atritech developed a novel device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke the watchman left atrial appendage closure technology is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs and is approved for use in ce mark countries in august 2012 european regulators approved an expanded indication for the watchman 41table of contentsleft atrial appendage closure device the new indication offers patients with atrial fibrillation af and a contraindication to warfarin and the newer oral anticoagulants a new treatment option for stroke reduction we are integrating the operations of the atritech business and are leveraging expertise from both our electrophysiology and interventional cardiology divisions in the commercialization of the watchman device emerging marketsas part of our strategic imperatives to drive global expansion described in item 1 of this annual report we are seeking to grow net sales and market share by expanding our global presence in particular we are focusing our efforts and increasing our investment in certain countries whose economies and healthcare sectors are growing rapidly in order to maximize opportunities in those countries we significantly increased sales in brazil russia india and china and continued investments in infrastructure in those countries as well as others in 2011 and throughout 2012 as a result of these efforts during 2012 we experienced doubledigit sales growth in these markets as compared to 2011 we recently created a new asiapacific regional organization under new leadership to further increase our capabilities and strengthen our position in this fast growing region restructuring initiativeson an ongoing basis we monitor the dynamics of the economy the healthcare industry and the markets in which we compete and we continue to assess opportunities for improved operational effectiveness and efficiency and better alignment of expenses with revenues while preserving our ability to make the investments in research and development projects capital and our people that are essential to our longterm success as a result of these assessments we have undertaken various restructuring initiatives in order to enhance our growth potential and position us for longterm success these initiatives are described below and additional information can be found in results of operations and note h  restructuringrelated activities to our 2012 consolidated financial statements included in item 8 of this annual report2011 restructuring planon july 26 2011 our board of directors approved and we committed to a restructuring initiative the 2011 restructuring plan designed to strengthen operational effectiveness and efficiencies increase competitiveness and support new investments thereby increasing shareholder value the original estimate of the plan was a reduction of annual pretax operating expenses by approximately 225 million to 275 million exiting 2013 a substantial portion of which is expected to be reinvested in targeted areas necessary for future growth including strategic growth initiatives and emerging markets key activities under the plan include standardizing and automating certain processes and activities relocating select administrative and functional activities rationalizing organizational reporting structures leveraging preferred vendors and other efforts to eliminate inefficiency among these efforts we are expanding our ability to deliver bestinclass global shared services for certain functions and divisions at several locations in emerging markets this action is intended to enable us to grow our global commercial presence in key geographies and take advantage of many costreducing and productivityenhancing opportunities in addition we are undertaking efforts to streamline various corporate functions eliminate bureaucracy increase productivity and better align corporate resources to our key business strategies on january 25 2013 our board of directors approved and we committed to an expansion of our 2011 restructuring program the expansion the expansion is intended to further strengthen our operational effectiveness and efficiencies and support new investments which we expect to increase shareholder value we estimate that the expansion will reduce gross annual pretax operating expenses by approximately 100 million to 115 million exiting 2013 and that the total 2011 restructuring program including the expansion the total program will reduce gross annual pretax operating expenses by approximately 340 million to 375 million exiting 2013 we expect a substantial portion of the total program savings to be reinvested in targeted areas for future growth including strategic growth initiatives and emerging markets key activities under the expansion include further initiatives to standardize and automate certain processes and activities relocate select administrative and functional activities rationalize organizational reporting structures expand shared services and align expenses to revenues within certain divisions and geographic regions in addition they include further efforts to streamline various corporate functions eliminate bureaucracy increase productivity and better align corporate resources to our key business strategies key activities under the total program are expected to be substantially completed by the end of 20132010 restructuring planon february 6 2010 our board of directors approved and we committed to a series of management changes and restructuring initiatives the 2010 restructuring plan designed to focus our business drive innovation accelerate profitable revenue growth and increase both accountability and shareholder value key activities under the plan included the restructuring of certain of our businesses and corporate functions the realignment of our international structure to reduce our administrative costs and invest in expansion opportunities including significant investments in emerging markets and the reprioritization and diversification of 42table of contentsour product portfolio activities under the 2010 restructuring plan were initiated in the first quarter of 2010 and were completed by the end of 2012 and resulted in gross reductions in pretax operating expenses of approximately 250 million a portion of these savings were reinvested into customerfacing positions and other commercial resources and infrastructure plant network optimizationin january 2009 our board of directors approved and we committed to a plant network optimization program intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and by closing certain other facilities the program was a complement to our 2007 restructuring plan and was intended to improve overall gross profit margins the program has resulted in annualized runrate reductions of manufacturing costs of approximately 65 million exiting 2012 these savings are in addition to the 35 million of annual reductions of manufacturing costs from activities under our 2007 restructuring plan activities under the plant network optimization program were initiated in the first quarter of 2009 and were substantially completed during 2012neurovascular divestiturein january 2011 we closed the sale of our neurovascular business to stryker corporation for a purchase price of 15 billion in cash we received 1450 billion during 2011 10 million during 2012 and will receive an additional 40 million contingent upon the transfer or separation of certain manufacturing facilities which we expect will occur during 2013 we are providing transitional services through a transition services agreement and are also manufacturing and supplying products to stryker through a supply agreement these transition services and supply arrangements are expected to end in 2013 we recorded revenue of 122 million during 2012 related to this divested business as compared to 141 million during 2011 and 344 million of sales of neurovascular and other divested product lines in 2010 our sales related to divested businesses will continue to decline as the various transition services and supply agreements terminate in 2013 see results of operations and note c  divestitures and assets held for sale for additional informationhealthcare reformthe patient protection and affordable care act and health care and education affordability reconciliation act were enacted into law in the us in 2010 certain provisions of the law have yet to be implemented and there are many programs and requirements for which the details have not yet been fully established or consequences not yet fully understood therefore it is unclear what the full impact will be from the law the legislation imposes on medical device manufacturers a 23 percent excise tax on us sales of class i ii and iii medical devices beginning in january 2013 we intend to record this tax within our selling general and administrative expenses and expect that our excise tax liability for 2013 will be up to 80 million other provisions of this law including medicare provisions aimed at improving quality and decreasing costs comparative effectiveness research an independent payment advisory board and pilot programs to evaluate alternative payment methodologies could meaningfully change the way healthcare is developed and delivered and will place a significant emphasis on clinical and economic data to demonstrate efficacy and justify the economic benefits of technology purchases any changes that lower reimbursement for our products or reduce medical procedure volumes could adversely affect our business and results of operations further we cannot predict what healthcare programs and regulations will be ultimately implemented at the federal or state level or the effect of any future legislation or regulation in the us or internationally 43table of contentsresults of operationsnet salesas of december 31 2012 we had four reportable segments based on geographic regions the united states emea consisting of europe the middle east and africa japan and intercontinental consisting of our asia pacific and the americas operating segments which include the emerging markets of brazil china and india the reportable segments represent an aggregate of all operating divisions within each segment we manage our international operating segments on a constant currency basis and we manage market risk from currency exchange rate changes at the corporate level management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing regional and divisional revenue growth rates to facilitate an evaluation of current operating performance and comparison to past operating performance to calculate revenue growth rates that exclude the impact of changes in foreign currency exchange rates we convert current period and prior period net sales from local currency to us dollars using standard currency exchange rates the regional constant currency growth rates in the tables below can be recalculated from our net sales by reportable segment as presented in note o  segment reporting to our 2012 consolidated financial statements contained in item 8 of this annual report the following tables provide our worldwide net sales by region and the relative change on an as reported and constant currency basis we have restated regional net sales for 2011 and 2010 to exclude sales from our former neurovascular business which we sold to stryker corporation in january 2011 and present net sales from this business within divested businesses in the tables below net sales that exclude the impact of changes in foreign currency exchange rates and net sales from divested businesses are not financial measures prepared in accordance with us gaap and should not be considered in isolation from or as a replacement for the most directly comparable gaap financial measure refer to additional information of this item 7 for a further discussion of managements use of this nongaap financial measure    2012 versus 20112011 versus 2010 year endeddecember 31as reportedcurrencybasisconstantcurrencybasisas reportedcurrencybasisconstantcurrencybasisin millions201220112010  restatedrestated        united states3756401042156655emea1568172116629341japan9319518862272intercontinental872799699911149international3371347132473171subtotal core businesses7127748174625302divested businesses122141344na na na na worldwide7249762278065325 we have restated prior year regional detail to conform to current year presentation44table of contentsthe following tables provide our worldwide net sales by division and the relative change on an as reported and constant currency basis    2012 versus 20112011 versus 2010 year endeddecember 31as reportedcurrencybasisconstantcurrencybasisas reportedcurrencybasisconstantcurrencybasisin millions201220112010interventional cardiology217924952602131147cardiac rhythm management1908208721809747endoscopy12521187107957106peripheral interventions7747316696895urologywomens health500498481142neuromodulation367336304991110electrophysiology14714714712subtotal core businesses712774817462532divested businesses122141344na na na na worldwide7249762278065325the divisional constant currency growth rates in the tables above can be recalculated from the reconciliations provided below growth rates are based on actual nonrounded amounts and may not recalculate precisely  2012 net sales as compared to 2011 2011 net sales as compared to 2010  change estimatedimpact offoreigncurrency change estimatedimpact offoreigncurrency  as reportedcurrencybasis constantcurrencybasis  as reportedcurrencybasis constantcurrencybasis in millions      interventional cardiology 316 266 50 107 180 73cardiac rhythm management 179 145 34 93 144 51endoscopy 65 84 19 108 69 39peripheral interventions 43 56 13 62 36 26urologywomens health 2 5 3 17 9 8neuromodulation 31 32 1 32 31 1electrophysiology  2 2  3 3subtotal core businesses 354 232 122 19182 201divested businesses 19 18 1 203 206 3worldwide 373 250 123 184388 204us net salesduring 2012 our us net sales decreased 254 million or six percent as compared to 2011 the decrease was driven primarily by lower us interventional cardiology net sales of 232 million primarily as a result of lower market share due to competitive launches in 2012 continued average selling price declines in the us des market as a result of continued competitive pressures and declines in procedural volumes in addition our us crm sales declined 114 million due to lower procedural volumes as a result of a contraction in the us icd market lower average selling prices and lower replacement volumes partially offsetting these decreases were our endoscopy business that increased us net sales 43 million as compared to 2011 due to growth across several of its key product franchises our neuromodulation division which increased us net sales 25 million as compared to 2011 due to market share increases from strong commercial execution and continued market expansion and our peripheral interventions business which increased us net sales of 30 million as compared to 2011 on the strength of several new product launches refer to business and market overview for further discussion of our net salesduring 2011 our us net sales decreased 205 million or five percent as compared to 2010 the decrease was driven primarily by lower us crm net sales of 129 million resulting from the contraction in the us icd market in 2011 as well as lower us interventional cardiology net sales of 119 million driven by competitive and other pricing pressures and reductions in procedural volumes across our key markets partially offsetting these decreases our endoscopy business increased us net sales 21 million 45table of contentsas compared to 2010 due primarily to continued commercialization and adoption of products within our stent franchise and our neuromodulation division increased us net sales 29 million as compared to 2010 due primarily to higher procedural volumes and positive momentum from new product launchesinternational net salesduring 2012 our international net sales decreased 100 million or three percent as compared to 2011 changes in foreign currency exchange rates negatively impacted our international net sales by 122 million in 2012 as compared to 2011 excluding the negative impact of changes in foreign currency exchange rates of 122 million international net sales grew 22 million or one percent as compared to 2011 excluding the negative impact of changes in foreign currency exchange of 13 million sales in our intercontinental region increased 86 million or 11 percent in 2012 as compared to 2011 the increase in our intercontinental sales was due to growth across several of our businesses and continued growth in brazil india and china excluding the negative impact of changes in foreign currency exchange of 105 million net sales in our emea region decreased 48 million or three percent in 2012 as compared to 2011 driven primarily by a decline in crm and interventional cardiology net sales of 33 million and 37 million respectively partially offset by growth in all other businesses excluding the impact of changes in foreign currency exchange of 4 million our net sales in japan decreased 16 million or two percent in 2012 as compared to 2011 due primarily to a decline in interventional cardiology net sales refer to business and market overview for further discussion of our net salesduring 2011 our international net sales increased 224 million or seven percent as compared to 2010 changes in foreign currency exchange rates contributed 201 million to our international net sales in 2011 as compared to 2010 excluding the impact of changes in foreign currency exchange rates net sales in our intercontinental region increased 64 million or nine percent in 2011 as compared to 2010 primarily as a result of strong growth in brazil india and china as we began to see a return on our commercial investment in these areas net sales in our emea region decreased 20 million or one percent in 2011 as compared to 2010 excluding the impact of changes in foreign currency exchange rates driven primarily by a decline in crm net sales our net sales in japan decreased 21 million or two percent in 2011 as compared to 2010 excluding the impact of changes in foreign currency exchange rates due primarily to a decline in interventional cardiology net salesgross profitour gross profit was 4900 billion in 2012 4963 billion in 2011 and 5207 billion in 2010 as a percentage of net sales our gross profit increased to 676 percent in 2012 as compared to 651 percent in 2011 and 667 percent in 2010 the following is a reconciliation of our gross profit margins and a description of the drivers of the change from period to period year endeddecember 31 20122011gross profit  prior year651 667 promus supply trueup0606 neurovascular divestiture 14manufacturing cost reductions14  transitionrelated inventory charges credits07 07all other including other inventory charges other period expense and net impact of foreign currency13 03sales mix and pricing0302 gross profit  current year676 651 the increase in our gross profit margin for 2012 as compared to 2011 is primarily the result of cost reductions from our restructuring and other process improvement programs our gross margin was negatively impacted by declines in average selling prices related primarily to sales of our drugeluting stent and crm products however these declines were largely offset by the full conversion to our internallydeveloped and selfmanufactured nextgeneration promus element stent system during 2012 our promus element stent system has significantly higher gross margins than the prior generation promus stent system which was supplied to us by abbott laboratories additionally affecting our year over year comparison of year to date gross margin was the impact of a onetime 50 million credit to cost of products sold related to a twoyear retroactive pricing adjustment pursuant to our promus supply arrangement with abbott and product transitionrelated inventory charges of 54 million recorded in 2011 discussed further below46table of contentsthe primary factor contributing to the decrease in our gross profit margin during 2011 as compared to 2010 was the negative impact of lower sales of neurovascular products and at significantly lower gross profit margins as result of the divestiture of our neurovascular business in addition we recognized transitionrelated inventory charges of 54 million in 2011 primarily related to promus excess inventory and purchase commitments as a result of our fourth quarter 2011 launch of our internallydeveloped and selfmanufactured nextgeneration promus element stent system in the us the decreases in 2011 were partially offset by the positive impact of a 50 million credit to cost of products sold recognized in the first quarter of 2011 related to a twoyear retroactive pricing adjustment pursuant to our promus supply arrangement with abbott for historical purchases of promus stent systems  declines in average selling prices of our products particularly our drugeluting stent systems were offset by the positive impact of product mix related to sales of our drugeluting stent systems as we began shifting sales to our internallydeveloped and manufactured stent systems with more favorable gross profit margins during 2011 in addition our gross profit margin in 2010 was negatively impacted by the ship hold and product removal actions associated with our us crm businesswe are subject to a final retroactive pricing adjustment pursuant to our promus supply arrangement with abbott for historical purchases of promus stent systems we may record a onetime benefit or charge to our gross profit in the future as a result of this adjustment processoperating expensesthe following table provides a summary of certain of our operating expenses  year ended december 31  2012 2011 2010     of net    of net    of netin millions  sales  sales  salesselling general and administrative expenses 2535 350 2487 326 2580 331research and development expenses 886 122 895 117 939 120royalty expense 153 21 172 23 185 24selling general and administrative sgampa expensesin 2012 our sgampa expenses increased 48 million or two percent as compared to 2011 and were 240 basis points higher as a percentage of net sales this increase was driven primarily by continued investments in acquisitions and in commercial resources and infrastructure for global expansion particularly in emerging markets and a nonrecurring asset impairment charge as a result of a program termination also contributing to the yearoveryear increase was a benefit recorded in 2011 as a result of a reversal of previously established allowances for doubtful accounts against longoutstanding receivables in greece these increases in sgampa were partially offset by declines in spending as a result of our restructuring and other cost reduction initiatives and the impact of changes in foreign currency exchange rates beginning in january 2013 as a result of new legislation all medical device manufacturers will be subject to a 23 percent excise tax on us sales of class i ii and iii medical devices we intend to record this tax within our selling general and administrative expenses and expect that our excise tax liability for 2013 will be up to 80 million in 2011 our sgampa expenses decreased 93 million or four percent as compared to 2010 and were 50 basis points lower as a percentage of net sales our sgampa expenses were lower in 2011 as compared to 2010 as a result of the sale of our neurovascular business to stryker in january 2011 and lower expenses due to our restructuring initiatives and cost containment discipline in addition our sgampa expenses for 2011 benefited from the reversal of 20 million of previously established allowances for doubtful accounts against longoutstanding receivables in greece in 2011 these receivables had previously been fully reserved as we had determined that they had a high risk of being uncollectible due to the economic situation in greece during the first quarter of 2011 the greek government converted these receivables into bonds which we were able to monetize reducing our allowance for doubtful accounts as a credit to sgampa expense these decreases were partially offset by the unfavorable impact of changes in foreign currency exchange rates as well as additional sgampa expenses related to acquisitions and global expansion initiativesresearch and development rampd expensesin 2012 our rampd expenses decreased 9 million or approximately one percent as compared to 2011 and were 50 basis points higher as a percentage of net sales the slight decrease in overall spending in 2012 was due to continued focus on cost reduction initiatives associated with our restructuring programs and the benefits from our strategy to transform our research and development efforts to be more effective and cost efficient partially offset by increased rampd funding for our acquisitions we remain committed 47table of contentsto advancing medical technologies and investing in meaningful research and development projects across our businesses in order to maintain a healthy pipeline of new products that we believe will contribute to profitable sales growthin 2011 our rampd expenses decreased 44 million or approximately five percent as compared to 2010 and were 30 basis points lower as a percentage of net sales the decrease in 2011 was due to the elimination of spending related to our neurovascular business and cost reductions associated with our restructuring programsroyalty expensein 2012 our royalty expense decreased 19 million or 11 percent as compared to 2011 and was 20 basis points lower as a percentage of net sales the decrease relates primarily to lower sales of our royaltybearing products within our interventional cardiology businessin 2011 our royalty expense decreased 13 million or seven percent as compared to 2010 and was slightly lower as a percentage of net sales the decrease relates primarily to royalty expense attributable to neurovascular products which was eliminated with the sale of our neurovascular business in january 2011 these royalties represented 12 million of expense in 2010amortization expenseour amortization expense was 395 million in 2012 as compared to 421 million in 2011 a decrease of 26 million or six percent this decrease was due primarily to certain intangible assets associated with our acquisition of guidant corporation in 2006 reaching the end of their useful lives during the second quarter of 2011 this noncash charge is excluded by management for purposes of evaluating operating performance and assessing liquidityamortization expense was 421 million in 2011 as compared to 513 million in 2010 a decrease of 92 million or 18 percent this decrease was due primarily to certain intangible assets associated with our acquisition of guidant corporation in 2006 reaching the end of their useful lives during the second quarter of 2011goodwill impairment charges2012 chargeswe test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist in the second quarter of 2012 we performed our annual goodwill impairment test for all of our reporting units and concluded that the goodwill within our emea reporting unit was impaired and recorded a 3602 billion 3579 billion aftertax charge in the second quarter of 2012 we finalized the second step of the emea goodwill impairment test during the third quarter of 2012 in accordance with asc topic 350 intangibles goodwill and other and there were no adjustments to the charge upon finalization in the third quarter of 2012 we performed an interim goodwill impairment test and recorded a noncash 748 million pre and aftertax charge associated with our us crm reporting unit primarily driven by the reduction in the estimated size of the us crm market related adjustments to our business and other competitive factors which led to lower projected us crm results compared to prior forecasts we finalized the second step of the us crm goodwill impairment test during the fourth quarter of 2012 in accordance with asc topic 350 intangibles goodwill and other and there were no adjustments to the charge upon finalization in our goodwill impairment tests we used the income approach specifically the discounted cash flow dcf method to derive the fair value of our emea and us crm reporting units as described in our accounting policies we updated all aspects of the dcf models associated with the emea and us crm businesses including the amount and timing of future expected cash flows terminal value growth rates and the appropriate marketparticipant riskadjusted weighted average costs of capital wacc to applyemeaas a result of revised estimates developed during our annual strategic planning process and analysis performed in conjunction with our annual goodwill impairment test in the second quarter we concluded that the revenue growth rates projected for the emea reporting unit would be slightly lower than our previous estimates primarily driven by macroeconomic factors and our performance in the european market we updated shortterm operating projections based on our most recent strategic plan for emea prepared by management we reduced the emea longterm growth rates and terminal value growth rate projections and increased the discount rate within our 15year dcf model for emea by approximately 100 basis points due to increased risk associated with our projections in this market primarily as a result of the economic uncertainty in europe while we continue to 48table of contentsproject revenue growth in our emea business our expectations for future growth and profitability were lower than our previous estimates and reflected declines in average selling prices and volume pressures due to austerity measures the declines expected in the emea market did not impact our assumptions related to other reporting units the aggregate amount of goodwill that remains associated with our emea reporting unit is 556 million as of december 31 2012 in addition the remaining book value of our other emea intangible assets allocated to our emea reporting unit is approximately 1563 billion as of december 31 2012 in accordance with asc topic 350 we tested our emea amortizable intangible assets as of april 1 2012 for impairment on an undiscounted cash flow basis and determined that these assets were not impaired we also tested our indefinitelived intangible assets associated with emea as of april 1 2012 and recorded an impairment charge related to the inprocess research and development associated with our acquisition of sadra medical inc see intangible asset impairment charges below for a further discussion of this impairment us crmthe us crm market is dynamic highly competitive and difficult to forecast in the third quarter of 2012 we lowered our projections for the us crm market size and our future revenue levels within this market primarily to reflect recent changes in expectations of average selling prices and unit growth adjustments to our business and other competitive factors this reduction warranted an interim goodwill impairment test for our us crm reporting unit the declines expected in the us crm market did not impact our assumptions related to other reporting units the increased pricing pressure and lower unit volumes are primarily due to physician alignment with hospitals efforts to reduce health care costs focus on appropriate device usage replacement volumes and competition and have been more impactful to the us crm business than previously estimated in addition we recently aligned certain elements of our business and shifted investments to focus on areas expected to provide the highest future growth and financial return as a result of these factors we reduced the compound annual revenue growth rate of our 15 year dcf model for the us crm reporting unit by approximately 250 basis points we continue to analyze business trends using all available information and our us crm goodwill remains sensitive to changes in expectations of future growth of this market and our performance based on the remaining book value of our us crm reporting unit following the goodwill impairment charge recorded during the third quarter of 2012 the carrying value of our us crm reporting unit continues to exceed its fair value due primarily to the value of amortizable intangible assets allocated to this reporting unit the remaining book value of the amortizable intangible assets allocated to the us crm reporting unit was approximately 3303 billion as of december 31 2012 in accordance with asc topic 350 we tested the amortizable intangible assets as of september 30 2012 in conjunction with the interim goodwill impairment test of our us crm reporting unit we performed the impairment analysis of the amortizable intangible assets on an undiscounted cash flow basis and concluded that these assets were not impaired however following the recent declines in our crm projections the recoverability of our crmrelated amortizable intangibles 4636 billion globally are sensitive to changes in future cash flow assumptions and our crm business performance the 4636 billion of crmrelated amortizable intangibles are at higher risk of potential failure of the first step of the amortizable intangible recoverability test in future reporting periods an impairment of a material portion of our crmrelated amortizable intangibles carrying value would occur if the second step of the amortizable intangible test is required in a future reporting periodwe continue to identify three reporting units with goodwill that is at higher risk of potential failure of the first step of the goodwill impairment test in future reporting periods these reporting units include our us crm reporting unit which holds 216 million of remaining allocated goodwill our us cardiovascular reporting unit which holds 2380 billion of allocated goodwill and our us neuromodulation reporting unit which holds 1266 billion of allocated goodwill each as of december 31 2012 as of december 31 2012 the level of excess fair value over carrying value for these reporting units identified as being at higher risk with the exception of the us crm reporting unit whose carrying value continues to exceed its fair value was approximately seven  to 11 percent during the fourth quarter of 2012 the level of excess fair value over carrying value of our us cardiovascular reporting unit declined as a result of our performance declines in our market share due to competitive launches and continued average selling price declines in the us drugeluting stent des market as a result of continued competitive pressures and declines in procedural volumes on a quarterly basis we monitor the key drivers of fair value for these reporting units to detect events or other changes that would warrant an interim impairment test of our goodwill and intangible assets the key variables that drive the cash flows of our reporting units and amortizable intangibles are estimated revenue growth rates and levels of profitability terminal value growth rate assumptions as well as the wacc rate applied are additional key variables for reporting unit cash flows these assumptions are subject to uncertainty including our ability to grow revenue and improve profitability levels relatively small declines in the future performance and cash flows of a reporting unit or asset group or small changes in other key assumptions may result in the recognition of significant asset impairment charges for example keeping all other variables constant a 80 basis point decrease in the long term revenue and terminal growth rates would require that we perform the second step of the goodwill impairment test for the us neuromodulation reporting unit a 90 basis point decrease in the long term revenue and terminal growth rates would 49table of contentsrequire that we perform the second step of the goodwill impairment test for the us cardiovascular reporting unit an increase in the wacc applied of 70 basis points would require that we perform the second step of the goodwill impairment test for the us neuromodulation and us cardiovascular reporting units given that the carrying value of the us crm reporting unit continues to exceed its fair value any negative changes in the key variables or values associated with this reporting unit would likely require that we perform the second step of the goodwill impairment test in a future reporting period the estimates used for our future cash flows and discount rates represent managements best estimates which we believe to be reasonable but future declines in business performance may impair the recoverability of our goodwill and intangible asset balances future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units andor amortizable intangible assets include but are not limited todecreases in estimated market sizes or market growth rates due to greaterthanexpected declines in procedural volumes pricing pressures product actions andor competitive technology developmentsdeclines in our market share and penetration assumptions due to increased competition an inability to develop or launch new and nextgeneration products and technology features in line with our commercialization strategies and market andor regulatory conditions that may cause significant launch delays or product recallsdecreases in our profitability due to an inability to successfully implement and achieve timely and sustainable cost improvement measures consistent with our expectations increases in our marketparticipant tax rate andor changes in tax lawsnegative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain productsthe level of success of ongoing and future research and development efforts including those related to recent acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new productsthe level of success in managing the growth of acquired companies achieving sustained profitability consistent with our expectations establishing government and thirdparty payer reimbursement and increases in the costs and time necessary to integrate acquired businesses into our operations successfullychanges in our reporting units or in the structure of our business as a result of future reorganizations or divestitures of assets or businessesincreases in our marketparticipant riskadjusted wacc anddeclines in revenue as a result of loss of key members of our sales force and other key personnelnegative changes in one or more of these factors among others could result in additional impairment charges2011 chargebased on market information that became available to us toward the end of the first quarter of 2011 we concluded that there was a reduction in the estimated size of the us icd market which led to lower projected us crm results compared to prior forecasts and created an indication of potential impairment of the goodwill balance attributable to our us crm business unit therefore we performed an interim impairment test in accordance with us gaap and our accounting policies and recorded a nondeductible goodwill impairment charge of 697 million on both a pretax and aftertax basis associated with this business unit during the first quarter of 2011 2010 chargeas a result of ship hold and product removal actions associated with our us icd and crtd products which we announced on march 15 2010 and the forecasted corresponding financial impact on our operations we concluded there was an indication of potential impairment of the goodwill balance attributable to our us crm reporting unit during the first quarter of 2010 therefore we performed an interim impairment test in accordance with us gaap and our accounting policies and recorded a nondeductible goodwill impairment charge of 1817 billion on both a pretax and aftertax basis associated with our us crm reporting unitgoodwill impairment charges do not impact our debt covenants or our cash flows and are excluded by management for purposes of evaluating operating performance and assessing liquidity50table of contentsintangible asset impairment chargeson a quarterly basis we monitor for events or other potential indicators of impairment that would warrant an interim impairment test of our intangible assets 2012 chargesduring the third quarter of 2012 we performed our annual impairment test of all inprocess research and development projects and our indefinite lived core technology assets based on the results of our annual test we recorded total impairment charges of 13 million to writedown the balances of certain inprocess projects to their fair value these charges were primarily due to increased expectations in the cost to bring an inprocess project to market in a certain geographic region and lower future revenue expectations associated with an inprocess projectfollowing the recent declines in our crm projections the recoverability of our crmrelated amortizable intangibles 4636 billion globally are sensitive to changes in future cash flow assumptions and our crm business performance the 4636 billion of crmrelated amortizable intangibles are at higher risk of potential failure of the first step of the amortizable intangible recoverability test in future reporting periods an impairment of a material portion of our crmrelated amortizable intangibles carrying value would occur if the second step of the amortizable intangible test is required in a future reporting period see goodwill impairment charges above for discussion of future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units andor amortizable intangible assetsduring the second quarter of 2012 as a result of revised estimates developed in conjunction with our annual strategic planning process and annual goodwill impairment test we performed an interim impairment test of our inprocess research and development projects associated with our acquisition of sadra medical inc based on our impairment analysis we revised our expectations of the required effort time and cost involved in completing the inprocess projects and bringing the related products to market as a result of these changes we recorded an impairment charge of 129 million to writedown the balance of these intangible assets to their fair value during the second quarter of 2012 2011 chargesduring the third quarter of 2011 we recorded a 9 million intangible asset impairment charge attributable to lower projected cash flows associated with certain technologies during the second quarter of 2011 we recorded a 12 million intangible asset impairment charge associated with changes in the timing and amount of the expected cash flows related to certain purchased research and development projects 2010 chargesduring the first quarter of 2010 due to lower than anticipated net sales of one of our peripheral interventions technology offerings as well as changes in our expectations of future market acceptance of this technology we lowered our sales forecasts associated with a product in addition during the third quarter of 2010 as part of our initiatives to reprioritize and diversify our product portfolio we discontinued one of our internal research and development programs to focus on those with a higher likelihood of success as a result of these factors we tested the related intangible assets for impairment and recorded a 60 million charge in the first quarter of 2010 and a 5 million charge in the third quarter of 2010 to write down the balance of these intangible assets to their fair value intangible asset impairment charges are noncash charges that are excluded by management for purposes of evaluating operating performance and assessing liquiditycontingent consideration expensecertain of our acquisitions involve contingent consideration arrangements payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones including attaining specified revenue levels achieving product development targets or obtaining regulatory approvals in accordance with us gaap we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones51table of contentswe recorded a net benefit related to the change in fair value of our contingent consideration liabilities of 6 million in 2012 and net expenses of 7 million in 2011 and 2 million in 2010 contingent consideration expense is excluded by management for purposes of evaluating performance see note b  acquisitions to our 2012 consolidated financial statements contained in item 8 of this annual report for further discussion of our contingent consideration associated with our acquisitions acquisitionrelated milestonein connection with abbott laboratories 2006 acquisition of guidants vascular intervention and endovascular solutions businesses abbott agreed to pay us a milestone payment of 250 million upon receipt of an approval from the japanese ministry of health labor and welfare mhlw to market the xience v stent system in japan the mhlw approved the xience v stent system in the first quarter of 2010 and we received the milestone payment from abbott which we recorded as a 250 million pretax gain this nonrecurring acquisitionrelated gain is excluded by management for purposes of evaluating operating performancerestructuring charges and restructuringrelated activities2011 restructuring planon july 26 2011 our board of directors approved and we committed to a restructuring initiative the 2011 restructuring plan designed to strengthen operational effectiveness and efficiencies increase competitiveness and support new investments thereby increasing shareholder value the original estimate of the plan was a reduction of annual pretax operating expenses by approximately 225 million to 275 million exiting 2013 a substantial portion of which is expected to be reinvested in targeted areas necessary for future growth including strategic growth initiatives and emerging markets key activities under the plan include standardizing and automating certain processes and activities relocating select administrative and functional activities rationalizing organizational reporting structures leveraging preferred vendors and other efforts to eliminate inefficiency among these efforts we are expanding our ability to deliver bestinclass global shared services for certain functions and divisions at several locations in emerging markets this action is intended to enable us to grow our global commercial presence in key geographies and take advantage of many costreducing and productivityenhancing opportunities in addition we are undertaking efforts to streamline various corporate functions eliminate bureaucracy increase productivity and better align corporate resources to our key business strategies on january 25 2013 our board of directors approved and we committed to an expansion of the 2011 restructuring program the expansion the expansion is intended to further strengthen our operational effectiveness and efficiencies and support new investments which we expect to increase stockholder value we estimate that the expansion will reduce gross annual pretax operating expenses by approximately 100 million to 115 million exiting 2013 and that the total 2011 restructuring plan including the expansion total program will reduce gross annual pretax operating expenses by approximately 340 million to 375 million exiting 2013 we expect a substantial portion of the total program savings to be reinvested in targeted areas for future growth including strategic growth initiatives and emerging markets key activities under the expansion include further initiatives to standardize and automate certain processes and activities relocate select administrative and functional activities rationalize organizational reporting structures expand shared services and align expenses to revenues within certain divisions and geographic regions in addition they include further efforts to streamline various corporate functions eliminate bureaucracy increase productivity and better align corporate resources to our key business strategies key activities under the total program are expected to be substantially completed by the end of 201352table of contentswe estimate that the implementation of the expansion will result in pretax charges of approximately 140 million to 160 million of which approximately 100 million to 120 million is expected to result in future cash outlays we estimate that the implementation of the total program will result in total pretax charges of approximately 300 million to 355 million and that approximately 270 million to 300 million of these charges will result in future cash outlays of which we had made payments of 128 million as of december 31 2012 the following table provides a summary of our estimates of costs associated with the expansion and the total program by major type of costtype of costtotal estimated amount expected tobe incurredexpansiontotal programrestructuring charges  termination benefits55 million to 65 million185 million to 210 millionother 150 million to 55 million70 million to 90 millionrestructuringrelated expenses  other 235 million to 40 million45 million to 55 million 140 million to 160 million300 million to 355 million1includes primarily consulting fees fixed asset writeoffs and costs associated with contractual cancellations2comprised of other costs directly related to the restructuring program including program management accelerated depreciation retention and infrastructurerelated costsas of december 31 2012 we have recorded costs of 184 million since the inception of the 2011 restructuring plan and are recording a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations2010 restructuring planon february 6 2010 our board of directors approved and we committed to a series of management changes and restructuring initiatives the 2010 restructuring plan designed to focus our business drive innovation accelerate profitable revenue growth and increase both accountability and shareholder value key activities under the plan included the restructuring of certain of our businesses and corporate functions the realignment of our international structure to reduce our administrative costs and invest in expansion opportunities including significant investments in emerging markets and the reprioritization and diversification of our product portfolio activities under the 2010 restructuring plan were initiated in the first quarter of 2010 and were complete by the end of 2012 and resulted in gross reductions in pretax operating expenses of approximately 250 million a portion of these savings were reinvested into customerfacing positions and other commercial resources and infrastructurethe execution of the 2010 restructuring plan resulted in total pretax charges of 160 million and required cash outlays of 145 million of which we had made payments of 144 million to date we have recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operationsplant network optimization programin january 2009 our board of directors approved and we committed to a plant network optimization initiative the plant network optimization program intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and by closing certain other facilities the program was a complement to the restructuring initiatives approved by our board of directors in 2007 the 2007 restructuring plan and was intended to improve overall gross profit margins the program has resulted in annualized runrate reductions of manufacturing costs of approximately 65 million exiting 2012 these savings are in addition to the 35 million of annual reductions of manufacturing costs from activities under our 2007 restructuring plan activities under the plant network optimization program were initiated in the first quarter of 2009 and were substantially completed during 2012we expect that the execution of the plant network optimization program will result in total pretax charges of approximately 132 million to 135 million and that approximately 105 million to 110 million of these charges will result in cash outlays of which we had made payments of 102 million to date we have recorded related costs of 132 million since the inception of the plan and recorded a portion of these expenses as restructuring charges and the remaining portion through cost of products sold within our consolidated statements of operations53table of contentsin aggregate we recorded restructuring charges pursuant to our restructuring plans of 136 million during 2012 89 million during 2011 and 116 million during 2010 in addition we recorded expenses within other lines of our accompanying consolidated statements of operations related to our restructuring initiatives of 24 million during 2012 40 million during 2011 and 53 million during 2010 restructuring and restructuringrelated costs are excluded by management for purposes of evaluating operating performancewe made cash payments of 149 million in 2012 114 million in 2011 and 133 million in 2010 associated with our restructuring initiativessee note h  restructuring related activities to our 2012 consolidated financial statements included in item 8 of this annual report for additional details related to our restructuring planslitigationrelated charges and creditsduring 2012 and 2011 we recorded net litigationrelated charges in the amount of 192 million and 48 million respectively in 2010 we recorded a litigationrelated credit of 104 million associated with a settlement of a dispute we had with medinol ltd these charges and credits are excluded by management for purposes of evaluating operating performance we continue to assess certain litigation and claims to determine the amounts if any that management believes will be paid as a result of such claims and litigation and therefore additional losses may be accrued and paid in the future which could materially adversely impact our operating results cash flows andor our ability to comply with our debt covenantsgain on divestiturein january 2011 we closed the sale of our neurovascular business to stryker corporation for a purchase price of 1500 billion in cash we received 1450 billion during 2011 including an upfront payment of 1426 billion and 24 million which was placed into escrow and released throughout 2011 upon the completion of local closings in certain foreign jurisdictions during 2012 we received an additional 10 million of consideration which we recorded as a gain in our accompanying consolidated statements of operations we will receive the remaining 40 million of consideration upon the transfer or separation of certain manufacturing facilities which we expect will occur during 2013 due to our continuing involvement in the operations of the neurovascular business the divestiture does not meet the criteria for presentation as a discontinued operation we recorded a pretax gain of 778 million during 2011 associated with the transaction and a gain of 15 million during 2012 these divestiturerelated gains are excluded by management for purposes of evaluating operating performanceinterest expenseour interest expense decreased to 261 million in 2012 as compared to 281 million in 2011 the decrease in our interest expense was a result of lower average debt levels due to repayment of 1250 billion of debt during 2011 and the refinancing of our credit facility in april 2012 at lower average costs our average borrowing rate was 55 percent in 2012 and 54 percent in 2011 our 2011 interest expense included 6 million associated with the writeoff of debt issuance costs and a 3 million benefit associated with interest rate derivative contracts terminated during 2011 refer to liquidity and capital resources and note f  borrowings and credit arrangements to our 2012 consolidated financial statements contained in item 8 of this annual report for information regarding our debt obligationsour interest expense was 281 million in 2011 as compared to 393 million in 2010 the decrease in our interest expense was a result of lower average debt levels due to repayment of 1250 billion of debt during 2011 as well as lower average borrowing rates our average borrowing rate was 54 percent in 2011 and 60 percent in 2010 our 2010 interest expense included 25 million of writeoffs of debt issuance costs discounts and the impacts of the early termination of interest rate derivative contracts associated with loan prepayments54table of contentsother netour other net reflected income of 22 million in 2012 income of 19 million in 2011 and expense of 14 million in 2010 the following are the components of other net  year ended december 31in millions 201220112010interest income 5713foreign currency losses 18129net gains losses on investments 372712other expense net 236  221914during 2012 we recognized gains of 39 million associated with 2012 acquisitions in which we held prior equity interests which were partially offset by net losses of 2 million related to our investment portfolio during 2011 we recognized gains of 38 million associated with 2011 acquisitions in which we held prior equity interests which were partially offset by net losses of 11 million on our investment portfolio during 2010 we recognized net losses of 12 million relating to the writedown of investments in our portfolio the acquisitionrelated gains from previously held investments are excluded by management for purposes of evaluating operating performance tax ratethe following table provides a summary of our reported tax rate  year endeddecember 31  201220112010reported tax rate 10313 02impact of certain receiptscharges 127 120180  117 193 182these receiptscharges are taxed at different rates than our effective tax ratethe change in our reported tax rate for 2012 as compared to 2011 and 2010 relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate in 2012 these receipts and charges include goodwill and intangible asset impairment charges acquisition and divestiturerelated net credits and litigation and restructuringrelated charges our reported tax rate was also affected by discrete tax items related primarily to the resolution of an uncertain tax position resulting from an unfavorable court ruling in addition the decrease in the tax rate excluding the impact of these receipts and charges in 2012 as compared to 2011 is primarily the result of shifts in the geographic mix of our business in 2011 these receipts and charges included a gain on our divestiture of the neurovascular business a nondeductible goodwill impairment charge other intangible asset impairment charges and restructuring litigation and acquisitionrelated charges and credits our reported tax rate was also affected by discrete tax items related primarily to a release of valuation allowances resulting from a change in our expected ability to realize certain deferred tax assets changes in various state tax laws the resolution of various uncertain tax positions resulting from closing agreements with the internal revenue service irs the resolution of various uncertain tax positions resulting from the expiration of the statute of limitations for assessing tax in certain jurisdictions and the finalization of our 2010 us federal tax return in 2010 these receipts and charges included goodwill and intangible asset impairment charges a gain associated with the receipt of an acquisitionrelated milestone payment and restructuringrelated charges in 2010 our reported tax rate was also affected by discrete tax items related primarily to the remeasurement of an uncertain tax position resulting from a favorable court ruling issued in a similar thirdparty case and the resolution of an uncertain tax position resulting from a favorable taxpayer motion issued in a similar thirdparty casewe have received notices of deficiency from the irs reflecting proposed audit adjustments for guidant corporation for its 2001 through 2006 tax years and boston scientific corporation for its 2006 and 2007 tax years subsequent to issuing these notices the irs conceded a portion of its original assessment the total incremental tax liability now asserted by the irs for the applicable periods is 1162 billion plus interest the primary issue in dispute for all years is the transfer pricing in connection with the technology license agreements between domestic and foreign subsidiaries of guidant in addition the irs has proposed adjustments in connection with the financial terms of our transaction agreement with abbott laboratories pertaining to the sale of guidants vascular intervention business to abbott in april 2006 we do not agree with the transfer pricing methodologies applied by the 55table of contentsirs or its resulting assessment and we believe that the irs has exceeded its authority by attempting to adjust the terms of our negotiated thirdparty agreement with abbott in addition we believe that the irs positions with regard to these matters are inconsistent with the applicable tax laws and the existing treasury regulations we believe we have meritorious defenses for our tax filings and we have filed or will timely file petitions with the us tax court contesting the notices of deficiency for the tax years in challenge no payments on the net assessment would be required until the dispute is definitively resolved which based on experiences of other companies could take several years we believe that our income tax reserves associated with these matters are adequate and the final resolution will not have a material impact on our financial condition or results of operations however final resolution is uncertain and could have a material impact on our financial condition or results of operationsin january 2013 president obama signed into law the american taxpayer relief act of 2012 our current financial position and results of operations are not impacted by this act however for 2013 our results of operations are expected to be favorably impacted as certain provisions including the us rampd tax credit are retroactively reenacted for the year ending december 31 2012 refer to note j  income taxes for our 2012 consolidated financial statements contained in item 8 of this annual report for more informationliquidity and capital resourcesas of december 31 2012 we had 207 million of cash and cash equivalents on hand comprised of 39 million invested in money market and government funds and 168 million in interest bearing and noninterest bearing bank accounts we invest excess cash on hand in shortterm financial instruments that earn market interest rates while mitigating principal risk through instrument and counterparty diversification as well as what we believe to be prudent instrument selection we limit our direct exposure to securities in any one industry or issuer we also have full access to our 2000 billion revolving credit facility and 350 million of available borrowings under our credit and security facility secured by our us trade receivables both described belowthe following provides a summary and description of our net cash inflows outflows for the years ended december 31 2012 2011 and 2010  year ended december 31in millions 201220112010cash provided by operating activities 12601008325cash provided by used for investing activities 579776468cash used for financing activities 7441728508operating activitiesduring 2012 we generated 1260 billion from operating activities as compared to 1008 billion in 2011 an increase of 252 million this increase was driven primarily by accounts receivable and inventory reductions which generated approximately 103 million the impact of litigationrelated payments of approximately 300 million to the us department of justice in 2011 and lower taxrelated net cash outflows of approximately 40 million during 2012 partially offsetting these items was the impact of lower operating profit in 2012 and a 35 million increase in restructuringrelated payments as compared to 2011 our cash provided by operating activities in 2011 also included proceeds of approximately 80 million related to the termination of our outstanding interest rate derivative contracts and the receipt of a 75 million manufacturing cost trueup payment from abbott in accordance with our supply agreement during 2011 we generated 683 million more of operating cash flows than in 2010 this increase was driven primarily by lower litigationrelated payments of approximately 13 billion our 2011 litigationrelated payments primarily consisted of a payment of approximately 300 million to the us department of justice in the first quarter of 2011 during 2010 we made payments of 1725 billion to johnson amp johnson related to a patent litigation settlement and received 104 million in connection with a litigation settlement with medinol our cash provided by operating activities in 2011 also included proceeds of approximately 80 million related to the termination of our outstanding interest rate derivative contracts and the receipt of a 75 million manufacturing cost trueup payment from abbott in accordance with our supply agreement in 2011 we incurred net tax payments in the amount of 138 million as compared to net tax related receipts of 286 million in 2010 in addition our 2010 cash flows include the receipt of a 250 million milestone payment from abbott56table of contentsinvesting activitiesduring 2012 cash used for investing activities was 579 million our investing activities included capital expenditures of 226 million and payments for the acquisitions of cameron health inc bridgepoint medical inc rhythmia medical inc and vessix vascular inc totaling 366 million we expect to incur total capital expenditures of approximately 300 million during 2013during 2011 cash provided by investing activities was comprised primarily of proceeds from the sale of our neurovascular business to stryker we received 1440 billion of net cash proceeds during 2011 related to the sale of this business this cash inflow was partially offset by payments of 370 million for acquisitions consummated during 2011 and capital expenditures of 304 millionduring 2010 our investing activities were comprised primarily of capital expenditures of 272 million as well as payments of approximately 200 million to acquire asthmatx inc and certain other strategic assetsfinancing activitiesour cash flows from financing activities reflect issuances and repayments of debt proceeds from stock issuances related to our equity incentive programs and repurchases of common stock pursuant to our authorized repurchase programs discussed in note l  stockholders equity to our 2012 consolidated financial statements included in item 8 of this annual report additionally our financing activities included 146 million of contingent payments primarily associated with the achievement of receiving fda approval of the sicd system in september 2012debtwe had total debt of 4256 billion as of december 31 2012 and 4261 billion as of december 31 2011 the debt maturity schedule for the significant components of our debt obligations as of december 31 2012 is as follows    in millions2013 2014 2015 2016 2017 thereafter totalsenior notes  600 1250 600 250 1500 4200   600 1250 600 250 1500 4200notethe table above does not include unamortized discounts associated with our senior notes or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notesin july 2011 fitch ratings upgraded our corporate credit rating to bbb an investmentgrade rating and in february 2012 moodys investors service upgraded our corporate credit rating to baa3 an investmentgrade rating in addition standard amp poors ratings services has maintained an investmentgrade corporate credit rating for us since 2009 we believe our investment grade credit profile reflects the size and diversity of our product portfolio our leading share position in several of our served markets our strong cash flow our solid financial fundamentals and our financial strategy term loan and revolving credit facilityduring 2011 we prepaid the remaining 1000 billion of our term loan maturities without premium or penaltyin the second quarter of 2012 we established a 2000 billion revolving credit facility maturing in april 2017 with a global syndicate of commercial bank and terminated our previous revolving credit facility eurodollar and multicurrency loans under the new revolving credit facility bear interest at libor plus an interest margin of between 0875 percent and 1475 percent based on our corporate credit ratings and consolidated leverage ratio 1275 percent as of december 31 2012 in addition we are required to pay a facility fee based on our credit ratings consolidated leverage ratio and the total amount of revolving credit commitments regardless of usage under the agreement 0225 percent as of december 31 2012 there were no amounts borrowed under our revolving credit facility as of december 31 2012 or december 31 2011 57table of contentsour revolving credit facility agreement requires that we maintain certain financial covenants as follows covenant requirement actual as ofdecember 31 2012 maximum leverage ratio 135 times 24 timesminimum interest coverage ratio 230 times 69 times1ratio of total debt to consolidated ebitda as defined by the credit agreement for the preceding four consecutive fiscal quarters2ratio of consolidated ebitda as defined by the credit agreement to interest expense for the preceding four consecutive fiscal quartersthe credit agreement provides for an exclusion from the calculation of consolidated ebitda as defined by the agreement through the credit agreement maturity of up to 500 million in restructuring charges and restructuringrelated expenses related to our current or future restructuring plans as of december 31 2012 we had 357 million of the combined restructuring charge exclusion remaining any noncash charges as defined by the agreement are excluded from the calculation of consolidated ebitda in addition any cash litigation payments as defined by the agreement are excluded from the calculation of consolidated ebitda and any new debt issued to fund any tax deficiency payments is excluded from consolidated total debt as defined in the agreement provided that the sum of any excluded cash litigation payments and any new debt issued to fund any tax deficiency payments shall not exceed 2300 billion in the aggregate as of december 31 2012 we had 2271 billion of the combined legal and debt exclusion remaining as of and through december 31 2012 we were in compliance with the required covenantsany inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facilities or seek waivers from compliance with these covenants both of which could result in additional borrowing costs further there can be no assurance that our lenders would grant such waiverssenior noteswe had senior notes outstanding in the amount of 4200 billion as of december 31 2012 and december 31 2011 in january 2011 we paid 250 million of our senior notes at maturityother arrangementswe also maintain a 350 million credit and security facility secured by our us trade receivables in june 2012 we extended the maturity of this facility to june 2013 subject to further extension there were no amounts borrowed under this facility as of december 31 2012 or december 31 2011we have accounts receivable factoring programs in certain european countries that we account for as sales under asc topic 860 transfers and servicing these agreements provide for the sale of accounts receivable to third parties without recourse of up to approximately 300 million as of december 31 2012 we have no retained interests in the transferred receivables other than collection and administrative responsibilities and once sold the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy we derecognized 191 million of receivables as of december 31 2012 at an average interest rate of 16 percent and 390 million as of december 31 2011 at an average interest rate of 33 percent the european sovereign debt crisis may impact our future ability to transfer receivables to third parties in certain southern european countries third parties such as banks offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt this could result in terminations of or changes to the costs or credit limits of our existing factoring programs such terminations or changes could have a negative impact on our cash flow and days sales outstanding within italy spain and portugal the number of days our receivables are outstanding has increased above historical levels we believe we have adequate allowances for doubtful accounts related to our italy spain and portugal accounts receivable however we will continue to monitor the european economic environment for any collectibility issues related to our outstanding receivables in addition we are currently pursuing alternative factoring providers and financing arrangements to mitigate our credit exposure to receivables in this region during the first quarter of 2011 the greek government converted a significant portion of our outstanding receivables into bonds which we monetized during the first quarter and reduced our credit exposure in this countryin addition we have uncommitted credit facilities with a japanese bank that provide for borrowings promissory notes discounting and receivables factoring of up to 185 billion japanese yen translated to approximately 214 million as of december 31 2012 we derecognized 182 million of notes receivable as of december 31 2012 at an average interest rate of 16 percent and 188 million of notes receivable as of december 31 2011 at an average interest rate of 17 percent derecognized accounts and notes 58table of contentsreceivable are excluded from trade accounts receivable net in the accompanying consolidated balance sheets included in item 8 of this annual report equityduring 2012 and 2011 we received approximately 21 million in proceeds from stock issuances related to our stock option and employee stock purchase plans as compared 31 million in 2010 proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon among other factors fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of employeesin march and may 2011 our board of directors and stockholders respectively approved our 2011 longterm incentive plan the 2011 ltip authorizing the issuance of up to 1456 million shares of our common stock the 2011 ltip provides for the grant of restricted or unrestricted common stock deferred stock units dsu options to acquire our common stock stock appreciation rights performance awards marketbased and performancebased dsus and other stock and nonstock awards in addition in july 2011 our board of directors approved a share repurchase program authorizing the repurchase of up to 10 billion in shares of our common stock and reapproved the repurchase of approximately 37 million shares remaining under a previous share repurchase program any repurchased shares may be used for general corporate purposes during 2012 we repurchased 105 million shares of our common stock for approximately 600 million pursuant to our share repurchase authorizations during 2011 we repurchased approximately 82 million shares of our common stock for approximately 492 million we did not repurchase any shares of our common stock in 2010 as of december 31 2012 we had completed our share repurchase program authorized in 2011 and had remaining 21 million shares authorized under our previous share repurchase programs stockbased compensation expense related to our stock equity compensation and ownership plans was 108 million in 2012 128 million in 2011 and 150 million in 2010 stockbased compensation expense varies from period to period based upon among other factors the timing number and fair value of awards granted during the period forfeiture levels related to unvested awards and employee contributions to our employee stock purchase planon january 25 2013 our board of directors approved a new stock repurchase program authorizing the repurchase of up to 10 billion of our common stockcontractual obligations and commitmentsthe following table provides a summary of certain information concerning our obligations and commitments to make future payments and is based on conditions in existence as of december 31 2012    in millions 2013 2014 2015 2016 2017 thereafter totallongterm debt obligations   600 1250 600 250 1500 4200interest payments 1 250 232 177 133 99 1030 1921operating lease obligations 1 69 50 40 33 23 44 259purchase obligations 1 220 16 13 5   5 259minimum royalty obligations 1 2 1 1 1 1 2 8unrecognized tax benefits 24           24  565 899 1481 772 3732581 66711in accordance with us gaap these obligations relate to expenses associated with future periods and are not reflected in our consolidated balance sheetsthe amounts in the table above with respect to operating lease obligations represent amounts pursuant to contractual arrangements for the lease of property plant and equipment used in the normal course of business purchase obligations relate primarily to noncancellable inventory commitments and capital expenditures entered in the normal course of business royalty obligations reported above represent minimum contractual obligations under our current royalty agreements the table above does not reflect unrecognized tax benefits of 1392 billion the timing of which is uncertain refer to note j  income taxes to our 2012 consolidated financial statements included in item 8 of this annual report for more information on these unrecognized tax benefitswith certain of our acquisitions we acquired inprocess research and development projects that require future funding to complete the projects the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory 59table of contentsapproval to market the underlying products in an applicable geographic region we estimate that the total remaining cost to complete the inprocess research and development projects acquired in 20102012 is between 250 million and 350 million and we expect material net cash inflows from the projects in development to commence in 2013 through 2017 following the respective launches of these technologies in the us emea and japan regions certain of our acquisitions also involve the potential payment of contingent consideration the table above does not reflect any such obligations as the timing and amounts are uncertain see note b  acquisitions to our 2012 consolidated financial statements included in item 8 of this annual report for the estimated maximum potential amount of future contingent consideration we could be required to pay associated with prior acquisitions and the fair value of our contingent consideration liabilities as of december 31 2012legal mattersthe medical device market in which we primarily participate is largely technology driven as a result intellectual property rights particularly patents and trade secrets play a significant role in product development and differentiation over the years there has been litigation initiated against us by others including our competitors claiming that our current or former product offerings infringe patents owned or licensed by them intellectual property litigation is inherently complex and unpredictable in addition competing parties frequently file multiple suits to leverage patent portfolios across product lines technologies and geographies and to balance risk and exposure between the parties in some cases several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices these forces frequently drive settlement not only for individual cases but also for a series of pending and potentially related and unrelated cases although monetary and injunctive relief is typically sought remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal accordingly the outcomes of individual cases are difficult to time predict or quantify and are often dependent upon the outcomes of other cases in other geographies during recent years we successfully negotiated closure of several longstanding legal matters and recently received favorable legal rulings in several other matters however there continues to be outstanding intellectual property litigation particularly in the coronary stent market adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins financial position results of operations andor liquidityin the normal course of business product liability securities and commercial claims are asserted against us similar claims may be asserted against us in the future related to events not known to management at the present time we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims or adverse decisions product liability claims securities and commercial litigation and other legal proceedings in the future regardless of their outcome could have a material adverse effect on our financial position results of operations andor liquidityin addition like other companies in the medical device industry we are subject to extensive regulation by national state and local government agencies in the united states and other countries in which we operate from time to time we are the subject of qui tam actions and governmental investigations often involving regulatory marketing and other business practices these qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings substantial fines penalties and administrative remedies and have a material adverse effect on our financial position results of operations andor liquidityour accrual for legal matters that are probable and estimable was 491 million as of december 31 2012 and 299 million as of december 31 2011 and includes estimated costs of settlement damages and defense we continue to assess certain litigation and claims to determine the amounts if any that management believes will be paid as a result of such claims and litigation and therefore additional losses may be accrued and paid in the future which could materially adversely impact our operating results cash flows andor our ability to comply with our debt covenantssee further discussion of our material legal proceedings in note k  commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual reportcritical accounting estimatesour financial results are affected by the selection and application of accounting policies we have adopted accounting policies to prepare our consolidated financial statements in conformity with us gaap we describe these accounting policies in note asignificant accounting policies to our 2012 consolidated financial statements included in item 8 of this annual report60table of contentsto prepare our consolidated financial statements in accordance with us gaap management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities the disclosure of contingent liabilities as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting period our actual results may differ from these estimates we consider estimates to be critical if i we are required to make assumptions about material matters that are uncertain at the time of estimation or if ii materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period the following are areas requiring managements judgment that we consider criticalrevenue recognitionwe allow our customers to return defective damaged and in certain cases expired products for credit we base our estimate for sales returns upon historical trends and record these amounts as a reduction of revenue when we sell the initial product in addition we may allow customers to return previously purchased products for nextgeneration product offerings for these transactions we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount to be returned when the nextgeneration products are shipped to the customer uncertain timing of nextgeneration product approvals variability in product launch strategies product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimatesmany of our crm product offerings combine the sale of a device with our latitude patient management system which represents a future service obligation for revenue arrangements with multiple deliverables where the sale of a device is combined with a future service obligation we defer revenue on the undelivered element and recognize this revenue over the related service period we do not have vendor specific objective evidence of selling price available related to our future service obligations therefore we determine our estimates of selling price using third party evidence when available otherwise we use our best estimate of selling price we allocate arrangement consideration using the relative selling price method the use of alternative estimates of fair value could result in a different amount of revenue deferralinventory provisionswe base our provisions for excess expired and obsolete inventory primarily on our estimates of forecasted net sales a significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess expired and obsolete inventory in the future further the industry in which we participate is characterized by rapid product development and frequent new product introductions uncertain timing of nextgeneration product approvals variability in product launch strategies product recalls and variation in product utilization all affect our estimates related to excess expired and obsolete inventoryvaluation of intangible assets and contingent consideration liabilitieswe base the fair value of identifiable intangible assets acquired in a business combination including purchased research and development on detailed valuations that use information and assumptions provided by management which consider managements best estimates of inputs and assumptions that a market participant would use further for those arrangements that involve potential future contingent consideration we record on the date of acquisition a liability equal to the discounted fair value of the estimated additional consideration we may be obligated to make in the future we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones the use of alternative valuation assumptions including estimated revenue projections growth rates cash flows and discount rates and alternative estimated useful life assumptions or probabilities surrounding the achievement of clinical regulatory or revenuebased milestones could result in different purchase price allocations amortization expense and contingent consideration expense in current and future periodswe review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life if an impairment indicator exists we test the intangible asset for recoverability if the carrying value of the intangible asset is not recoverable as discussed in note a  significant accounting policies we will write the carrying value down to fair value in the period identified in addition we test our indefinitelived intangible assets at least annually for impairment and reassess their classification as indefinitelived assets we assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with asc topic 350 intangiblesgoodwill and other  if the carrying value exceeds the fair value of the indefinitelived intangible asset we write the carrying value down to the fair value61table of contentswe generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a riskadjusted discount rate in determining our estimated future cash flows associated with our intangible assets we use estimates and assumptions about future revenue contributions cost structures and remaining useful lives of the asset asset group the use of alternative assumptions including estimated cash flows discount rates and alternative estimated remaining useful lives could result in different calculations of impairmentgoodwill valuationwe allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill we test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist in performing the assessment we utilize the twostep approach prescribed under asc topic 350 intangiblesgoodwill and other the first step requires a comparison of the carrying value of the reporting units as defined to the fair value of these units we assess goodwill for impairment at the reporting unit level which is defined as an operating segment or one level below an operating segment referred to as a component we determine our reporting units by first identifying our operating segments and then assess whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component we aggregate components within an operating segment that have similar economic characteristics for our 2012 annual impairment assessments we identified six reporting units within the us including our crm neuromodulation endoscopy urologywomens health electrophysiology and cardiovascular consisting of interventional cardiology and peripheral interventions franchises which in aggregate make up the us reportable segment in addition we identified four international reporting units including emea japan asia pacific and the americas when allocating goodwill from business combinations to our reporting units we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition in addition for purposes of performing our goodwill impairment tests assets and liabilities including corporate assets which relate to a reporting units operations and would be considered in determining its fair value are allocated to the individual reporting units we allocate assets and liabilities not directly related to a specific reporting unit but from which the reporting unit benefits based primarily on the respective revenue contribution of each reporting unitduring 2012 2011 and 2010 we used only the income approach specifically the dcf method to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments this approach calculates fair value by estimating the aftertax cash flows attributable to a reporting unit and then discounting these aftertax cash flows to a present value using a riskadjusted discount rate we selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets we have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technologybased assets within our reporting units for application of the cost approach therefore we believe that the income approach represents the most appropriate valuation technique for which sufficient data is available to determine the fair value of our reporting unitsin applying the income approach to our accounting for goodwill we make assumptions about the amount and timing of future expected cash flows terminal value growth rates and appropriate discount rates the amount and timing of future cash flows within our dcf analysis is based on our most recent operational budgets long range strategic plans and other estimates the terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our dcf analysis and reflects our best estimates for stable perpetual growth of our reporting units we use estimates of marketparticipant riskadjusted wacc as a basis for determining the discount rates to apply to our reporting units future expected cash flowsif the carrying value of a reporting unit exceeds its fair value we then perform the second step of the goodwill impairment test to measure the amount of impairment loss if any the second step of the goodwill impairment test compares the estimated fair value of a reporting units goodwill to its carrying value if we were unable to complete the second step of the test prior to the issuance of our financial statements and an impairment loss was probable and could be reasonably estimated we would recognize our best estimate of the loss in our current period financial statements and disclose that the amount is an estimate we would then recognize any adjustment to that estimate in subsequent reporting periods once we have finalized the second step of the impairment testalthough we use consistent methodologies in developing the assumptions and estimates underlying the fair value calculations used in our impairment tests these estimates are uncertain by nature and can vary from actual results the use of alternative valuation assumptions including estimated revenue projections growth rates cash flows and discount rates could result in different fair value estimateswe continue to identify three reporting units with goodwill that is at higher risk of potential failure of the first step of the goodwill impairment test in future reporting periods these reporting units include our us crm reporting unit which holds 216 million 62table of contentsof remaining allocated goodwill our us cardiovascular reporting unit which holds 2380 billion of allocated goodwill and our us neuromodulation reporting unit which holds 1266 billion of allocated goodwill each as of december 31 2012 as of december 31 2012 the level of excess fair value over carrying value for these reporting units identified as being at higher risk with the exception of the us crm reporting unit whose carrying value continues to exceed its fair value was approximately seven  to 11 percent during the fourth quarter of 2012 the level of excess fair value over carrying value of our us cardiovascular reporting unit declined as a result of our performance declines in our market share due to competitive launches and continued average selling price declines in the us drugeluting stent des market as a result of continued competitive pressures and declines in procedural volumes on a quarterly basis we monitor the key drivers of fair value for these reporting units to detect events or other changes that would warrant an interim impairment test of our goodwill and intangible assets the key variables that drive the cash flows of our reporting units and amortizable intangibles are estimated revenue growth rates and levels of profitability terminal value growth rate assumptions as well as the wacc rate applied are additional key variables for reporting unit cash flows these assumptions are subject to uncertainty including our ability to grow revenue and improve profitability levels relatively small declines in the future performance and cash flows of a reporting unit or asset group or small changes in other key assumptions may result in the recognition of significant asset impairment charges for example keeping all other variables constant a 80 basis point decrease in the long term revenue and terminal growth rates would require that we perform the second step of the goodwill impairment test for the us neuromodulation reporting unit a 90 basis point decrease in the long term revenue and terminal growth rates would require that we perform the second step of the goodwill impairment test for the us cardiovascular reporting unit an increase in the wacc applied of 70 basis points would require that we perform the second step of the goodwill impairment test for the us neuromodulation and us cardiovascular reporting units given that the carrying value of the us crm reporting unit continues to exceed its fair value any negative changes in the key variables or values associated with this reporting unit would likely require that we perform the second step of the goodwill impairment test in a future reporting period the estimates used for our future cash flows and discount rates represent managements best estimates which we believe to be reasonable but future declines in business performance may impair the recoverability of our goodwill and intangible asset balances future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units andor amortizable intangible assets include but are not limited todecreases in estimated market sizes or market growth rates due to greaterthanexpected declines in procedural volumes pricing pressures product actions andor competitive technology developmentsdeclines in our market share and penetration assumptions due to increased competition an inability to develop or launch new and nextgeneration products and technology features in line with our commercialization strategies and market andor regulatory conditions that may cause significant launch delays or product recallsdecreases in our profitability due to an inability to successfully implement and achieve timely and sustainable cost improvement measures consistent with our expectations increases in our marketparticipant tax rate andor changes in tax lawsnegative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain productsthe level of success of ongoing and future research and development efforts including those related to recent acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new productsthe level of success in managing the growth of acquired companies achieving sustained profitability consistent with our expectations establishing government and thirdparty payer reimbursement and increases in the costs and time necessary to integrate acquired businesses into our operations successfullychanges in our reporting units or in the structure of our business as a result of future reorganizations or divestitures of assets or businessesincreases in our marketparticipant riskadjusted wacc anddeclines in revenue as a result of loss of key members of our sales force and other key personnelnegative changes in one or more of these factors among others could result in additional impairment charges63table of contentsincome taxeswe provide for potential amounts due in various tax jurisdictions in the ordinary course of conducting business in multiple countries and tax jurisdictions there are many transactions and calculations where the ultimate tax outcome is uncertain judgment is required in determining our worldwide income tax provision in our opinion we have made adequate provisions for income taxes for all years subject to audit although we believe our estimates are reasonable the final outcome of these matters may be different from that which we have reflected in our historical income tax provisions and accruals such differences could have a material impact on our income tax provision and operating resultswe reduce our deferred tax assets by a valuation allowance if based upon the weight of available evidence it is more likely than not that we will not realize some portion or all of the deferred tax assets we consider relevant evidence both positive and negative to determine the need for a valuation allowance information evaluated includes our financial position and results of operations for the current and preceding years the availability of deferred tax liabilities and tax carrybacks as well as an evaluation of currently available information about future yearsnew accounting pronouncementsstandards implementedasc update no 201104in may 2011 the fasb issued asc update no 201104 fair value measurement topic 820 amendments to achieve common fair value measurement and disclosure requirements in us gaap and ifrss update no 201104 clarifies the fasbs intent about the application of certain existing fair value measurement and disclosure requirements and changes certain principles or requirements for measuring or disclosing information about fair value it requires for all level 3 fair value measurements new quantitative information about significant unobservable inputs used we adopted update no 201104 beginning in our first quarter ended march 31 2012 the adoption of update no 201104 did not impact our results of operations or financial position see note b  acquisitions and note d  goodwill and other intangible assets for relevant disclosuresasc update no 201105in may 2011 the fasb issued asc update no 201105 comprehensive income topic 220 presentation of comprehensive income update no 201105 requires that net income items of other comprehensive income and total comprehensive income be presented in one continuous statement or two separate consecutive statements the amendments in this update also require that reclassifications from other comprehensive income to net income be presented on the face of the financial statements we adopted update no 201105 beginning in our first quarter ended march 31 2012 update no 201105 is related to presentation only and its adoption did not impact our results of operations or financial position asc update no 201202in july 2012 the fasb issued asc update no 201202 intangibles  goodwill and other topic 350 testing indefinitelived intangible assets for impairment update no 201202 provides companies with the option to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinitelived intangible asset is impaired if the company concludes that it is more likely than not that the asset is impaired it is required to determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with topic 350 if a company concludes otherwise no further quantitative assessment is required we adopted update no 201202 beginning in our third quarter ended september 30 2012 the adoption of update no 201202 did not impact our results of operations or financial position see note b  acquisitions and note d  goodwill and other intangible assets for relevant disclosuresstandards to be implementedin december 2011 the fasb issued asc update no 201111 disclosures about offsetting assets and liabilities topic 210 requiring enhanced disclosures about certain financial instruments and derivative instruments that are offset in the statement of financial position or that are subject to enforceable master netting arrangements or similar agreements this accounting standard update will be effective for us beginning in the first quarter of 2013 at which time we will include the required applicable disclosures update no 201111 disclosures about offsetting assets and liabilities topic 210 will not impact our future results of operations or financial position64table of contentsadditional informationuse of nongaap financial measures used by boston scientificto supplement our consolidated financial statements presented on a gaap basis we disclose certain nongaap financial measures including adjusted net income loss and adjusted net income loss per share that exclude certain amounts and regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates these nongaap financial measures are not in accordance with us gaap  the gaap financial measure most directly comparable to adjusted net income loss is gaap net income loss and the gaap financial measure most directly comparable to adjusted net income per share is gaap net income per share to calculate regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates we convert actual net sales from local currency to us dollars using constant foreign currency exchange rates in the current and prior period the gaap financial measure most directly comparable to this nongaap financial measure is growth rate percentages using net sales on a gaap basis reconciliations of each of these nongaap financial measures to the corresponding gaap financial measure are included in the accompanying schedules management uses these supplemental nongaap financial measures to evaluate performance period over period to analyze the underlying trends in our business to assess its performance relative to its competitors and to establish operational goals and forecasts that are used in allocating resources in addition management uses these nongaap financial measures to further its understanding of the performance of our operating segments the adjustments excluded from our nongaap financial measures are consistent with those excluded from its operating segments measures of profit or loss these adjustments are excluded from the segment measures that are reported to the our chief operating decision maker that are used to make operating decisions and assess performance  we believe that presenting adjusted net income adjusted net income per share and regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates in addition to the corresponding gaap financial measures provides investors greater transparency to the information used by our management for our financial and operational decisionmaking and allows investors to see our results through the eyes of management we further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance the following is an explanation of each of the adjustments that management excluded as part of these nongaap financial measures as well as reasons for excluding each of these individual itemsadjusted net income loss and adjusted net income loss per sharegoodwill and other intangible asset impairment charges  these amounts represent noncash writedowns of our goodwill balances attributable to its a us cardiac rhythm management reporting unit in the third quarter of 2012 b europemiddle eastafrica emea reporting unit recorded in the second quarter of 2012 and c us cardiac rhythm management reporting unit recorded in the first quarter of 2011 and noncash writedowns of certain other intangible asset balances management removes the impact of noncash goodwill and other intangible asset impairment charges from our operating performance to assist in assessing our cash generated from operations management believes this is a critical metric for us in measuring our ability to generate cash and invest in our growth therefore these charges are excluded from managements assessment of operating performance and are also excluded for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to the our past operating performance particularly in terms of liquidityacquisition and divestiture related net credits  these adjustments consist of a acquisitionrelated gains on previously held investments b contingent consideration fair value adjustments c inventory stepup adjustments d due diligence and other fees exit costs and other costs and credits related to current and prior period acquisitions e gains resulting from business divestitures and f fees and separation costs associated with business divestitures the acquisitionrelated gains on previously held investments are nonrecurring benefits associated with acquisitions completed in the second quarter and fourth quarters of 2012 and the first quarter of 2011 the contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value these adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments the inventory stepup adjustment is a charge related to acquired inventory directly attributable to prior acquisitions and is not indicative of our ongoing operations or ongoing cost of products sold due diligence exit costs and other costs and credits include legal tax severance and other expenses and credits associated with prior acquisitions that are not representative of ongoing operations the divestiturerelated net credits are related to the 65table of contentssale of our neurovascular business in january 2011 the resulting gains are not indicative of future operating performance and are not used by management to assess operating performance fees and separation costs represent those associated with our divestiture of its neurovascular business and are not representative of ongoing operations accordingly management excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performancerestructuring and restructuringrelated charges  these adjustments represent primarily severance costs to transfer production lines from one facility to another and other direct costs associated with the companys 2011 restructuring plan 2010 restructuring plan and plant network optimization program these expenses are excluded by management in assessing the our operating performance as well as from our operating segments measures of profit and loss used for making operating decisions and assessing performance accordingly management excluded these charges for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performancelitigationrelated charges  these adjustments include certain significant product liability and other litigationrelated charges and credits these amounts are excluded by management in assessing our operating performance as well as from our operating segments measures of profit and loss used for making operating decisions and assessing performance accordingly management excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performancediscrete tax items  these items represent adjustments of certain tax positions which were initially established in prior periods as a result of intangible asset impairment charges acquisition divestiture restructuring or litigationrelated charges credits these adjustments do not reflect expected ongoing operating results accordingly management excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performanceamortization expense  amortization expense is a noncash charge and does not impact our liquidity or compliance with the covenants included in its credit facility agreement management removes the impact of amortization from our operating performance to assist in assessing our cash generated from operations management believes this is a critical metric for us in measuring our ability to generate cash and invest in our growth therefore amortization expense is excluded from managements assessment of operating performance and is also excluded from the measures management uses to set employee compensation accordingly management has excluded amortization expense for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance particularly in terms of liquidityregional and divisional revenue growth rates excluding the impact of changes in foreign currency exchange rateschanges in foreign currency exchange rates  the impact of changes in foreign currency exchange rates is highly variable and difficult to predict accordingly management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing regional and divisional revenue growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performanceadjusted net income loss adjusted net income loss per share and regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates are not in accordance with generally accepted accounting principles in the united states and should not be considered in isolation from or as a replacement for the most directly comparable gaap financial measures further other companies may calculate these nongaap financial measures differently than us which may limit the usefulness of those measures for comparative purposesrule 10b51 trading plansperiodically certain of our executive officers adopt written stock trading plans in accordance with rule 10b51 under the securities exchange act of 1934 and our own stock trading policy a rule 10b51 trading plan is a written document that preestablishes the amounts prices and dates or formulas for determining the amounts prices and dates of future purchases or sales of our stock including the exercise and sale of stock options and is entered into at a time when the person is not in possession of material nonpublic information about the company66table of contentsmanagements annual report on internal control over financial reportingas the management of boston scientific corporation we are responsible for establishing and maintaining adequate internal control over financial reporting we designed our internal control process to provide reasonable assurance to management and the board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principleswe assessed the effectiveness of our internal control over financial reporting as of december 31 2012 in making this assessment we used the criteria set forth by the committee of sponsoring organizations of the treadway commission in internal controlintegrated framework based on our assessment we believe that as of december 31 2012 our internal control over financial reporting is effective at a reasonable assurance level based on these criteriaernst amp young llp an independent registered public accounting firm has issued an audit report on the effectiveness of our internal control over financial reporting this report in which they expressed an unqualified opinion is included below        s michael f mahoney s jeffrey d capello        michael f mahoney  jeffrey d capello   president and chief executive officer  executive vice president and chieffinancial officer 67table of contentsreport of independent registered public accounting firmthe board of directors and stockholders of boston scientific corporationwe have audited boston scientific corporations internal control over financial reporting as of december 31 2012 based on criteria established in internal controlintegrated framework issued by the committee of sponsoring organizations of the treadway commission the coso criteria boston scientific corporations management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying managements annual report on internal control over financial reporting our responsibility is to express an opinion on the companys internal control over financial reporting based on our auditwe conducted our audit in accordance with the standards of the public company accounting oversight board united states those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects our audit included obtaining an understanding of internal control over financial reporting assessing the risk that a material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedures as we considered necessary in the circumstances we believe that our audit provides a reasonable basis for our opiniona companys internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles a companys internal control over financial reporting includes those policies and procedures that 1 pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company 2 provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company and 3 provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the companys assets that could have a material effect on the financial statementsbecause of its inherent limitations internal control over financial reporting may not prevent or detect misstatements also projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deterioratein our opinion boston scientific corporation maintained in all material respects effective internal control over financial reporting as of december 31 2012 based on the coso criteriawe also have audited in accordance with the standards of the public company accounting oversight board united states the consolidated balance sheets of boston scientific corporation as of december 31 2012 and 2011 and the related consolidated statements of operations comprehensive income loss stockholders equity and cash flows for each of the three years in the period ended december 31 2012 of boston scientific corporation and our report dated february 22 2013 expressed an unqualified opinion thereons ernst amp young llpboston massachusettsfebruary 22 201368table of contentsitem 7a quantitative and qualitative disclosures about market riskwe develop manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates we address these risks through a risk management program that includes the use of derivative financial instruments we operate the program pursuant to documented corporate risk management policies we do not enter derivative transactions for speculative purposes gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures furthermore we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positionsour currency risk consists primarily of foreign currency denominated firm commitments forecasted foreign currency denominated intercompany and thirdparty transactions and net investments in certain subsidiaries we use both nonderivative primarily european manufacturing operations and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates we had currency derivative instruments outstanding in the contract amount of 4411 billion as of december 31 2012 and 4297 billion as of december 31 2011 we recorded 121 million of other assets and 57 million of other liabilities to recognize the fair value of these derivative instruments as of december 31 2012 as compared to 87 million of other assets and 131 million of other liabilities as of december 31 2011 a ten percent appreciation in the us dollars value relative to the hedged currencies would increase the derivative instruments fair value by 270 million as of december 31 2012 and 230 million as of december 31 2011 a ten percent depreciation in the us dollars value relative to the hedged currencies would decrease the derivative instruments fair value by 319 million as of december 31 2012 and by 281 million as of december 31 2011 any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset liability or forecasted transaction resulting in minimal impact on our consolidated statements of operationsour interest rate risk relates primarily to us dollar borrowings partially offset by us dollar cash investments we have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates we entered into interest rate derivative contracts having a notional amount of 850 million in the first quarter of 2011 to convert fixedrate debt associated with certain of our senior notes into floatingrate debt and subsequently terminated these hedges during the third quarter of 2011 we had no interest rate derivative instruments outstanding as of december 31 2012 and december 31 2011 as of december 31 2012 4250 billion of our outstanding debt obligations was at fixed interest rates representing approximately 100 percent of our total debtsee note e  fair value measurements to our 2012 consolidated financial statements contained in item 8 of this annual report for further information regarding our derivative financial instruments69table of contentsreport of independent registered public accounting firmthe board of directors and stockholders of boston scientific corporationwe have audited the accompanying consolidated balance sheets of boston scientific corporation as of december 31 2012 and 2011 and the related consolidated statements of operations comprehensive income loss stockholders equity and cash flows for each of the three years in the period ended december 31 2012 our audits also included the financial statement schedule listed in the index at item 15a2 these financial statements and schedule are the responsibility of the companys management our responsibility is to express an opinion on these financial statements and schedule based on our auditswe conducted our audits in accordance with the standards of the public company accounting oversight board united states those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement an audit includes examining on a test basis evidence supporting the amounts and disclosures in the financial statements an audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation we believe that our audits provide a reasonable basis for our opinionin our opinion the financial statements referred to above present fairly in all material respects the consolidated financial position of boston scientific corporation at december 31 2012 and 2011 and the consolidated results of its operations and its cash flows for each of the three years in the period ended december 31 2012 in conformity with us generally accepted accounting principles also in our opinion the related financial statement schedule when considered in relation to the basic financial statements taken as a whole presents fairly in all material respects the information set forth thereinwe also have audited in accordance with the standards of the public company accounting oversight board united states boston scientific corporations internal control over financial reporting as of december 31 2012 based on criteria established in internal controlintegrated framework issued by the committee of sponsoring organizations of the treadway commission and our report dated february 22 2013 expressed an unqualified opinion thereons ernst amp young llpboston massachusettsfebruary 22 201370table of contentsitem 8 financial statements and supplementary databoston scientific corporation and subsidiariesconsolidated statements of operations year ended december 31in millions except per share data201220112010    net sales724976227806cost of products sold234926592599gross profit490049635207    operating expenses   selling general and administrative expenses253524872580research and development expenses886895939royalty expense153172185amortization expense395421513goodwill impairment charges43506971817intangible asset impairment charges1422165contingent consideration expense benefit672acquisitionrelated milestone250restructuring charges13689116litigationrelated charges credits19248104gain on divestiture15778 876840595863operating income loss3868904656    other income expense   interest expense261281393other net221914income loss before income taxes41076421063income tax expense benefit392012net income loss40684411065    net income loss per common share  basic289029070net income loss per common share  assuming dilution289029070    weightedaverage shares outstanding   basic140671509315178assuming dilution140671519015178see notes to the consolidated financial statements71table of contentsboston scientific corporation and subsidiariesconsolidated balance sheets as of december 31in millions except share and per share data2012 2011    assets   current assets   cash and cash equivalents207 267trade accounts receivable net1217 1246inventories884 931deferred income taxes433 458prepaid expenses and other current assets281 203total current assets3022 3105property plant and equipment net1564 1670goodwill5973 9761other intangible assets net6289 6473other longterm assets306 281total assets17154 21290    liabilities and stockholders equity   current liabilities   current debt obligations4 4accounts payable232 203accrued expenses1284 1327other current liabilities252 273total current liabilities1772 1807longterm debt4252 4257deferred income taxes1713 1865other longterm liabilities2547 2008    commitments and contingencies     stockholders equity   preferred stock 001 par value  authorized 50000000 shares none issued and outstanding common stock 001 par value  authorized 2000000000 shares issued 1542347188 shares as of december 31 2012 and 1531006390 shares as of december 31 201115 15treasury stock at cost  186635532 shares as of december 31 2012 and 81950716 shares as of december 31 20111092 492additional paidin capital16429 16349accumulated deficit8449 4381accumulated other comprehensive loss net of tax   foreign currency translation adjustment26 58unrealized gain loss on derivative financial instruments34 48unrealized costs associated with certain retirement plans41 32total stockholders equity6870 11353total liabilities and stockholders equity17154 21290see notes to the consolidated financial statements72table of contentsboston scientific corporation and subsidiariesconsolidated statements of stockholders equity            accumulated        additional   other  common stock treasury paidin accumulated comprehensivein millions except share data shares issued par value stock capital deficit income lossbalance as of december 31 2009 1510753934 15  16086 3757 43comprehensive income           net loss        1065  other comprehensive loss net of tax           foreign currency translation adjustment          58net change in derivative financial instruments          28impact of stockbased compensation plans net of tax 10026178    146    balance as of december 31 2010 1520780112 15  16232 4822 129comprehensive income           net income        441  other comprehensive income loss net of tax           foreign currency translation adjustment          8net change in derivative financial instruments          17net change in certain retirement plans      18impact of stockbased compensation plans net of tax 10226278   117    acquisition of treasury stock   492   balance as of december 31 2011 1531006390 15 492 16349 4381 138comprehensive income           net loss        4068  other comprehensive income loss net of tax          foreign currency translation adjustment          32net change in derivative financial instruments          82net change in certain retirement plans      9impact of stockbased compensation plans net of tax 11340798   80    acquisition of treasury stock   600   balance as of december 31 2012 1542347188 15 1092 16429 8449 33             see notes to the consolidated financial statements73table of contentsboston scientific corporation and subsidiariesconsolidated statements of comprehensive income loss  year ended december 31in millions 2012 2011 2010net loss income 4068 441 1065other comprehensive loss income      foreign currency translation adjustment 32 8 58net change in unrealized gains and losses on derivative financial instruments net of tax 82 17 28net change in certain retirement plans 9 18  total other comprehensive loss income 105 9 86total comprehensive loss income 3963 432 1151see notes to the consolidated financial statements74table of contentsboston scientific corporation and subsidiariesconsolidated statements of cash flows  year ended december 31in millions201220112010operating activities   net loss income40684411065adjustments to reconcile net income loss to cash provided by operating activities   gain on sale of businesses15778depreciation and amortization683717816deferred income taxes16646110stockbased compensation expense108128150goodwill impairment charges43506971817intangible asset impairment charges1422165net gains losses on investments and notes receivable372712contingent consideration income expense672payment of contingent consideration in excess of amounts established in purchase accounting8  other net7711increase decrease in cash flows from operating assets and liabilities   trade accounts receivable374252inventories66545other assets6860132accounts payable and accrued expenses1312711148other liabilities380106404cash provided by operating activities12601008325    investing activities   property plant and equipment   purchases of property plant and equipment226304272proceeds on disposals16165acquisitions   payments for acquisitions of businesses net of cash acquired366370199divestitures   proceeds from business divestitures net of costs101440other investing activity   payments for investments and acquisitions of certain technologies22116proceeds from investments and collections of notes receivable954cash used for provided by investing activities579776468    financing activities   debt   payments of contingent consideration amounts previously established in purchase accounting146712proceeds from longterm borrowings net of debt issuance costs973payments on longterm borrowings1012501500proceeds from borrowings on credit facilities371565200payments on borrowings from credit facilities380565200equity   payments for acquisitions of treasury stock600492proceeds from issuances of shares of common stock212131cash used for financing activities7441728508    effect of foreign exchange rates on cash32    net increase decrease in cash and cash equivalents6054651cash and cash equivalents at beginning of period267213864cash and cash equivalents at end of period207267213    supplemental information   cash paid received for income taxes net97138286cash paid for interest255277328fair value of contingent consideration recorded46528769see notes to the consolidated financial statements75table of contentsnotes to the consolidated financial statementsnote a  significant accounting policiesprinciples of consolidationour consolidated financial statements include the accounts of boston scientific corporation and our whollyowned subsidiaries after the elimination of intercompany transactions we assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity vie  for any vies we perform an analysis to determine whether our variable interests give us a controlling financial interest in a vie the analysis identifies the primary beneficiary of a vie as the enterprise that has both 1 the power to direct activities of a vie that most significantly impact the entitys economic performance and 2 the obligation to absorb losses of the entity or the right to receive benefits from the entity based on our assessments under the applicable guidance we did not have significant interests in any vies and therefore did not consolidate any vies during the years ended december 31 2012 2011 and 2010on january 3 2011 we closed the sale of our neurovascular business to stryker corporation we are providing transitional services to stryker through a transition services agreement we are also manufacturing and supplying products to stryker through a supply agreement these transition services and supply agreements are expected to end in 2013 due to our continuing involvement in the operations of the neurovascular business the divestiture does not meet the criteria for presentation as a discontinued operation and therefore the results of the neurovascular business are included in our results of operations for all periods presented refer to note c  divestitures and assets held for sale for a description of this business divestiturebasis of presentationthe accompanying consolidated financial statements of boston scientific corporation have been prepared in accordance with accounting principles generally accepted in the united states us gaap and with the instructions to form 10k and article 10 of regulation sxreclassificationwe have reclassified certain prior year amounts to conform to the current years presentation see note o  segment reporting for further detailssubsequent eventswe evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our financial statements we did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements recognized subsequent events those items requiring disclosure unrecognized subsequent events in the financial statements have been disclosed accordingly refer to note k commitments and contingencies note l  stockholders equity and note h  restructuringrelated activities for more informationaccounting estimatesto prepare our consolidated financial statements in accordance with us gaap management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities the disclosure of contingent liabilities as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting period our actual results may differ from these estimates refer to critical accounting estimates included in item 7 of this annual report for further discussioncash and cash equivalentswe record cash and cash equivalents in our consolidated balance sheets at cost which approximates fair value our policy is to invest excess cash in shortterm marketable securities earning a market rate of interest without assuming undue risk to principal and we limit our direct exposure to securities in any one industry or issuer we consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalentswe record availableforsale investments at fair value and exclude unrealized gains and temporary losses on availableforsale securities from earnings reporting such gains and losses net of tax as a separate component of stockholders equity until realized we compute realized gains and losses on sales of availableforsale securities based on the average cost method adjusted for any otherthantemporary declines in fair value we held no availableforsale securities during 2012 2011 and 2010 76table of contentsconcentrations of credit riskfinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents derivative financial instrument contracts and accounts and notes receivable our investment policy limits exposure to concentrations of credit risk and changes in market conditions counterparties to financial instruments expose us to creditrelated losses in the event of nonperformance we transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure we provide credit in the normal course of business to hospitals healthcare agencies clinics doctors offices and other private and governmental institutions and generally do not require collateral we record our accounts receivable in our consolidated balance sheets at net realizable value we perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses based on historical information and managements best estimates amounts determined to be uncollectible are written off against this reserve we recorded writeoffs of uncollectible accounts receivable of 7 million in 2012 13 million in 2011 and 15 million in 2010 we are not dependent on any single institution and no single customer accounted for more than ten percent of our net sales in 2012 2011 or 2010 or accounts receivable at december 31 2012 or 2011 however large group purchasing organizations hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our us net saleswe closely monitor outstanding receivables for potential collection risks including those that may arise from economic conditions in both the us and international economies our european sales to governmentowned or supported customers in southern europe specifically greece italy spain and portugal are subject to an increased number of days outstanding above historical levels prior to payment due to the fiscal and debt crises in these countries historically receivable balances with certain publiclyowned hospitals in these countries accumulate over a period of time and are then subsequently settled as large lump sum payments while we believe our allowance for doubtful accounts in these countries is adequate as of december 31 2012 if significant changes were to occur in the payment practices of these european governments or if government funding becomes unavailable we may not be able to collect on receivables due to us from these customers and our writeoffs of uncollectible amounts may increase as of december 31 2012 our net receivables in these countries greater than 180 days past due totaled 51 million of which 17 million were past due greater than 365 days  revenue recognitionwe generate revenue primarily from the sale of singleuse medical devices and present revenue net of sales taxes in our consolidated statements of operations we sell our products primarily through a direct sales force in certain international markets we sell our products through independent distributors we consider revenue to be realized or realizable and earned when all of the following criteria are met persuasive evidence of a sales arrangement exists delivery has occurred or services have been rendered the price is fixed or determinable and collectibility is reasonably assured revenue is recognized upon passage of title and risk of loss to customers unless a consignment arrangement exists or we are required to provide additional services and provided we can form an estimate for sales returns we recognize revenue from consignment arrangements based on product usage or implant which indicates that the sale is complete many of our cardiac rhythm management crm product offerings combine the sale of a device with our latitude patient management system which represents a future service obligation for revenue arrangements with multiple deliverables where the sale of a device is combined with a future service obligation we defer revenue on the undelivered element and recognize this revenue over the related service period we do not have vendor specific objective evidence of selling price available related to our future service obligations therefore we determine our estimates of selling price using third party evidence when available otherwise we use our best estimate of selling price we allocate arrangement consideration using the relative selling price methodwe generally allow our customers to return defective damaged and in certain cases expired products for credit we base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product in addition we may allow customers to return previously purchased products for nextgeneration product offerings for these transactions we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the nextgeneration products are shipped to the customerwe also offer sales rebates and discounts to certain customers we treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current we estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates if we are unable to estimate the expected rebates reasonably we record a liability for the maximum rebate percentage offered we have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices we recognize revenue from these agreements following the same revenue recognition criteria discussed above77table of contentswarranty obligationswe offer warranties on certain of our product offerings the majority of our warranty liability relates to implantable devices offered by our crm business which include defibrillator and pacemaker systems our crm products come with a standard limited warranty covering the replacement of these devices we offer a full warranty for a portion of the period postimplant and a partial warranty for a period of time thereafter we estimate the costs that we may incur under our warranty programs based on the number of units sold historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs we assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessarychanges in our product warranty accrual during 2012 2011 and 2010 consisted of the following in millions  year ended december 31  2012 2011 2010beginning balance 30 43 55provision 8 9 15settlements reversals 12 22 27ending balance 26 30 43inventorieswe state inventories at the lower of firstin firstout cost or market we base our provisions for excess expired and obsolete inventory primarily on our estimates of forecasted net sales a significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess expired and obsolete inventory in the future further the industry in which we participate is characterized by rapid product development and frequent new product introductions uncertain timing of nextgeneration product approvals variability in product launch strategies product recalls and variation in product utilization all affect our estimates related to excess expired and obsolete inventory approximately 40 percent of our finished goods inventory as of december 31 2012 and 2011 was at customer locations pursuant to consignment arrangements property plant and equipmentwe state property plant equipment and leasehold improvements at historical cost we charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset we provide for depreciation using the straightline method at rates that approximate the estimated useful lives of the assets we depreciate buildings and improvements over a 20 to 40 year life equipment furniture and fixtures over a three to ten year life and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease depreciation expense was 288 million in 2012 296 million in 2011 and 303 million in 2010valuation of business combinationswe allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the dates of acquisition including identifiable intangible assets and purchased research and development which either arise from a contractual or legal right or are separable from goodwill we base the fair value of identifiable intangible assets acquired in a business combination including purchased research and development on detailed valuations that use information and assumptions provided by management which consider managements best estimates of inputs and assumptions that a market participant would use we allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired to goodwill the use of alternative valuation assumptions including estimated revenue projections growth rates cash flows discount rates estimated useful lives and probabilities surrounding the achievement of clinical regulatory or revenuebased milestones could result in different purchase price allocations and amortization expense in current and future periods transaction costs associated with these acquisitions are expensed as incurred through selling general and administrative costsin those circumstances where an acquisition involves a contingent consideration arrangement we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones 78table of contentsindefinitelived intangibles including inprocess research and developmentour indefinitelived intangible assets that are not subject to amortization primarily include acquired stent and balloon technology which is foundational to our continuing operations within the cardiovascular market and other markets within interventional medicine and purchased research and development intangible assets acquired in a business combination our purchased research and development represents intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility regardless of whether they have alternative future use the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region we classify purchased research and development acquired in a business combination as an indefinitelived intangible asset until the completion or abandonment of the associated research and development efforts upon completion of the associated research and development efforts we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives upon permanent abandonment we would writeoff the remaining carrying amount of the associated purchased research and development intangible asset we test our indefinitelived intangible assets at least annually for impairment and reassess their classification as indefinitelived assets we assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with asc topic 350 intangiblesgoodwill and other  if the carrying value exceeds the fair value of the indefinitelived intangible asset we write the carrying value down to the fair valuewe use the income approach to determine the fair values of our purchased research and development this approach calculates fair value by estimating the aftertax cash flows attributable to an inprocess project over its useful life and then discounting these aftertax cash flows back to a present value we base our revenue assumptions on estimates of relevant market sizes expected market growth rates expected trends in technology and expected levels of market share in arriving at the value of the inprocess projects we consider among other factors the inprocess projects stage of completion the complexity of the work completed as of the acquisition date the costs already incurred the projected costs to complete the contribution of other acquired assets the expected regulatory path and introduction dates by region and the estimated useful life of the technology we apply a marketparticipant riskadjusted discount rate to arrive at a present value as of the date of acquisition we believe that the estimated inprocess research and development amounts so determined represent the fair value and do not exceed the amount a third party would pay for the projects however if the projects are not successful or completed in a timely manner we may not realize the financial benefits expected for these projects or for the acquisition as a wholewe test our purchased research and development intangible assets acquired in a business combination for impairment at least annually during the third quarter and more frequently if events or changes in circumstances indicate that the assets may be impaired for asset purchases outside of business combinations we expense any purchased research and development assets as of the acquisition date amortization and impairment of intangible assetswe record intangible assets at historical cost and amortize them over their estimated useful lives we use a straightline method of amortization unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined the approximate useful lives for amortization of our intangible assets is as follows patents and licenses two to 20 years definitelived technologyrelated five to 25 years customer relationships five to 25 years other intangible assets variouswe review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life conditions that may indicate impairment include but are not limited to a significant adverse change in legal factors or business climate that could affect the value of an asset a product recall or an adverse action or assessment by a regulator if an impairment indicator exists we test the intangible asset for recoverability for purposes of the recoverability test we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities if the carrying value of the intangible asset asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset asset group we will write the carrying value down to the fair value in the period identified we generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a riskadjusted discount rate in determining our estimated future cash flows associated with our intangible assets we use estimates and assumptions about future revenue contributions cost structures and remaining useful lives of the asset asset group the use of alternative assumptions including estimated cash flows discount rates and alternative estimated 79table of contentsremaining useful lives could result in different calculations of impairment however we believe our assumptions and estimates are reasonable and represent our best estimates see note d  goodwill and other intangible assets for more information related to impairments of intangible assets during 2012 2011 and 2010for patents developed internally we capitalize costs incurred to obtain patents including attorney fees registration fees consulting fees and other expenditures directly related to securing the patent goodwill valuationwe allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill we test our april 1 goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist in performing the assessment we utilize the twostep approach prescribed under asc topic 350 intangiblesgoodwill and other the first step requires a comparison of the carrying value of the reporting units as defined to the fair value of these units we assess goodwill for impairment at the reporting unit level which is defined as an operating segment or one level below an operating segment referred to as a component we determine our reporting units by first identifying our operating segments and then assess whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component we aggregate components within an operating segment that have similar economic characteristics for our 2012 impairment assessments we identified six reporting units within the us including our crm neuromodulation endoscopy urologywomens health electrophysiology and cardiovascular consisting of interventional cardiology and peripheral interventions franchises which in aggregate make up the us reportable segment in addition we identified four international reporting units including emea japan asia pacific and the americas when allocating goodwill from business combinations to our reporting units we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition in addition for purposes of performing our goodwill impairment tests assets and liabilities including corporate assets which relate to a reporting units operations and would be considered in determining its fair value are allocated to the individual reporting units we allocate assets and liabilities not directly related to a specific reporting unit but from which the reporting unit benefits based primarily on the respective revenue contribution of each reporting unitduring 2012 2011 and 2010 we used only the income approach specifically the discounted cash flow dcf method to derive the fair value of each of our reporting units in preparing our goodwill impairment assessment this approach calculates fair value by estimating the aftertax cash flows attributable to a reporting unit and then discounting these aftertax cash flows to a present value using a riskadjusted discount rate we selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets we have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technologybased assets within our reporting units for application of the cost approach therefore we believe that the income approach represents the most appropriate valuation technique for which sufficient data is available to determine the fair value of our reporting unitsin applying the income approach to our accounting for goodwill we make assumptions about the amount and timing of future expected cash flows terminal value growth rates and appropriate discount rates the amount and timing of future cash flows within our dcf analysis is based on our most recent operational budgets long range strategic plans and other estimates the terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our dcf analysis and reflects our best estimates for stable perpetual growth of our reporting units we use estimates of marketparticipant riskadjusted weightedaverage costs of capital wacc as a basis for determining the discount rates to apply to our reporting units future expected cash flowsif the carrying value of a reporting unit exceeds its fair value we then perform the second step of the goodwill impairment test to measure the amount of impairment loss if any the second step of the goodwill impairment test compares the estimated fair value of a reporting units goodwill to its carrying value if we were unable to complete the second step of the test prior to the issuance of our financial statements and an impairment loss was probable and could be reasonably estimated we would recognize our best estimate of the loss in our current period financial statements and disclose that the amount is an estimate we would then recognize any adjustment to that estimate in subsequent reporting periods once we have finalized the second step of the impairment test see note d  goodwill and other intangible assets for discussion of our goodwill impairment chargesinvestments in publicly traded and privately held entitieswe account for our publicly traded investments as availableforsale securities based on the quoted market price at the end of the reporting period we compute realized gains and losses on sales of availableforsale securities based on the average cost method 80table of contentsadjusted for any otherthantemporary declines in fair value we account for our investments in privately held entities for which fair value is not readily determinable in accordance with asc topic 323 investments  equity method and joint ventures we account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a vie in which we are the primary beneficiary we record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee including all adjustments similar to those made in preparing consolidated financial statements the book value of investments that we accounted for under the equity method of accounting was 16 million as of december 31 2012 and 7 million as of december 31 2011 we account for investments in entities in which we have less than a 20 percent ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee the aggregate carrying amount of our cost method investments was 13 million as of december 31 2012 and 16 million as of december 31 2011 in addition we had notes receivable from certain companies of 5 million as of december 31 2012 and 44 million as of december 31 2011each reporting period we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment examples of such impairment indicators include but are not limited to a significant deterioration in earnings performance recent financing rounds at reduced valuations a significant adverse change in the regulatory economic or technological environment of an investee or a significant doubt about an investees ability to continue as a going concern if we identify an impairment indicator we will estimate the fair value of the investment and compare it to its carrying value our estimation of fair value considers all available financial information related to the investee including valuations based on recent thirdparty equity investments in the investee if the fair value of the investment is less than its carrying value the investment is impaired and we make a determination as to whether the impairment is otherthantemporary we deem an impairment to be otherthantemporary unless we have the ability and intent to hold an investment for a period sufficient for a market recovery up to the carrying value of the investment further evidence must indicate that the carrying value of the investment is recoverable within a reasonable period for otherthantemporary impairments we recognize an impairment loss equal to the difference between an investments carrying value and its fair value impairment losses on our investments are included in other net in our consolidated statements of operationsincome taxeswe utilize the asset and liability method of accounting for income taxes under this method we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities we measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse we reduce our deferred tax assets by a valuation allowance if based upon the weight of available evidence it is more likely than not that we will not realize some portion or all of the deferred tax assets we consider relevant evidence both positive and negative to determine the need for a valuation allowance information evaluated includes our financial position and results of operations for the current and preceding years the availability of deferred tax liabilities and tax carrybacks as well as an evaluation of currently available information about future yearswe do not provide income taxes on unremitted earnings of our foreign subsidiaries where we have indefinitely reinvested such earnings in our foreign operations it is not practical to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations unremitted earnings of our foreign subsidiaries that we have indefinitely reinvested in foreign operations are 11041 billion as of december 31 2012 and 10346 billion as of december 31 2011we provide for potential amounts due in various tax jurisdictions in the ordinary course of conducting business in multiple countries and tax jurisdictions there are many transactions and calculations where the ultimate tax outcome is uncertain judgment is required in determining our worldwide income tax provision in our opinion we have made adequate provisions for income taxes for all years subject to audit although we believe our estimates are reasonable the final outcome of open tax matters may be different from that which we have reflected in our historical income tax provisions and accruals such differences could have a material impact on our income tax provision and operating results see note j  income taxes for further information and discussion of our income tax provision and balanceslegal and product liability costswe are involved in various legal and regulatory proceedings including intellectual property breach of contract securities litigation and product liability suits in some cases the claimants seek damages as well as other relief which if granted could require significant expenditures or impact our ability to sell our products we are also the subject of certain governmental investigations which could result in substantial fines penalties and administrative remedies we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims we generally record losses for claims in excess of the limits of purchased insurance in earnings at the time and to the extent they are probable and estimable we accrue anticipated costs of 81table of contentssettlement damages losses for general product liability claims and under certain conditions costs of defense based on historical experience or to the extent specific losses are probable and estimable otherwise we expense these costs as incurred if the estimate of a probable loss is a range and no amount within the range is more likely we accrue the minimum amount of the range we analyze litigation settlements to identify each element of the arrangement we allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit see note k  commitments and contingencies for discussion of our individual material legal proceedingscosts associated with exit activitieswe record employee termination costs in accordance with asc topic 712 compensation  nonretirement and postemployment benefits if we pay the benefits as part of an ongoing benefit arrangement which includes benefits provided as part of our domestic severance policy or that we provide in accordance with international statutory requirements we accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered the rights to the benefits have vested the payment is probable and we can reasonably estimate the liability we account for employee termination benefits that represent a onetime benefit in accordance with asc topic 420 exit or disposal cost obligations we record such costs into expense over the employees future service period if any in addition in conjunction with an exit activity we may offer voluntary termination benefits to employees these benefits are recorded when the employee accepts the termination benefits and the amount can be reasonably estimated other costs associated with exit activities may include contract termination costs including costs related to leased facilities to be abandoned or subleased and impairments of longlived assets and are expensed in accordance with asc topic 420 and asc topic 360 property plant and equipmenttranslation of foreign currencywe translate all assets and liabilities of foreign subsidiaries from local currency into us dollars using the yearend exchange rate and translate revenues and expenses at the average exchange rates in effect during the year we show the net effect of these translation adjustments in our consolidated financial statements as a component of accumulated other comprehensive loss for any significant foreign subsidiaries located in highly inflationary economies we would remeasure their financial statements as if the functional currency were the us dollar we did not record any highly inflationary economy translation adjustments in 2012 2011 or 2010foreign currency transaction gains and losses are included in other net in our consolidated statements of operations net of losses and gains from any related derivative financial instruments we recognized net foreign currency transaction losses of 18 million in 2012 12 million in 2011 and 9 million in 2010financial instrumentswe recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with asc topic 815 derivatives and hedging and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements in accordance with topic 815 for those derivative instruments that are designated and qualify as hedging instruments the hedging instrument must be designated based upon the exposure being hedged as a fair value hedge cash flow hedge or a hedge of a net investment in a foreign operation the accounting for changes in the fair value ie gains or losses of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further on the type of hedging relationship our derivative instruments do not subject our earnings or cash flows to material risk as gains and losses on these derivatives generally offset losses and gains on the item being hedged we do not enter into derivative transactions for speculative purposes and we do not have any nonderivative instruments that are designated as hedging instruments pursuant to topic 815 refer to note e  fair value measurements for more information on our derivative instrumentsshipping and handling costswe generally do not bill customers for shipping and handling of our products shipping and handling costs of 105 million in 2012 100 million in 2011 and 88 million in 2010 are included in selling general and administrative expenses in the accompanying consolidated statements of operationsresearch and developmentwe expense research and development costs including new product development programs regulatory compliance and clinical research as incurred refer to purchased research and development for our policy regarding inprocess research and development acquired in connection with our business combinations and asset purchases82table of contentsemployee retirement plansin connection with our 2006 acquisition of guidant corporation we sponsor the guidant retirement plan a frozen noncontributory defined benefit plan covering a select group of current and former employees the funding policy for the plan is consistent with us employee benefit and taxfunding regulations plan assets which are maintained in a trust consist primarily of equity and fixedincome instruments further we sponsor the guidant supplemental retirement plan a frozen nonqualified defined benefit plan for certain former officers and employees of guidant the guidant supplemental retirement plan was funded through a rabbi trust that contains segregated company assets used to pay the benefit obligations related to the plan in addition certain current and former employees of guidant are eligible to receive a portion of their healthcare retirement benefits under a frozen defined benefit planin addition we maintain an executive retirement plan a defined benefit plan covering executive officers and division presidents participants may retire with unreduced benefits once retirement conditions have been satisfied we also maintain retirement plans covering certain international employeeswe use a december 31 measurement date for these plans and record the underfunded portion as a liability recognizing changes in the funded status through other comprehensive income the outstanding obligation as of december 31 2012 and 2011 is as follows  as of december 31 2012 as of december 31 2011in millions projectedbenefitobligation pbo fair value of plan assets underfundedpbo recognized projectedbenefitobligation pbo fair value of plan assets underfundedpbo recognizedexecutive retirement plan 13  13 14  14guidant retirement plan frozen 131 87 44 118 75 43guidant supplemental retirement plan frozen 34  34 32  32guidant healthcare retirement benefit plan frozen 5  5 10  10international retirement plans 85 43 42 75 40 35  268 130 138 249 115 134the value of the rabbi trust assets used to pay the guidant supplemental retirement plan benefits included in our accompanying consolidated financial statements was approximately 21 million as of december 31 2012 and 25 million as of december 31 2011the critical assumptions associated with our employee retirement plans as of december 31 2012 are as follows     longtermhealthcare rate of discountrate expected returnon plan assets costtrend rate compensationincreaseexecutive retirement plan350     300guidant retirement plan frozen425 750    guidant supplemental retirement plan frozen400      guidant healthcare retirement benefit plan frozen175   500  international retirement plans100  400 275  400   300we base our discount rate on the rates of return available on highquality bonds with maturities approximating the expected period over which benefits will be paid the rate of compensation increase is based on historical and expected rate increases we review external data and historical trends in healthcare costs to determine healthcare cost trend rate assumptions we base our rate of expected return on plan assets on historical experience our investment guidelines and expectations for longterm rates of return83table of contentsa rollforward of the changes in the fair value of plan assets for our funded retirement plans during 2012 and 2011 is as follows  year ended december 31in millions 2012 2011beginning fair value 115 113actual return on plan assets 11 employer contributions 20 17benefits paid 13 13net transfers in out  3foreign currency exchange 3 1ending fair value 130 115we also sponsor a voluntary 401k retirement savings plan for eligible employees we match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and fifty percent of employee elective deferrals greater than two percent but not exceeding six percent of employee eligible compensation total expense for our matching contributions to the plan was 63 million in 2012 65 million in 2011 and 64 million in 2010net income loss per common sharewe base net income loss per common share upon the weightedaverage number of common shares and common stock equivalents outstanding during each year potential common stock equivalents are determined using the treasury stock method we exclude stock options whose effect would be antidilutive from the calculationnote b  acquisitionsover the past three years we have completed several acquisitions as part of our strategic initiatives and have acquired technologies in the areas of hypertension cardiology cardiac rhythm management crm structural heart therapy deep brain stimulation peripheral vascular disease endoscopic pulmonary intervention and atrial fibrillationour consolidated financial statements include the operating results for each acquired entity from its respective date of acquisition we do not present pro forma financial information for these acquisitions given their results are not material to our consolidated financial statements transaction costs associated with these acquisitions were expensed as incurred and are not material for the years ended december 31 2012 2011 or 20102012 acquisitionscameron health incon june 8 2012 we completed the acquisition of the remaining equity of cameron health inc cameron cameron has developed the worlds first and only commercially available subcutaneous implantable cardioverter defibrillator  the sicd system the sicd system has received ce mark approval and is currently sold in europe middle east and africa emea in addition in late september 2012 we received us food and drug administration fda approval for the sicd system and commenced a limited commercial launch of this system in the united states during the fourth quarter of 2012 we are integrating the operations of the cameron business into our crm business total consideration includes an initial 150 million cash payment at closing of the transaction a payment of 150 million upon fda approval of the sicd system and up to an additional 105 billion of potential payments upon achievement of specified revenuebased milestones over a sixyear period following fda approval due to our receipt of fda approval of camerons sicd system we paid the related 150 million milestone payment to the former shareholders of cameron during the fourth quarter of 2012 bridgepoint medical incon october 4 2012 we completed the acquisition of 100 percent of the fully diluted equity of bridgepoint medical inc bridgepoint a developer of catheterbased systems to treat coronary chronic total occlusions ctos bridgepoint has the only us approved crossing and reentry system indicated for use in coronary ctos the system has also received ce mark approval and tga approval in australia and is currently sold in emea australia and the us we are integrating the operations of the bridgepoint business into our interventional cardiology business total consideration includes an initial 20 million at closing of the transaction and up to an additional 90 million of revenuebased earnouts and milestones through 201684table of contentsrhythmia medical incon october 8 2012 we completed the acquisition of 100 percent of the fully diluted equity of rhythmia medical inc rhythmia rhythmia is a developer of nextgeneration mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures including atrial fibrillation and atrial flutter we are integrating the operations of the rhythmia business into our electrophysiology business total consideration includes an initial 90 million at closing of the transaction and up to an additional 175 million of regulatory and revenuebased milestones and revenuebased earnouts through 2017vessix vascular incon november 19 2012 we completed the acquisition of 100 percent of the fully diluted equity of vessix vascular inc vessix vessix is a developer of a potential breakthrough therapy to treat uncontrolled hypertension or high blood pressure the vessix vascular v2 renal denervation system has received ce mark in europe and tga approval in australia vessix vascular has initiated the reducehtn postmarket surveillance study and expects to initiate a full launch of the product in ce mark countries in 2013 we are integrating the operations of the vessix business into our peripheral interventions business total consideration includes an initial 125 million at closing of the transaction and up to an additional 300 million of clinical and revenuebased milestones and revenuebased earnouts through 2016purchase price allocationwe accounted for these acquisitions as business combinations and in accordance with financial accounting standards board fasb accounting standards codification asc topic 805 business combinations we have recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date the components of the aggregate preliminary purchase price for acquisitions consummated in 2012 are as follows in millionscash net of cash acquired366fair value of contingent consideration465fair value of prior interests79fair value of debt assumed9 919total consideration for the 2012 acquisitions included initial 366 million cash payments net of cash acquired at closing of the transactions with potential payments of up to an additional 1615 billion based upon achievement of certain regulatory and commercializationrelated milestones and revenue through 2018 as of the respective acquisition dates we recorded total contingent consideration liabilities of 465 million representing the estimated fair value of the contingent consideration we expected to pay to the former shareholders of the acquired companies the fair value of the contingent consideration liabilities was estimated by discounting to present value contingent payments expected to be made in certain circumstances we utilized a probabilityweighted approach or monte carlo revenue simulation model to determine the fair value of contingent consideration prior to the acquisition of cameron we had an equity interest in cameron and held 40 million of notes receivable we remeasured our previously held investments to their estimated acquisitiondate fair value of 79 million and recorded a gain of 39 million in other net in the accompanying consolidated statements of operations during the second quarter of 2012 we measured the fair values of the previously held investments based on the liquidation preferences and priority of the equity interests and debt including accrued interest in addition we prepaid the assumed debt obligation of cameron for approximately 9 million during the second quarter of 2012the following summarizes the aggregate preliminary purchase price allocation for the 2012 acquisitions as of december 31 2012 in millionsgoodwill563amortizable intangible assets189indefinitelived intangible assets132other net assets15deferred income taxes20 91985table of contentswe allocated a portion of the preliminary purchase price to specific intangible asset categories as of the respective acquisition dates as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated187 8 14 to 28 customer relationships2 5 14indefinitelived intangible assets     purchased research and development132   14 to 28 321    our technologyrelated intangible assets consist of technical processes intellectual property and institutional understanding with respect to products and processes that we will leverage in future products or processes and will carry forward from one product generation to the next the technologyrelated intangible assets are being amortized on a straightline basis over their assigned estimated useful lives purchased research and development represents the estimated fair value of acquired inprocess research and development projects which have not yet reached technological feasibility these indefinitelived intangible assets are tested for impairment on an annual basis or more frequently if impairment indicators are present in accordance with us gaap and our accounting policies upon completion of the associated research and development efforts we determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products we believe that the estimated intangible asset values represent the fair value at the dates of acquisition and do not exceed the amount a third party would pay for the assets we used the income approach to derive the fair value of the amortizable intangible assets and purchased research and development these fair value measurements are based on significant unobservable inputs including management estimates and assumptions and accordingly are classified as level 3 within the fair value hierarchy prescribed by asc topic 820 fair value measurements and disclosureswe recorded the excess of the aggregate purchase price over the estimated fair values of the identifiable assets acquired as goodwill which is nondeductible for tax purposes goodwill was established due primarily to revenue and cash flow projections associated with future technologies as well as synergies expected to be gained from the integration of these businesses into our existing operations and has been allocated to our reportable segments based on the relative expected benefit as follows in millionsus292emea154intercontinental86japan31 5632011 acquisitionssadra medical incon january 4 2011 we completed the acquisition of the remaining fully diluted equity of sadra medical inc prior to the acquisition we held a 14 percent equity ownership in sadra sadra is developing a fully repositionable and retrievable device for transcatheter aortic valve replacement tavr to treat patients with severe aortic stenosis the lotus valve system consists of a stentmounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve the lowprofile delivery system and introducer sheath are designed to enable accurate positioning repositioning and retrieval at any time prior to release of the aortic valve implant the acquisition was intended to broaden and diversify our product portfolio by expanding into the structural heart market and tavr is one of the fastest growing medical device markets we have integrated the operations of the sadra business into our interventional cardiology business total consideration included a net cash payment of 193 million at closing to acquire the remaining 86 percent of sadra and potential payments up to 193 million through 2016 that are contingent upon the achievement of certain regulatory and revenuebased milestones86table of contentsintelect medical incon january 5 2011 we completed the acquisition of the remaining fully diluted equity of intelect medical inc prior to the acquisition we held a 15 percent equity ownership in intelect intelect is developing advanced visualization and programming technology for deepbrain stimulation we have integrated the operations of the intelect business into our neuromodulation business the acquisition was intended to leverage the core architecture of our vercisetm platform and advance our technology in the field of deepbrain stimulation we paid 60 million at the closing of the transaction using cash on hand to acquire the remaining 85 percent of intelect there is no contingent consideration related to the intelect acquisitionrevascular therapeutics incon february 15 2011 we completed the acquisition of 100 percent of the fully diluted equity of revascular therapeutics inc rvt rvt has developed the truepath intraluminal chronic total occlusion crossing device enabling endovascular treatment in cases that typically cannot be treated with standard endovascular devices this acquisition complements our portfolio of devices for lower extremity peripheral artery disease and we have integrated the operations of rvt into our peripheral interventions business total consideration included a cash payment of 19 million at closing of the transaction and potential payments of up to 16 million through 2014 that are contingent upon the achievement of certain regulatory and commercializationbased milestones and revenueatritech incon march 3 2011 we completed the acquisition of 100 percent of the fully diluted equity of atritech inc atritech has developed a device designed to close the left atrial appendage of the heart the watchman left atrial appendage closure technology developed by atritech is the first device proven to offer an alternative to anticoagulant drugs for patients with atrial fibrillation and at high risk for stroke the acquisition was intended to broaden our portfolio of lessinvasive devices for cardiovascular care by expanding into the areas of atrial fibrillation and structural heart therapy we have integrated the operations of the atritech business and are leveraging expertise from both our electrophysiology and interventional cardiology divisions in the commercialization of the watchman device total consideration included a net cash payment of 98 million at closing of the transaction and potential payments up to 275 million through 2015 that are contingent upon achievement of certain regulatorybased milestones and revenuepurchase price allocationthe components of the aggregate purchase price as of the acquisition date for acquisitions consummated in 2011 are as follows in millionscash net of cash acquired370fair value of contingent consideration287prior investments55 712prior to our acquisition of the remaining equity ownership in sadra and intelect we held equity interests in these companies of 14 percent and 15 percent respectively carried at an aggregate value of 11 million and a note receivable carried at a value of 6 million as a result of remeasuring these previously held investments to fair value estimated at 55 million as of the respective acquisition dates we recorded a gain of 38 million in other net in the accompanying consolidated statements of operations during the first quarter of 2011 we measured the fair values of the previously held investments based on a prorata allocation of the consideration paid for the controlling interests acquired less an estimated minority interest discount in certain circumstances after considering previous financing rounds and liquidation preferences of the equity interests the following summarizes the aggregate purchase price allocation for the 2011 acquisitions in millionsgoodwill266amortizable intangible assets97indefinitelived intangible assets470deferred income taxes121 71287table of contentswe allocated the aggregate purchase price to specific intangible asset categories as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated97 7 23  25indefinitelived intangible assets     purchased research and development470   23  30 567    2010 acquisitionsasthmatx incon october 26 2010 we completed the acquisition of 100 percent of the fully diluted equity of asthmatx inc asthmatx designs manufactures and markets a lessinvasive catheterbased bronchial thermoplasty procedure for the treatment of severe persistent asthma the acquisition was intended to broaden and diversify our product portfolio by expanding into the area of endoscopic pulmonary intervention we have integrated the operations of the asthmatx business into our endoscopy business total consideration included a net cash payment of 194 million at closing of the transaction and potential payments up to 250 million that are contingent upon the achievement of certain revenuebased milestones si therapies ltdon november 3 2010 we completed the acquisition of 100 percent of the fully diluted equity of si therapies ltd si therapies has developed the offroad reentry catheter to treat peripheral ctos a cto which represents a complete artery blockage typically cannot be treated with standard endovascular devices such as guidewires and other catheterbased technologies a cto device permits endovascular treatment in cases that otherwise might require a patient to undergo surgery or lower extremity amputation this acquisition complements our portfolio of devices for lower extremity peripheral artery disease and we have integrated the operations of si therapies into our peripheral interventions business we paid approximately 5 million at the closing of the transaction using cash on hand and may be required to pay future consideration up to 24 million that is contingent upon the achievement of certain commercial and revenuebased milestones the components of the purchase price as of the acquisition date for our 2010 acquisitions are as follows   in millions totalcash 199fair value of contingent consideration 69  268the following summarizes the purchase price allocations   in millions totalgoodwill 81amortizable intangible assets 175indefinitelived intangible assets 45other net assets 3deferred income taxes 36  26888table of contentswe allocated the purchase price to specific intangible asset categories as follows  amount assignedin millions weightedaverageamortization periodin years range of riskadjusted discount rates used in purchase priceallocationamortizable intangible assets      technologyrelated 175 119 280  355       indefinitelived intangible assets      purchased research and development 45   290  360  220    contingent considerationcertain of our acquisitions involve contingent consideration arrangements payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones including attaining specified revenue levels achieving product development targets or obtaining regulatory approvals in accordance with us gaap we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations changes in our contingent consideration liability were as follows in millionsbalance as of december 31 201071amounts recorded related to new acquisitions287net fair value adjustments7payments made7balance as of december 31 2011358amounts recorded related to new acquisitions465net fair value adjustments6payments made154balance as of december 31 2012663as of december 31 2012 the maximum amount of future contingent consideration undiscounted that we could be required to make associated with our acquisitions is approximately 23 billion increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones the recurring level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputscontingent consideration liabilityfair value as of december 31 2012valuation techniqueunobservable inputrangerampd regulatory and commercializationbased milestones212 millionprobability weighted discounted cash flowdiscount rate09  24probability of payment0  95projected year of payment2013  2017revenuebased payments218 milliondiscounted cash flowdiscount rate12  18probability of payment65  100projected year of payment2013  2018233 millionmonte carlorevenue volatility15  29risk free ratelibor term structureprojected year of payment2013201889table of contentscontingent consideration liabilities are remeasured to fair value each reporting period using projected revenues discount rates probabilities of payment and projected payment dates projected contingent payment amounts related to rampd regulatory and commercializationbased milestones and certain revenuebased milestones are discounted back to the current period using a discounted cash flow model other revenuebased payments are valued using a monte carlo valuation model which simulates future revenues during the earn outperiod using managements best estimates projected revenues are based on our most recent internal operational budgets and longrange strategic plans increases in projected revenues and probabilities of payment may result in higher fair value measurements increases in discount rates and the time to payment may result in lower fair value measurements increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement note c  divestitures and assets held for salein january 2011 we closed the sale of our neurovascular business to stryker corporation for a purchase price of 1500 billion in cash we received 1450 billion during 2011 including an upfront payment of 1426 billion and 24 million which was placed into escrow and released throughout 2011 upon the completion of local closings in certain foreign jurisdictions during 2012 we received an additional 10 million of consideration which we recorded as a gain in our accompanying consolidated statements of operations we will receive the remaining 40 million of consideration upon the transfer or separation of certain manufacturing facilities which we expect will occur during 2013 due to our continuing involvement in the operations of the neurovascular business the divestiture does not meet the criteria for presentation as a discontinued operation we recorded a pretax gain of 778 million 545 million aftertax during 2011 and a pretax gain of 15 million during 2012 associated with the transaction we recorded revenue related to the neurovascular business following its divestiture of 122 million in 2012 and 141 million in 2011 as compared to 2010 revenue generated by the neurovascular business of 340 million we continue to generate net sales pursuant to our supply agreements with stryker however these net sales are at significantly lower levels and at reduced gross profit margins as compared to periods prior to the divestiturenote d  goodwill and other intangible assetsthe gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated writeoffs of goodwill as of december 31 2012 and 2011 is as follows   as of december 31 2012 as of december 31 2011  gross carrying accumulatedamortization gross carrying accumulatedamortizationin millions amount writeoffs amount writeoffsamortizable intangible assets        technologyrelated 8020 3005 7823 2734patents 559 352 539 331other intangible assets 810 428 808 376  9389 3785 9170 3441unamortizable intangible assets        goodwill 15450 9477 14888 5127technologyrelated 242   242    15692 9477 15130 5127in addition we had 443 million and 502 million of purchased research and development intangible assets as of december 31 2012 and december 31 2011 respectivelygoodwill as of december 31 2012 as allocated to our us emea japan and intercontinental reportable segments for purposes of our goodwill impairment testing is presented below our us goodwill is further allocated to our us reporting units for our goodwill testing90table of contentsthe following is a rollforward of our goodwill balance by reportable segmentin millions united states emea japan intercontinental totalbalance as of december 31 2010 5189 3915 551 531 10186purchase price adjustments 14 10 2   6goodwill acquired 161 99 1 5 266goodwill written off 697       697balance as of december 31 2011 4667 4004 554 536 9761purchase price adjustments 2   1 1goodwill acquired 292 154 31 86 563goodwill written off 748 3602   4350balance as of december 31 2012 4209 556 585 623 5973the 2011 and 2012 purchase price adjustments relate primarily to adjustments in taxes payable and deferred income taxes including changes in the liability for unrecognized tax benefitsgoodwill impairment charges2012 chargeswe test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist in the second quarter of 2012 we performed our annual goodwill impairment test for all of our reporting units and concluded that the goodwill within our emea reporting unit was impaired and recorded a 3602 billion 3579 billion aftertax charge in the second quarter of 2012 we finalized the second step of the emea goodwill impairment test during the third quarter of 2012 in accordance with asc topic 350 intangibles goodwill and other and there were no adjustments to the charge upon finalization in the third quarter of 2012 we performed an interim goodwill impairment test and recorded a noncash 748 million pre and aftertax charge associated with our us cardiac rhythm management us crm reporting unit primarily driven by the reduction in the estimated size of the us crm market related adjustments to our business and other competitive factors which led to lower projected us crm results compared to prior forecasts we finalized the second step of the us crm goodwill impairment test during the fourth quarter of 2012 in accordance with asc topic 350 intangibles goodwill and other and there were no adjustments to the charge upon finalization in our goodwill impairment tests we used the income approach specifically the discounted cash flow dcf method to derive the fair value of our emea and us crm reporting units as described in our accounting policies we updated all aspects of the dcf models associated with the emea and us crm businesses including the amount and timing of future expected cash flows terminal value growth rates and the appropriate marketparticipant riskadjusted weighted average costs of capital wacc to applyemeaas a result of revised estimates developed during our annual strategic planning process and analysis performed in conjunction with our annual goodwill impairment test in the second quarter we concluded that the revenue growth rates projected for the emea reporting unit would be slightly lower than our previous estimates primarily driven by macroeconomic factors and our performance in the european market we updated shortterm operating projections based on our most recent strategic plan for emea prepared by management we reduced the emea longterm growth rates and terminal value growth rate projections and increased the discount rate within our 15year dcf model for emea by approximately 100 basis points due to increased risk associated with our projections in this market primarily as a result of the economic uncertainty in europe while we continue to project revenue growth in our emea business our expectations for future growth and profitability were lower than our previous estimates and reflected declines in average selling prices and volume pressures due to austerity measures the declines expected in the emea market did not impact our assumptions related to other reporting units the aggregate amount of goodwill that remains associated with our emea reporting unit is 556 million as of december 31 2012 in addition the remaining book value of our other emea intangible assets allocated to our emea reporting unit is approximately 1563 billion as of december 31 2012 in accordance with asc topic 350 we tested our emea amortizable intangible assets as of april 1 2012 for impairment on an undiscounted cash flow basis and determined that these assets were not impaired we also tested our indefinitelived intangible assets associated with emea as of april 1 2012 and recorded an 91table of contentsimpairment charge related to the inprocess research and development associated with our acquisition of sadra medical inc see intangible asset impairment charges below for a further discussion of this impairment us crmthe us crm market is dynamic highly competitive and difficult to forecast in the third quarter of 2012 we lowered our projections for the us crm market size and our future revenue levels within this market primarily to reflect recent changes in expectations of average selling prices and unit growth adjustments to our business and other competitive factors this reduction warranted an interim goodwill impairment test for our us crm reporting unit the declines expected in the us crm market did not impact our assumptions related to other reporting units the increased pricing pressure and lower unit volumes are primarily due to physician alignment with hospitals efforts to reduce health care costs focus on appropriate device usage replacement volumes and competition and have been more impactful to the us crm business than previously estimated in addition we recently aligned certain elements of our business and shifted investments to focus on areas expected to provide the highest future growth and financial return as a result of these factors we reduced the compound annual revenue growth rate of our 15 year dcf model for the us crm reporting unit by approximately 250 basis points we continue to analyze business trends using all available information and our us crm goodwill remains sensitive to changes in expectations of future growth of this market and our performance based on the remaining book value of our us crm reporting unit following the goodwill impairment charge recorded during the third quarter of 2012 the carrying value of our us crm reporting unit continues to exceed its fair value due primarily to the value of amortizable intangible assets allocated to this reporting unit the remaining book value of the amortizable intangible assets allocated to the us crm reporting unit was approximately 3303 billion as of december 31 2012 in accordance with asc topic 350 we tested the amortizable intangible assets as of september 30 2012 in conjunction with the interim goodwill impairment test of our us crm reporting unit we performed the impairment analysis of the amortizable intangible assets on an undiscounted cash flow basis and concluded that these assets were not impaired however following the recent declines in our crm projections the recoverability of our crmrelated amortizable intangibles 4636 billion globally are sensitive to changes in future cash flow assumptions and our crm business performance the 4636 billion of crmrelated amortizable intangibles are at higher risk of potential failure of the first step of the amortizable intangible recoverability test in future reporting periods an impairment of a material portion of our crmrelated amortizable intangibles carrying value would occur if the second step of the amortizable intangible test is required in a future reporting periodwe continue to identify three reporting units with goodwill that is at higher risk of potential failure of the first step of the goodwill impairment test in future reporting periods these reporting units include our us crm reporting unit which holds 216 million of remaining allocated goodwill our us cardiovascular reporting unit which holds 2380 billion of allocated goodwill and our us neuromodulation reporting unit which holds 1266 billion of allocated goodwill each as of december 31 2012 as of december 31 2012 the level of excess fair value over carrying value for these reporting units identified as being at higher risk with the exception of the us crm reporting unit whose carrying value continues to exceed its fair value was approximately seven  to 11 percent during the fourth quarter of 2012 the level of excess fair value over carrying value of our us cardiovascular reporting unit declined as a result of our performance declines in our market share due to competitive launches and continued average selling price declines in the us drugeluting stent des market as a result of continued competitive pressures and declines in procedural volumes on a quarterly basis we monitor the key drivers of fair value for these reporting units to detect events or other changes that would warrant an interim impairment test of our goodwill and intangible assets the key variables that drive the cash flows of our reporting units and amortizable intangibles are estimated revenue growth rates and levels of profitability terminal value growth rate assumptions as well as the wacc rate applied are additional key variables for reporting unit cash flows these assumptions are subject to uncertainty including our ability to grow revenue and improve profitability levels relatively small declines in the future performance and cash flows of a reporting unit or asset group or small changes in other key assumptions may result in the recognition of significant asset impairment charges for example keeping all other variables constant an 80 basis point decrease in the long term revenue and terminal growth rates would require that we perform the second step of the goodwill impairment test for the us neuromodulation reporting unit a 90 basis point decrease in the long term revenue and terminal growth rates would require that we perform the second step of the goodwill impairment test for the us cardiovascular reporting unit an increase in the wacc applied of 70 basis points would require that we perform the second step of the goodwill impairment test for the us neuromodulation and us cardiovascular reporting units given that the carrying value of the us crm reporting unit continues to exceed its fair value any negative changes in the key variables or values associated with this reporting unit would likely require that we perform the second step of the goodwill impairment test in a future reporting period the estimates used for our future cash flows and discount rates represent managements best estimates which we believe to be reasonable but future declines in business performance may impair the recoverability of our goodwill and intangible asset balances 92table of contentsfuture events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units andor amortizable intangible assets include but are not limited todecreases in estimated market sizes or market growth rates due to greaterthanexpected declines in procedural volumes pricing pressures product actions andor competitive technology developmentsdeclines in our market share and penetration assumptions due to increased competition an inability to develop or launch new and nextgeneration products and technology features in line with our commercialization strategies and market andor regulatory conditions that may cause significant launch delays or product recallsdecreases in our profitability due to an inability to successfully implement and achieve timely and sustainable cost improvement measures consistent with our expectations increases in our marketparticipant tax rate andor changes in tax lawsnegative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain productsthe level of success of ongoing and future research and development efforts including those related to recent acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new productsthe level of success in managing the growth of acquired companies achieving sustained profitability consistent with our expectations establishing government and thirdparty payer reimbursement and increases in the costs and time necessary to integrate acquired businesses into our operations successfullychanges in our reporting units or in the structure of our business as a result of future reorganizations or divestitures of assets or businessesincreases in our marketparticipant riskadjusted wacc anddeclines in revenue as a result of loss of key members of our sales force and other key personnelnegative changes in one or more of these factors among others could result in additional impairment charges2011 chargebased on market information that became available to us toward the end of the first quarter of 2011 we concluded that there was a reduction in the estimated size of the us icd market which led to lower projected us crm results compared to prior forecasts and created an indication of potential impairment of the goodwill balance attributable to our us crm business unit therefore we performed an interim impairment test in accordance with us gaap and our accounting policies and recorded a nondeductible goodwill impairment charge of 697 million on both a pretax and aftertax basis associated with this business unit during the first quarter of 2011 we used the income approach specifically the discounted cash flow dcf method to derive the fair value of the us crm reporting unit we updated all aspects of the dcf model associated with the us crm business including the amount and timing of future expected cash flows terminal value growth rate and the appropriate marketparticipant riskadjusted weighted average cost of capital wacc to applyas a result of physician reaction to study results published by the journal of the american medical association regarding evidencebased guidelines for icd implants and us department of justice doj investigations into hospitals icd implant practices and the expansion of medicare recovery audits among other factors we estimated the us crm market would experience negative growth rates in 2011 as compared to 2010 due to these estimated nearterm market reductions as well as the economic impact of physician alignment to hospitals recent demographic information released by the american heart association indicating a lower prevalence of heart failure and increased competitive and other pricing pressures we lowered our estimated average us crm net sales growth rates within our 15year dcf model from the midsingle digits to the lowsingle digits partially offsetting these factors were increased levels of profitability as a result of costreduction initiatives and process efficiencies within the us crm business the impact of the reduction in the size of the us icd market and the related reduction in our forecasted 2011 us crm net sales as well as the change in our expected sales growth rates thereafter as a result of the trends noted above were the key factors contributing to the first quarter 2011 goodwill impairment charge93table of contents2010 chargeas a result of ship hold and product removal actions associated with our us icd and crtd products which we announced on march 15 2010 and the forecasted corresponding financial impact on our operations we concluded there was an indication of potential impairment of the goodwill balance attributable to our us crm reporting unit during the first quarter of 2010 therefore we performed an interim impairment test in accordance with us gaap and our accounting policies and recorded a nondeductible goodwill impairment charge of 1817 billion on both a pretax and aftertax basis associated with our us crm reporting unitat the time we performed our 2010 interim goodwill impairment test we estimated that our us defibrillator market share would decrease approximately 400 basis points exiting 2010 as a result of the ship hold and product removal actions as compared to our market share exiting 2009 and that these actions would negatively impact our 2010 us crm revenues by approximately 300 million in addition we expected that our ongoing us crm net sales and profitability would likely continue to be adversely impacted as a result of the ship hold and product removal actions therefore as a result of these product actions as well as lower expectations of market growth in new areas and increased competitive and other pricing pressures we lowered our estimated average us crm net sales growth rates within our 15year discounted cash flow dcf model as well as our terminal value growth rate by approximately a couple of hundred basis points to derive the fair value of the us crm reporting unit the reduction in our forecasted 2010 us crm net sales the change in our expected sales growth rates thereafter and the reduction in profitability as a result of the recently enacted excise tax on medical device manufacturers were several key factors contributing to the impairment charge partially offsetting these factors was a 50 basis point reduction in our estimated marketparticipant riskadjusted weightedaverage cost of capital wacc used in determining our discount ratethe following is a rollforward of accumulated goodwill writeoffs by reportable segment  united     inter  in millions states emea japan continental totalaccumulated writeoffs as of december 31 2010 4430    4430goodwill written off 697       697accumulated writeoffs as of december 31 2011 5127    5127goodwill written off 748 3602   4350accumulated writeoffs as of december 31 2012 5875 3602   9477goodwill impairment charges do not impact our debt covenants or our cash flows and are excluded by management for purposes of evaluating operating performance and assessing liquidityintangible asset impairment charges2012 chargesduring the third quarter of 2012 we performed our annual impairment test of all inprocess research and development projects and our indefinite lived core technology assets based on the results of our annual test we recorded total impairment charges of 13 million 10 million aftertax to writedown the balances of certain inprocess projects to their fair value these charges were primarily due to increased expectations in the cost to bring an inprocess project to market in a certain geographic region and lower future revenue expectations associated with an inprocess projectinprocess research and development fair value is measured using projected revenues projected expenses discount rates and probability of expected launch the nonrecurring level 3 fair value measurements of the impairment charges taken in the third quarter of 2012 included the following significant unobservable inputsintangible assetfair value as of july 1 2012valuation techniqueunobservable inputrangeinprocess rampd26 millionincome approach  excess earnings methoddiscount rate202594table of contentsduring the third quarter of 2012 in conjunction with the interim goodwill impairment test of our us crm reporting unit we performed an impairment analysis of the amortizable intangible assets allocated to our us crm reporting unit as of september 30 2012 on an undiscounted cash flow basis and concluded that these assets were not impaired however following the recent declines in our crm projections the recoverability of our crmrelated amortizable intangibles 4636 billion globally as of december 31 2012 are sensitive to changes in future cash flow assumptions and our crm business performance the 4636 billion of crmrelated amortizable intangibles are at higher risk of potential failure of the first step of the amortizable intangible recoverability test in future reporting periods an impairment of a material portion of our crmrelated amortizable intangibles carrying value would occur if the second step of the amortizable intangible test is required in a future reporting period see goodwill impairment charges above for discussion of future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units andor amortizable intangible assetsduring the second quarter of 2012 as a result of revised estimates developed in conjunction with our annual strategic planning process and annual goodwill impairment test we performed an interim impairment test of our inprocess research and development projects associated with our acquisition of sadra medical inc based on our impairment analysis we revised our expectations of the required effort time and cost involved in completing the inprocess projects and bringing the related products to market as a result of these changes we recorded an impairment charge of 129 million 110 million aftertax to writedown the balance of these intangible assets to their fair value during the second quarter of 2012 the nonrecurring level 3 fair value measurements of the impairment charges taken in the second quarter of 2012 included the following significant unobservable inputsintangible assetfair value as of april 1 2012valuation techniqueunobservable inputrangeinprocess rampd184 millionincome approach  excess earnings methoddiscount rate202011 chargesduring the third quarter of 2011 we recorded a 9 million intangible asset impairment charge attributable to lower projected cash flows associated with certain technologies during the second quarter of 2011 we recorded a 12 million intangible asset impairment charge associated with changes in the timing and amount of the expected cash flows related to certain purchased research and development projects 2010 chargesduring the first quarter of 2010 due to lower than anticipated net sales of one of our peripheral interventions technology offerings as well as changes in our expectations of future market acceptance of this technology we lowered our sales forecasts associated with the product in addition during the third quarter of 2010 as part of our initiatives to reprioritize and diversify our product portfolio we discontinued one of our internal research and development programs to focus on those with a higher likelihood of success as a result of these factors we tested the related intangible assets for impairment and recorded a 60 million charge in the first quarter of 2010 and a 5 million charge in the third quarter of 2010 to write down the balance of these intangible assets to their fair value the intangible asset category and associated write downs recorded in 2012 2011 and 2010 were as follows  year ended december 31in millions 2012 2011 2010technologyrelated  9 65purchased research and development 142 12   142 21 6595table of contentsestimated amortization expense for each of the five succeeding fiscal years based upon our intangible asset portfolio as of december 31 2012 is as follows     estimated amortization expensefiscal year in millions 2013 4072014 4242015 4292016 4282017 417our technologyrelated intangible assets that are not subject to amortization represent technical processes intellectual property andor institutional understanding acquired through business combinations that are fundamental to the ongoing operations of our business and have no limit to their useful life our technologyrelated intangible assets that are not subject to amortization are comprised primarily of certain acquired stent and balloon technology which is foundational to our continuing operations within the cardiovascular market and other markets within interventional medicine we assess our indefinitelived intangible assets at least annually for impairment and reassess their classification as indefinitelived assets we assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with asc topic 350 intangiblesgoodwill and othernote e  fair value measurementsderivative instruments and hedging activitieswe develop manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates and interest rates we address these risks through a risk management program that includes the use of derivative financial instruments and operate the program pursuant to documented corporate risk management policies we recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with asc topic 815 derivatives and hedging in accordance with topic 815 for those derivative instruments that are designated and qualify as hedging instruments the hedging instrument must be designated based upon the exposure being hedged as a fair value hedge cash flow hedge or a hedge of a net investment in a foreign operation the accounting for changes in the fair value ie gains or losses of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further on the type of hedging relationship our derivative instruments do not subject our earnings or cash flows to material risk as gains and losses on these derivatives generally offset losses and gains on the item being hedged we do not enter into derivative transactions for speculative purposes and we do not have any nonderivative instruments that are designated as hedging instruments pursuant to topic 815currency hedgingwe are exposed to currency risk consisting primarily of foreign currency denominated monetary assets and liabilities forecasted foreign currency denominated intercompany and thirdparty transactions and net investments in certain subsidiaries we manage our exposure to changes in foreign currency exchange rates on a consolidated basis to take advantage of offsetting transactions we use both derivative instruments currency forward and option contracts and nonderivative transactions primarily european manufacturing and distribution operations to reduce the risk that our earnings and cash flows associated with these foreign currency denominated balances and transactions will be adversely affected by foreign currency exchange rate changesdesignated foreign currency hedgesall of our designated currency hedge contracts outstanding as of december 31 2012 and december 31 2011 were cash flow hedges under topic 815 intended to protect the us dollar value of our forecasted foreign currency denominated transactions we record the effective portion of any change in the fair value of foreign currency cash flow hedges in other comprehensive income oci until the related thirdparty transaction occurs once the related thirdparty transaction occurs we reclassify the effective portion of any related gain or loss on the foreign currency cash flow hedge to earnings in the event the hedged forecasted transaction does not occur or it becomes no longer probable that it will occur we reclassify the amount of any gain or loss on the related cash 96table of contentsflow hedge to earnings at that time we had currency derivative instruments designated as cash flow hedges outstanding in the contract amount of 2469 billion as of december 31 2012 and 2088 billion as of december 31 2011we recognized net losses of 39 million during 2012 on our cash flow hedges as compared to 95 million of net losses during 2011 and 30 million of net losses during 2010 all currency cash flow hedges outstanding as of december 31 2012 mature within 36 months as of december 31 2012 31 million of net gains net of tax were recorded in accumulated other comprehensive income aoci to recognize the effective portion of the fair value of any currency derivative instruments that are or previously were designated as foreign currency cash flow hedges as compared to net losses of 52 million as of december 31 2011 as of december 31 2012 2 million of net losses net of tax may be reclassified to earnings within the next twelve monthsthe success of our hedging program depends in part on forecasts of transaction activity in various currencies primarily japanese yen euro british pound sterling australian dollar and canadian dollar we may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility in addition changes in foreign currency exchange rates related to any unhedged transactions may impact our earnings and cash flowsnondesignated foreign currency contractswe use currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities these currency forward contracts are not designated as cash flow fair value or net investment hedges under topic 815 are markedtomarket with changes in fair value recorded to earnings and are entered into for periods consistent with currency transaction exposures generally less than one year we had currency derivative instruments not designated as hedges under topic 815 outstanding in the contract amount of 1942 billion as of december 31 2012 and 2209 billion as of december 31 2011interest rate hedgingour interest rate risk relates primarily to us dollar borrowings partially offset by us dollar cash investments we have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates by converting floatingrate debt into fixedrate debt or fixedrate debt into floatingrate debtwe designate these derivative instruments either as fair value or cash flow hedges under topic 815 we record changes in the value of fair value hedges in interest expense which is generally offset by changes in the fair value of the hedged debt obligation interest payments made or received related to our interest rate derivative instruments are included in interest expense we record the effective portion of any change in the fair value of derivative instruments designated as cash flow hedges as unrealized gains or losses in oci net of tax until the hedged cash flow occurs at which point the effective portion of any gain or loss is reclassified to earnings we record the ineffective portion of our cash flow hedges in interest expense in the event the hedged cash flow does not occur or it becomes no longer probable that it will occur we reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time in the first quarter of 2011 we entered interest rate derivative contracts having a notional amount of 850 million to convert fixedrate debt into floatingrate debt which we designated as fair value hedges we terminated these hedges during the third quarter of 2011 and received total proceeds of approximately 80 million which included approximately 5 million of accrued interest receivable we are amortizing the gains and losses of these derivative instruments upon termination into earnings over the term of the hedged debt the carrying amount of certain of our senior notes included unamortized gains of 64 million as of december 31 2012 and 73 million as of december 31 2011 and unamortized losses of 3 million as of december 31 2012 and 4 million as of december 31 2011 related to the fixedtofloating interest rate contracts in addition we had pretax net gains within aoci related to terminated floatingtofixed treasury locks of 4 million as of december 31 2012 and 7 million as of december 31 2011 the gains that we recognized in earnings related to previously terminated interest rate derivatives were 11 million in 2012 and were not material in 2011 as of december 31 2012 10 million of net gains may be reclassified to earnings within the next twelve months from amortization of our previously terminated interest rate derivative contractscounterparty credit riskwe do not have significant concentrations of credit risk arising from our derivative financial instruments whether from an individual counterparty or a related group of counterparties we manage our concentration of counterparty credit risk on our derivative instruments by limiting acceptable counterparties to a diversified group of major financial institutions with investment grade credit ratings limiting the amount of credit exposure to each counterparty and by actively monitoring their credit ratings and outstanding fair values on an ongoing basis furthermore none of our derivative transactions are subject to collateral or other security arrangements and none contain provisions that are dependent on our credit ratings from any credit rating agency97table of contentswe also employ master netting arrangements that reduce our counterparty payment settlement risk on any given maturity date to the net amount of any receipts or payments due between us and the counterparty financial institution thus the maximum loss due to credit risk by counterparty is limited to the unrealized gains in such contracts net of any unrealized losses should any of these counterparties fail to perform as contracted although these protections do not eliminate concentrations of credit risk as a result of the above considerations we do not consider the risk of counterparty default to be significantfair value of derivative instrumentsthe following presents the effect of our derivative instruments designated as cash flow hedges under topic 815 on our accompanying consolidated statements of operations during 2012 and 2011 in millions amount of pretaxgain lossrecognized in ocieffective portion amount of pretaxgain lossreclassified fromaoci into earningseffective portion location in statement ofoperationsyear ended december 31 2012     interest rate hedge contracts 2 interest expensecurrency hedge contracts95 39 cost of products sold 95 37  year ended december 31 2011     interest rate hedge contracts 1 interest expensecurrency hedge contracts66 95 cost of products sold 66 94  the amount of gain loss recognized in earnings related to the ineffective portion of our hedging relationships was de minimus in 2012 in 2011 we recognized a 5 million gain related to the ineffective portion of hedging relationshipsnet gains and losses on currency hedge contracts not designated as hedging instruments were offset by net losses and gains from foreign currency transaction exposures as shown in the following tablein millions year ended location in statement ofoperations december 31   2012 2011 2010  gain loss on currency hedge contracts 23 12 77 other netgain loss on foreign currency transaction exposures 41 24 68 other netnet foreign currency gain loss 18 12 9  topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet we determine the fair value of our derivative instruments using the framework prescribed by asc topic 820 fair value measurements and disclosures by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date and by taking into account current interest rates foreign currency exchange rates the creditworthiness of the counterparty for assets and our creditworthiness for liabilities in certain instances we may utilize financial models to measure fair value generally we use inputs that include quoted prices for similar assets or liabilities in active markets quoted prices for identical or similar assets or liabilities in markets that are not active other observable inputs for the asset or liability and inputs derived principally from or corroborated by observable market data by correlation or other means as of december 31 2012 we have classified all of our derivative assets and liabilities within level 2 of the fair value hierarchy prescribed by topic 820 as discussed below because these observable inputs are available for substantially the full term of our derivative instruments98table of contentsthe following are the balances of our derivative assets and liabilities as of december 31 2012 and december 31 2011  as of  december 31 december 31in millionslocation in balance sheet 12012 2011derivative assets    designated hedging instruments    currency hedge contractsprepaid and other current assets25 31currency hedge contractsother longterm assets63 20  88 51nondesignated hedging instruments    currency hedge contractsprepaid and other current assets33 36total derivative assets 121 87     derivative liabilities    designated hedging instruments    currency hedge contractsother current liabilities20 69currency hedge contractsother longterm liabilities10 49  30 118nondesignated hedging instruments    currency hedge contractsother current liabilities27 13total derivative liabilities 57 1311we classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or lessother fair value measurementsrecurring fair value measurementson a recurring basis we measure certain financial assets and financial liabilities at fair value based upon quoted market prices where available where quoted market prices or other observable inputs are not available we apply valuation techniques to estimate fair value topic 820 establishes a threelevel valuation hierarchy for disclosure of fair value measurements the categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value the three levels of the hierarchy are defined as followslevel 1  inputs to the valuation methodology are quoted market prices for identical assets or liabilitieslevel 2  inputs to the valuation methodology are other observable inputs including quoted market prices for similar assets or liabilities and marketcorroborated inputslevel 3  inputs to the valuation methodology are unobservable inputs based on managements best estimate of inputs market participants would use in pricing the asset or liability at the measurement date including assumptions about risk99table of contentsassets and liabilities measured at fair value on a recurring basis consist of the following as of december 31 2012 and december 31 2011 as of december 31 2012 as of december 31 2011in millionslevel 1 level 2 level 3 total level 1 level 2 level 3 totalassets               money market and government funds39     39 78     78currency hedge contracts  121   121   87   87 39 121  160 78 87   165liabilities               currency hedge contracts  57   57   131   131accrued contingent consideration    663 663     358 358  57 663 720   131 358 489our investments in money market and government funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices these investments are classified as cash and cash equivalents within our accompanying consolidated balance sheets in accordance with us gaap and our accounting policiesin addition to 39 million invested in money market and government funds as of december 31 2012 we had 168 million in interest bearing and noninterest bearing bank accounts in addition to 78 million invested in money market and government funds as of december 31 2011 we had 88 million in shortterm time deposits and 101 million in interest bearing and noninterest bearing bank accountsour recurring fair value measurements using significant unobservable inputs level 3 relate solely to our contingent consideration liability refer to note b  acquisitions for a discussion of the changes in the fair value of our contingent consideration liabilitynonrecurring fair value measurementswe hold certain assets and liabilities that are measured at fair value on a nonrecurring basis in periods subsequent to initial recognition the fair value of a cost method investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment the aggregate carrying amount of our cost method investments was 13 million as of december 31 2012 and 16 million as of december 31 2011 during 2012 and 2011 we recorded losses of 4492 billion and 718 million respectively to adjust our goodwill and certain other intangible asset balances to their fair value refer to note d  goodwill and other intangible assets for further detailed information related to these charges and significant unobservable inputsthe fair value of our outstanding debt obligations was 4793 billion as of december 31 2012 and 4649 billion as of december 31 2011 which was determined by using primarily quoted market prices for our publiclyregistered senior notes classified as level 1 within the fair value hierarchy refer to note f  borrowings and credit arrangements for a discussion of our debt obligationsnote f  borrowings and credit arrangementswe had total debt of 4256 billion as of december 31 2012 and 4261 billion as of december 31 2011 in 2012 no prepayments were made on our senior notes during 2011 we prepaid the remaining 10 billion of our term loan and paid 250 million of our senior notes at maturity 100table of contentsthe debt maturity schedule for the significant components of our debt obligations as of december 31 2012 is as followsin millions2013 2014 2015 2016 2017 thereafter totalsenior notes 600 1250 600 250 1500 4200  600 1250 600 250 1500 4200 note the table above does not include unamortized discounts associated with our senior notes or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notesterm loan and revolving credit facilityduring 2011 we prepaid the remaining 10 billion of our term loan maturities without premium or penaltyin the second quarter of 2012 we established a 20 billion revolving credit facility maturing in april 2017 with a global syndicate of commercial banks and terminated our previous revolving credit facility eurodollar and multicurrency loans under the new revolving credit facility bear interest at libor plus an interest margin of between 0875 percent and 1475 percent based on our corporate credit ratings and consolidated leverage ratio 1275 percent as of december 31 2012 in addition we are required to pay a facility fee based on our credit ratings consolidated leverage ratio and the total amount of revolving credit commitments regardless of usage under the agreement 0225 percent as of december 31 2012 there were no amounts borrowed under our revolving credit facility as of december 31 2012 or december 31 2011 as of december 31 2012 we had outstanding letters of credit of 94 million as compared to 128 million as of december 31 2011 which consisted primarily of bank guarantees and collateral for workers compensation insurance arrangements as of december 31 2012 and 2011 none of the beneficiaries had drawn upon the letters of credit or guarantees accordingly we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of december 31 2012 or 2011 we believe we will generate sufficient cash from operations to fund these payments and intend to fund these payments without drawing on the letters of creditour revolving credit facility agreement requires that we maintain certain financial covenants as follows covenantrequirement december 31 2012maximum leverage ratio 135 times 24 timesminimum interest coverage ratio 230 times 69 times1ratio of total debt to consolidated ebitda as defined by the credit agreement for the preceding four consecutive fiscal quarters 2ratio of consolidated ebitda as defined by the credit agreement to interest expense for the preceding four consecutive fiscal quartersthe credit agreement provides for an exclusion from the calculation of consolidated ebitda as defined by the agreement through the credit agreement maturity of up to 500 million in restructuring charges and restructuringrelated expenses related to our current or future restructuring plans as of december 31 2012 we had 357 million of the combined restructuring charge exclusion remaining any noncash charges as defined by the agreement are excluded from the calculation of consolidated ebitda in addition any cash litigation payments as defined by the agreement are excluded from the calculation of consolidated ebitda and any new debt issued to fund any tax deficiency payments is excluded from consolidated total debt as defined in the agreement provided that the sum of any excluded cash litigation payments and any new debt issued to fund any tax deficiency payments shall not exceed 23 billion in the aggregate as of december 31 2012 we had 2271 billion of the combined legal and debt exclusion remaining as of and through december 31 2012 we were in compliance with the required covenantsany inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facilities or seek waivers from compliance with these covenants both of which could result in additional borrowing costs further there can be no assurance that our lenders would grant such waiverssenior noteswe had senior notes outstanding of 4200 billion as of december 31 2012 and 4200 billion as of december 31 2011 these notes are publicly registered securities are redeemable prior to maturity and are not subject to any sinking fund requirements our senior notes are unsecured unsubordinated obligations and rank on a parity with each other these notes are effectively junior to 101table of contentsborrowings under our credit and security facility and liabilities of our subsidiaries in january 2011 we paid 250 million of our senior notes at maturity our senior notes consist of the following as of december 31 2012 amountin millions issuancedate maturity date semiannualcoupon ratejune 2014 notes600 june 2004 june 2014 5450january 2015 notes 850 december 2009 january 2015 4500november 2015 notes400 november 2005 november 2015  5500june 2016 notes600 june 2006 june 2016 6400january 2017 notes250 november 2004 january 2017 5125january 2020 notes850 december 2009 january 2020 6000november 2035 notes350 november 2005 november 2035 6250january 2040 notes300 december 2009 january 2040 7375 4200      our 20 billion of senior notes issued in 2009 contain a changeincontrol provision which provides that each holder of the senior notes may require us to repurchase all or a portion of the notes at a price equal to 101 percent of the aggregate repurchased principal plus accrued and unpaid interest if a rating event as defined in the indenture occurs as a result of a changeincontrol as defined in the indenture any other credit rating changes may impact our borrowing cost but do not require us to repay any borrowings the interest rate payable on our november 2015 notes is currently 625 percent and the interest rate payable on our november 2035 notes is currently 700 percent corporate credit rating improvements may result in a decrease in the adjusted interest rate on our november 2015 and november 2035 notes to the extent that our lowest credit rating is above bbb or baa3 the interest rates on our november 2015 and november 2035 notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either a or a3 or higherother arrangementswe also maintain a 350 million credit and security facility secured by our us trade receivables in june 2012 we extended the maturity of this facility to june 2013 subject to further extension there were no amounts borrowed under this facility as of december 31 2012 or december 31 2011in addition we have accounts receivable factoring programs in certain european countries that we account for as sales under asc topic 860 transfers and servicing these agreements provide for the sale of accounts receivable to third parties without recourse of up to approximately 300 million as of december 31 2012 we have no retained interests in the transferred receivables other than collection and administrative responsibilities and once sold the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy we derecognized 191 million of receivables as of december 31 2012 at an average interest rate of 16 percent and 390 million as of december 31 2011 at an average interest rate of 33 percent the european sovereign debt crisis may impact our future ability to transfer receivables to third parties in certain southern european countries third parties such as banks offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt this could result in terminations of or changes to the costs or credit limits of our existing factoring programsin addition we have uncommitted credit facilities with a commercial japanese bank that provide for borrowings promissory notes discounting and receivables factoring of up to 185 billion japanese yen translated to approximately 214 million as of december 31 2012 we derecognized 182 million of notes receivable as of december 31 2012 at an average interest rate of 16 percent and 188 million of notes receivable as of december 31 2011 at an average interest rate of 17 percent derecognized accounts and notes receivable are excluded from trade accounts receivable net in the accompanying consolidated balance sheetsnote g  leasesrent expense amounted to 80 million in 2012 90 million in 2011 and 92 million in 2010our obligations under noncancelable capital leases were not material as of december 31 2012 and 2011 102table of contentsfuture minimum rental commitments as of december 31 2012 under other noncancelable lease agreements are as follows in millions201369201450201540201633201723thereafter44   259  note h  restructuringrelated activitieson an ongoing basis we monitor the dynamics of the economy the healthcare industry and the markets in which we compete and we continue to assess opportunities for improved operational effectiveness and efficiency and better alignment of expenses with revenues while preserving our ability to make the investments in research and development projects capital and our people that are essential to our longterm success as a result of these assessments we have undertaken various restructuring initiatives in order to enhance our growth potential and position us for longterm success these initiatives are described below2011 restructuring planon july 26 2011 our board of directors approved and we committed to a restructuring initiative the 2011 restructuring plan designed to strengthen operational effectiveness and efficiencies increase competitiveness and support new investments thereby increasing shareholder value key activities under the plan include standardizing and automating certain processes and activities relocating select administrative and functional activities rationalizing organizational reporting structures leveraging preferred vendors and other efforts to eliminate inefficiency among these efforts we are expanding our ability to deliver bestinclass global shared services for certain functions and divisions at several locations in emerging markets this action is intended to enable us to grow our global commercial presence in key geographies and take advantage of many costreducing and productivityenhancing opportunities in addition we are undertaking efforts to streamline various corporate functions eliminate bureaucracy increase productivity and better align corporate resources to our key business strategies on january 25 2013 our board of directors approved and we committed to an expansion of the 2011 restructuring program the expansion the expansion is intended to further strengthen our operational effectiveness and efficiencies and support new investments which we expect to increase stockholder value activities under the 2011 restructuring plan were initiated in the third quarter of 2011 and all activities including those related to the expansion are expected to be substantially complete by the end of 2013we estimate that the 2011 restructuring plan including the expansion will result in total pretax charges of approximately 300 million to 355 million and that approximately 270 million to 300 million of these charges will result in future cash outlays of which we have made payments of 128 million to date we have recorded related costs of 184 million since the inception of the plan and are recording a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations the following provides a summary of our expected total costs associated with the plan by major type of costtype of costtotal estimated amount expected tobe incurredrestructuring charges termination benefits185 million to 210 millionother 170 million to 90 millionrestructuringrelated expenses other 245 million to 55 million 300 million to 355 million1includes primarily consulting fees fixed asset writeoffs and costs associated with contractual cancellations 2comprised of other costs directly related to the 2011 restructuring plan including the expansion such as program management accelerated depreciation retention and infrastructurerelated costs 103table of contents2010 restructuring planon february 6 2010 our board of directors approved and we committed to a series of management changes and restructuring initiatives the 2010 restructuring plan designed to focus our business drive innovation accelerate profitable revenue growth and increase both accountability and shareholder value key activities under the plan included the restructuring of certain of our businesses and corporate functions the realignment of our international structure to reduce our administrative costs and invest in expansion opportunities including significant investments in emerging markets and the reprioritization and diversification of our product portfolio activities under the 2010 restructuring plan were initiated in the first quarter of 2010 and were complete by the end of 2012 the execution of the 2010 restructuring plan resulted in total pretax charges of 160 million and required cash outlays of 145 million of which we have made payments of 144 million to date we have recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations the following provides a summary of our costs associated with the plan by major type of costtype of costtotal amount incurredrestructuring charges termination benefits90 millionfixed asset writeoffs11 millionother 151 millionrestructuringrelated expenses other 28 million 160 million1includes primarily consulting fees and costs associated with contractual cancellations2comprised of other costs directly related to the 2010 restructuring plan including accelerated depreciation and infrastructurerelated costsplant network optimization programin january 2009 our board of directors approved and we committed to a plant network optimization program intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and by closing certain other facilities the program was a complement to our 2007 restructuring plan and was intended to improve overall gross profit margins activities under the plant network optimization program were initiated in the first quarter of 2009 and were substantially completed during 2012we expect that the execution of the plant network optimization program will result in total pretax charges of approximately 132 million to 135 million and that approximately 105 million to 110 million of these charges will result in cash outlays of which we have made payments of 102 million to date we have recorded related costs of 132 million since the inception of the plan and have recorded a portion of these expenses as restructuring charges and the remaining portion through cost of products sold within our consolidated statements of operations 104table of contentsthe following provides a summary of our estimates of costs associated with the plant network optimization program by major type of costtype of costtotal estimated amount expected to be incurredrestructuring charges termination benefits36 million  restructuringrelated expenses accelerated depreciation22 milliontransfer costs 174 million to 77 million 132 million to 135 million1consists primarily of costs to transfer product lines among facilities including costs of transfer teams freight idle facility and product line validationsin aggregate we recorded restructuring charges pursuant to our restructuring plans of 136 million during 2012 89 million during 2011 and 116 million during 2010 in addition we recorded expenses within other lines of our accompanying consolidated statements of operations related to our restructuring initiatives of 24 million during 2012 40 million during 2011 and 53 million during 2010 the following presents these costs by major type and line item within our accompanying consolidated statements of operations as well as by programyear ended december 31 2012           in millionsterminationbenefits accelerateddepreciation transfercosts fixed assetwriteoffs other totalrestructuring charges79     14 43 136restructuringrelated expenses           cost of products sold   8     8selling general and administrative expenses  2     14 16  2 8  14 24 79 2 8 14 57 160            in millionsterminationbenefits accelerateddepreciation transfercosts fixed assetwriteoffs other total2011 restructuring plan78 2   14 55 1492010 restructuring plan1       2 3plant network optimization program    8     8 79 2 8 14 57 160            105table of contentsyear ended december 31 2011           in millionsterminationbenefits accelerateddepreciation transfercosts fixed assetwriteoffs other totalrestructuring charges55       34 89restructuringrelated expenses           cost of products sold  9 27     36selling general and administrative expenses        4 4  9 27  4 40 55 9 27  38 129            in millionsterminationbenefits accelerateddepreciation transfercosts fixed assetwriteoffs other total2011 restructuring plan21       14 352010 restructuring plan24 1     24 49plant network optimization program10 8 27     45 55 9 27  38 129            year ended december 31 2010           in millionsterminationbenefits accelerateddepreciation transfercosts fixed assetwriteoffs other totalrestructuring charges70     11 35 116restructuringrelated expenses           cost of products sold  7 41     48selling general and administrative expenses        5 5   7 41   5 53 70 7 41 11 40 169            in millionsterminationbenefits accelerateddepreciation transfercosts fixed assetwriteoffs other total2010 restructuring plan66     11 33 110plant network optimization program4 7 28     392007 restructuring plan    13   7 20 70 7 41 11 40 169            termination benefits represent amounts incurred pursuant to our ongoing benefit arrangements and amounts for onetime involuntary termination benefits and have been recorded in accordance with asc topic 712 compensation  nonretirement postemployment benefits and asc topic 420 exit or disposal cost obligations we expect to record additional termination benefits related to our restructuring initiatives in 2013 when we identify with more specificity the job classifications functions and locations of the remaining head count to be eliminated other restructuring costs which represent primarily consulting fees are being recorded as incurred in accordance with asc topic 420 accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets and production line transfer costs are being recorded as incurred 106table of contentswe have incurred cumulative restructuring charges related to our 2011 restructuring plan 2010 restructuring plan and plant network optimization program of 355 million and restructuringrelated costs of 125 million since we committed to each plan the following presents these costs by major type and by planin millions2011restructuringplan 2010restructuringplan plantnetworkoptimization totaltermination benefits99 90 36 225fixed asset writeoffs14 11  25other54 51  105total restructuring charges167 152 36 355accelerated depreciation2  22 24transfer costs  74 74other15 8  23restructuringrelated expenses17 8 96 121 184 160 132 476we made cash payments of 149 million in 2012 associated with restructuring initiatives pursuant to these plans and have made total cash payments of 375 million related to our 2011 restructuring plan 2010 restructuring plan and plant network optimization program since committing to each plan each of these payments was made using cash generated from operations and are comprised of the followingin millions2011restructuringplan 2010restructuringplan plantnetworkoptimization totalyear ended december 31 2012       termination benefits60 4 24 88transfer costs  8 8other53   53 113 4 32 149        program to date       termination benefits63 89 29 181transfer costs  73 73other65 56  121 128 145 102 375we also made cash payments of 5 million during 2012 associated with our 2007 restructuring plan and have made total cash payments of approximately 375 million related to the 2007 restructuring plan since committing to the plan in the fourth quarter of 2007107table of contentsour restructuring liability is primarily comprised of accruals for termination benefits the following is a rollforward of the termination benefit liability associated with our 2011 restructuring plan 2010 restructuring plan and plant network optimization program since the inception of the respective plan which is reported as a component of accrued expenses included in our accompanying consolidated balance sheets  restructuring plan termination benefits      plantnetwork  in millions 2011 2010 optimization totalaccrued as of december 31 2009   22 22charges  66 4 70cash payments  45  45accrued as of december 31 2010  21 26 47charges 21 24 10 55cash payments 3 39 3 45accrued as of december 31 2011 18 6 33 57charges 78 1  79cash payments 60 4 24 88accrued as of december 31 2012 36 3 9 48in addition to our accrual for termination benefits we had a 5 million liability as of december 31 2012 and a 3 million liability as of december 31 2011 for other restructuringrelated itemsnote i  supplemental balance sheet informationcomponents of selected captions in our accompanying consolidated balance sheets are as followstrade accounts receivable net  as ofin millions december 31 2012december 31 2011accounts receivable 13361362less allowance for doubtful accounts 8881less allowance for sales returns 3135  12171246the following is a rollforward of our allowance for doubtful accounts for 2012 2011 and 2010  year endeddecember 31in millions 201220112010beginning balance 818371net charges to expenses 141127utilization of allowances 71315ending balance 888183during the first quarter of 2011 we reversed 20 million of previously established allowances for doubtful accounts against longoutstanding receivables in greece these receivables had previously been fully reserved as we had determined that they had a high risk of being uncollectible due to the economic situation in greece during the first quarter of 2011 the greek government 108table of contentsconverted these receivables into bonds which we were able to monetize reducing our allowance for doubtful accounts as a credit to selling general and administrative expensesinventories  as ofin millions december 31 2012december 31 2011finished goods 598637workinprocess 7071raw materials 216223  884931property plant and equipment net  as ofin millions december 31 2012december 31 2011land 81111buildings and improvements 873923equipment furniture and fixtures 23481919capital in progress 218230  35203183less accumulated depreciation 19561513  15641670accrued expenses  as ofin millions december 31 2012december 31 2011legal reserves 100129payroll and related liabilities 452466accrued contingent consideration 12037other 612695  12841327other longterm liabilities  as ofin millions december 31 2012december 31 2011legal reserves 391170accrued income taxes 12151095accrued contingent consideration 543321other longterm liabilities 398422  25472008note j  income taxesour income loss before income taxes consisted of the following  year ended december 31in millions 201220112010domestic 12654371910foreign 28421079847  41076421063109table of contentsthe related provision benefit for income taxes consisted of the following  year ended december 31in millions 201220112010current     federal 334583 state 89 foreign 13991125  17214451     deferred     federal 2048625 state 784 foreign 2120  2115749  392012the reconciliation of income taxes at the federal statutory rate to the actual provision benefit for income taxes is as follows  year ended december 31  201220112010us federal statutory income tax rate 350350 350state income taxes net of federal benefit 0205 03 state law changes on deferred tax 12effect of foreign taxes 37637204nondeductible acquisition expenses 19research credit 3460valuation allowance 03 2925 divestitures 254 goodwill impairment charges 364 380 598 nondeductible expenses 01 57 18 other net 11 0228  10313 02      we had net deferred tax liabilities of 1237 billion as of december 31 2012 and 1379 billion as of december 31 2011 gross deferred tax liabilities of 2310 billion as of december 31 2012 and 2373 billion as of december 31 2011 relate primarily to intangible assets acquired in connection with our prior acquisitions gross deferred tax assets of 1073 billion as of december 31 2012 and 994 million as of december 31 2011 relate primarily to the establishment of inventory and productrelated reserves litigation product liability and other reserves and accruals stockbased compensation net operating loss carryforwards and tax credit carryforwards and the federal benefit of uncertain tax positions in light of our historical financial performance and the extent of our deferred tax liabilities we believe we will recover substantially all of these assetswe reduce our deferred tax assets by a valuation allowance if based upon the weight of available evidence it is more likely than not that we will not realize some portion or all of the deferred tax assets we consider relevant evidence both positive and negative to determine the need for a valuation allowance information evaluated includes our financial position and results of operations for the current and preceding years the availability of deferred tax liabilities and tax carrybacks as well as an evaluation of currently available information about future years 110table of contentssignificant components of our deferred tax assets and liabilities are as follows  as of december 31 in millions 2012 2011 deferred tax assets    inventory costs intercompany profit and related reserves 136 181tax benefit of net operating loss and credits 497 440reserves and accruals 300 232restructuringrelated charges and purchased research and development 13 20litigation and product liability reserves 48 53unrealized gains and losses on derivative financial instruments  22investment writedown 13 38stockbased compensation 171 219federal benefit of uncertain tax positions 157 141other 54 10  1389 1356less valuation allowance 316 362  1073 994 deferred tax liabilities    property plant and equipment 101 118unrealized gains and losses on derivative financial instruments 21  intangible assets 2187 2241other 1 14  2310 2373 net deferred tax liabilities 1237 1379our deferred tax assets and liabilities are included in the following locations within our accompanying consolidated balance sheets in millions location in as of december 31componentbalance sheet 2012 2011current deferred tax assetdeferred income taxes 433 458noncurrent deferred tax assetother longterm assets 54 31 deferred tax assets  487 489current deferred tax liabilityother current liabilities 11 3noncurrent deferred tax liabilitydeferred income taxes 1713 1865 deferred tax liabilities  1724 1868 net deferred tax liabilities  1237 1379as of december 31 2012 we had us tax net operating loss carryforwards capital loss and tax credits the tax effect of which was 184 million as compared to 69 million as of december 31 2011 in addition we had foreign tax net operating loss carryforwards and tax credits the tax effect of which was 341 million as of december 31 2012 as compared to 371 million as of december 31 2011 these tax attributes will expire periodically beginning in 2013 after consideration of all positive and negative evidence we believe that it is more likely than not that a portion of the deferred tax assets will not be realized as a result we established a valuation allowance of 316 million as of december 31 2012 and 362 million as of december 31 2011 the decrease in the valuation allowance as of december 31 2012 as compared to december 31 2011 is attributable primarily to foreign net operating losses written off during the year offset by a change in judgment related to expected ability to realize certain deferred tax assets the income tax impact of the unrealized gain or loss component of other comprehensive income was a charge of 43 million in 2012 benefit of 1 million in 2011 and a benefit of 16 million in 2010we do not provide income taxes on unremitted earnings of our foreign subsidiaries where we have indefinitely reinvested such earnings in our foreign operations we do not believe it is practical to estimate the amount of income taxes payable on the earnings 111table of contentsthat are indefinitely reinvested in foreign operations unremitted earnings of our foreign subsidiaries that we have indefinitely reinvested in foreign operations were 11041 billion as of december 31 2012 and 10346 billion as of december 31 2011as of december 31 2012 we had 1052 billion of gross unrecognized tax benefits of which a net 902 million if recognized would affect our effective tax rate as of december 31 2011 we had 987 million of gross unrecognized tax benefits of which a net 847 million if recognized would affect our effective tax rate a reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows in millions  year ended december 31  2012 2011 2010    restated  beginning balance 987 965 1038additions based on positions related to the current year 54 104 55additions based on positions related to prior years 43 8 44reductions for tax positions of prior years 27 72 124settlements with taxing authorities 1 3 35statute of limitation expirations 4 15 13ending balance 1052 987 965we are subject to us federal income tax as well as income tax of multiple state and foreign jurisdictions we have concluded all us federal income tax matters through 2000 and substantially all material state local and foreign income tax matters through 2001we have received notices of deficiency from the irs reflecting proposed audit adjustments for guidant corporation for its 2001 through 2006 tax years and boston scientific corporation for its 2006 and 2007 tax years subsequent to issuing these notices the irs conceded a portion of its original assessment the total incremental tax liability now asserted by the irs for the applicable periods is 1162 billion plus interest the primary issue in dispute for all years is the transfer pricing in connection with the technology license agreements between domestic and foreign subsidiaries of guidant in addition the irs has proposed adjustments in connection with the financial terms of our transaction agreement with abbott laboratories pertaining to the sale of guidants vascular intervention business to abbott in april 2006 we do not agree with the transfer pricing methodologies applied by the irs or its resulting assessment and we believe that the irs has exceeded its authority by attempting to adjust the terms of our negotiated thirdparty agreement with abbott in addition we believe that the irs positions with regard to these matters are inconsistent with the applicable tax laws and the existing treasury regulations we believe we have meritorious defenses for our tax filings and we have filed or will timely file petitions with the us tax court contesting the notices of deficiency for the tax years in challenge no payments on the net assessment would be required until the dispute is definitively resolved which based on experiences of other companies could take several years we believe that our income tax reserves associated with these matters are adequate and the final resolution will not have a material impact on our financial condition or results of operations however final resolution is uncertain and could have a material impact on our financial condition or results of operationswe recognize interest and penalties related to income taxes as a component of income tax expense we had 364 million accrued for gross interest and penalties as of december 31 2012 and 313 million as of december 31 2011 the increase in gross interest and penalties was the result of 51 million recognized in our consolidated statements of operations we recognized 34 million of interest and penalties related to income taxes in 2012 released 18 million in 2011 and recognized 14 million in 2010it is reasonably possible that within the next 12 months we will resolve multiple issues including transfer pricing and transactional related issues with foreign federal and state taxing authorities in which case we could record a reduction in our balance of unrecognized tax benefits of up to 20 millionnote k  commitments and contingenciesthe medical device market in which we primarily participate is largely technology driven as a result intellectual property rights particularly patents and trade secrets play a significant role in product development and differentiation over the years there has been litigation initiated against us by others including our competitors claiming that our current or former product offerings infringe patents owned or licensed by them intellectual property litigation is inherently complex and unpredictable in addition 112table of contentscompeting parties frequently file multiple suits to leverage patent portfolios across product lines technologies and geographies and to balance risk and exposure between the parties in some cases several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices these forces frequently drive settlement not only for individual cases but also for a series of pending and potentially related and unrelated cases although monetary and injunctive relief is typically sought remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal accordingly the outcomes of individual cases are difficult to time predict or quantify and are often dependent upon the outcomes of other cases in other geographies during recent years we successfully negotiated closure of several longstanding legal matters and recently received favorable legal rulings in several other matters however there continues to be outstanding intellectual property litigation particularly in the coronary stent market adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins financial position results of operations andor liquidityin the normal course of business product liability securities and commercial claims are asserted against us similar claims may be asserted against us in the future related to events not known to management at the present time we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims or adverse decisions product liability claims securities and commercial litigation and other legal proceedings in the future regardless of their outcome could have a material adverse effect on our financial position results of operations andor liquidityin addition like other companies in the medical device industry we are subject to extensive regulation by national state and local government agencies in the united states and other countries in which we operate from time to time we are the subject of qui tam actions and governmental investigations often involving regulatory marketing and other business practices these qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings substantial fines penalties and administrative remedies and have a material adverse effect on our financial position results of operations andor liquiditywe record losses for claims in excess of the limits of purchased insurance in earnings at the time and to the extent they are probable and estimable in accordance with asc topic 450 contingencies we accrue anticipated costs of settlement damages losses for general product liability claims and under certain conditions costs of defense based on historical experience or to the extent specific losses are probable and estimable otherwise we expense these costs as incurred if the estimate of a probable loss is a range and no amount within the range is more likely we accrue the minimum amount of the rangeour accrual for legal matters that are probable and estimable was 491 million as of december 31 2012 and 299 million as of december 31 2011 and includes estimated costs of settlement damages and defense the increase in our legal accruals was primarily due to litigationrelated charges recorded during the year during 2012 and 2011 we recorded litigationrelated charges in the amount of 192 million and 48 million respectively we continue to assess certain litigation and claims to determine the amounts if any that management believes will be paid as a result of such claims and litigation and therefore additional losses may be accrued and paid in the future which could materially adversely impact our operating results cash flows andor our ability to comply with our debt covenantsin managements opinion we are not currently involved in any legal proceedings other than those specifically identified below which individually or in the aggregate could have a material adverse effect on our financial condition operations andor cash flows unless included in our legal accrual or otherwise indicated below a range of loss associated with any individual material legal proceeding cannot be estimatedpatent litigation on february 1 2008 wyeth corporation and cordis corporation filed an amended complaint for patent infringement against abbott laboratories adding us and boston scientific scimed inc as additional defendants to the complaint the suit alleges that the promus coronary stent system supplied to us by abbott infringes three us patents the morris patents owned by wyeth and licensed to cordis the suit was filed in the us district court for the district of new jersey seeking monetary and injunctive relief in january 2011 wyeth and cordis withdrew their infringement claim as to one of the patents on january 19 2012 the district court found the remaining two patents invalid wyeth and cordis filed an appeal on february 14 2012on september 22 2009 cordis corporation cordis llc and wyeth corporation filed a complaint for patent infringement against abbott laboratories abbott cardiovascular systems inc boston scientific scimed inc and us alleging that the promus coronary stent system supplied to us by abbott infringes a patent the llanos patent owned by cordis and wyeth the suit was 113table of contentsfiled in the us district court for the district of new jersey seeking monetary and injunctive relief in august 2010 cordis filed an amended complaint to add an additional patent and in september 2010 we filed counterclaims of invalidity and noninfringement on october 26 2011 the district court granted cordis motion to add the promus element stent system to the case on february 6 2012 the district court granted our motion to stay the action until the conclusion of the reexaminations against the llanos patents that are pending in the us patent and trademark officeon december 4 2009 we along with boston scientific scimed inc filed a complaint for patent infringement against cordis corporation alleging that its cypher mini stent product infringes a us patent the jang patent owned by us in april 2011 the us district court for the district of delaware granted summary judgment that cordis willfully infringed the jang patent after a trial on damages in may 2011 the jury found in favor of boston scientific for lost profits of approximately 185 million and royalties of approximately 1 million on march 13 2012 the district court granted our motion for enhanced damages resulting in a total damages award of approximately 41 million on february 12 2013 the court of appeals affirmed the district courts judgment in favor of boston scientificon january 15 2010 cordis corporation filed a complaint against us and boston scientific scimed inc alleging that the promus coronary stent system supplied to us by abbott laboratories infringes three patents the fischell patents owned by cordis the suit was filed in the us district court for the district of delaware and seeks monetary and injunctive relief in march 2010 we filed counterclaims of invalidity and noninfringement on june 19 2012 the district court found that the promus stent system does not infringe the fischell patents and that our sales of this product were authorized on september 7 2012 cordis filed a notice of appealon may 19 2005 g david jang md filed suit against us alleging breach of contract relating to certain patent rights covering stent technology the suit was filed in the us district court for the central district of california seeking monetary damages and rescission of contract after a markman ruling relating to the jang patent rights dr jang stipulated to the dismissal of certain claims alleged in the complaint with a right to appeal and the parties subsequently agreed to settle the other claims in may 2007 dr jang filed an appeal with respect to the remaining patent claims and in july 2008 the court of appeals vacated the district courts consent judgment and remanded the case back to the district court for further clarification in august 2011 the district court entered a stipulated judgment that we did not infringe the jang patent dr jang filed an appeal on september 21 2011 and on august 22 2012 the court of appeals vacated the district courts judgment and remanded the case to the district court for further proceedingson may 25 2010 dr jang filed suit against boston scientific scimed inc and us alleging breach of contract relating to certain patent rights covering stent technology in october 2011 the us district court for the district of delaware entered judgment in favor of us on the pleadings on july 31 2012 the district court denied dr jangs october 2011 motion for reconsideration or in the alternative permission to amend his complaint dr jang filed an appeal on august 28 2012on march 16 2009 orbusneich medical inc filed suit against us alleging that our veriflex libert baremetal coronary stent system infringes two us patents the addonizio and pazienza patents owned by it the complaint also alleged breach of contract and misappropriation of trade secrets and seeks monetary and injunctive relief the suit is pending in the us district court for the district of massachusetts in september 2009 orbusneich filed an amended complaint against us alleging additional state law claims in march 2010 the district court dismissed orbusneichs unjust enrichment and fraud claims but denied our motion to dismiss the remaining state law claims orbusneich amended its complaint in april 2010 to add another patent another addonizio patent in january 2011 orbusneich amended its complaint to drop its misappropriation of trade secret statutory and unfair competition claims and in july 2011 it further amended its complaint to include allegations that our ion coronary stent system infringes two additional patents on february 24 2012 the district court granted our motion to stay the patent claims and on june 4 2012 the district court stayed the breach of contract claim in each case pending reexamination of the patents in suiton november 17 2009 boston scientific scimed inc filed suit against orbusneich medical inc and certain of its subsidiaries in the hague district court in the netherlands alleging that orbusneichs sale of the genous stent infringes a patent owned by us the keith patent and seeking monetary damages and injunctive relief on march 13 2012 the hague court of appeals denied our request for preliminary reliefon september 27 2010 boston scientific scimed inc boston scientific ltd endovascular technologies inc and we filed suit against taewoong medical co ltd standard scitech inc endochoice inc and sewoon medical co ltd for infringement of three patents on stents for use in the gi system the pulnev and hankh patents and against cook medical inc and related entities for infringement of the same three patents and an additional patent the thompson patent the suit was filed in the us district court for the district of massachusetts seeking monetary damages and injunctive relief in december 2010 we amended our complaint to add infringement of six additional pulnev patents in january 2011 the defendants filed a counterclaim of invalidity 114table of contentsand unenforceability in december 2011 we amended the complaint to add chekmed systems dba gi supply as a defendanton may 17 2010 dr luigi tellini filed suit against us and certain of our subsidiaries guidant italia srl and boston scientific spa in the civil tribunal in milan italy alleging certain of our cardiac rhythm management crm products infringe an italian patent the tellini patent owned by dr tellini and seeking monetary damages in january 2011 dr tellini refiled amended claims after his initial claims were dismissed without prejudice to refilein february 2013 orbus international bv filed suits against the company and two dutch subsidiaries in the hague district court in the netherlands and orbus medical gmbh filed suit against a german subsidiary of the company in the duesseldorf district court in germany each of these matters alleges that the companys sale of stent systems using the element design infringe european patents licensed to orbus in one dutch matter orbus is seeking cross border preliminary injunctive relief and a hearing is scheduled for april 3 2013 in the other dutch matter orbus is seeking damages and injunctive relief and a hearing is scheduled for december 20 2013 in the german matter orbus is seeking preliminary injunctive relief and a hearing is scheduled for march 26 2013 product liability litigation fewer than ten individual lawsuits remain pending in various state and federal jurisdictions against guidant alleging personal injuries associated with defibrillators or pacemakers involved in certain 2005 and 2006 product communications further we are aware of approximately 30 guidant product liability lawsuits pending in international jurisdictions associated with defibrillators or pacemakers including devices involved in the 2005 and 2006 product communications six of these suits are pending in canada and were filed as class actions four of which are stayed pending the outcome of two lead class actions on april 10 2008 the justice of ontario court certified a class of persons in whom defibrillators were implanted in canada and a class of family members with derivative claims on may 8 2009 the justice of ontario court certified a class of persons in whom pacemakers were implanted in canada and a class of family members with derivative claims in each case these matters generally seek monetary damages from the companyas of february 22 2013 there were over 3900 product liability cases or claims asserted against us in various federal and state courts across the country alleging personal injury associated with use of our transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse generally the plaintiffs allege design and manufacturing claims failure to warn breach of warranty fraud violations of state consumer protection laws and loss of consortium claims many of the cases have been specially assigned to one judge in state court in massachusetts on february 7 2012 the judicial panel on multidistrict litigation mdl established mdl2326 in the us district court for the southern district of west virginia and transferred the federal court transvaginal surgical mesh cases to mdl2326 for coordinated pretrial proceedings in addition in october 2012 we were contacted by the attorney general for the state of california informing us that their office and certain other state attorneys general offices intend to initiate a civil investigation into our sale of transvaginal surgical mesh productsgovernmental investigations and qui tam mattersin december 2007 we were informed by the us attorneys office for the northern district of texas that it was conducting an investigation of allegations related to improper promotion of biliary stents for offlabel uses the allegations were set forth in a qui tam complaint which named us and certain of our competitors following the federal governments decision not to intervene in the case the us district court for the northern district of texas unsealed the complaint in march 2011 the district court issued an order granting our motion to dismiss and in march 2012 issued its opinion ordering that all claims against us be dismissed some of which were dismissed with prejudice and some of which were dismissed without prejudice to the relators right to amend those claims on april 6 2012 the relator filed a motion for reconsideration of the dismissals of the claims that were dismissed with prejudice and on august 24 2012 the district court denied the motion for reconsideration on september 14 2012 the relator filed and served an amended complaint restating the claims that the district court dismissed without prejudice and on january 17 2013 the district court granted our motion to dismiss with prejudice all of the relators remaining claims against us on february 15 2013 the relator filed a notice of appeal with the us court of appeals for the fifth circuiton june 27 2008 the republic of iraq filed a complaint against our whollyowned subsidiary bssa france and 92 other defendants in the us district court of the southern district of new york the complaint alleges that the defendants acted improperly in connection with the sale of products under the united nations oil for food program the complaint also alleges racketeer influenced and corrupt organizations act rico violations conspiracy to commit fraud and the making of false statements and improper payments and it seeks monetary and punitive damages a hearing on the pending motion to dismiss was held on october 26 2012 and on february 6 2013 the district court dismissed the complaint with prejudice on standing and jurisdictional grounds115table of contentson october 17 2008 we received a subpoena from the us department of health and human services office of the inspector general requesting information related to the alleged use of a skin adhesive in certain of our crm products in early 2010 we learned that this subpoena was related to a qui tam action filed in the us district court for the western district of new york after the federal government declined to intervene in the original complaint the relator in the qui tam action filed an amended complaint alleging that guidant violated the false claims act by selling certain prizm 2 devices and seeking monetary damages in july 2010 we were served with the amended unsealed qui tam complaint filed by james allen an alleged device recipient the civil division of the department of justice doj was later allowed to intervene in the allen qui tam action and to transfer the litigation to the us district court for the district of minnesota in january 2011 the doj filed a civil false claims act complaint against us and guidant and other related entities in the allen qui tam action on april 5 2012 the district court entered a revised scheduling order setting the case for trial on november 18 2013 on march 12 2010 we received a civil investigative demand cid from the civil division of the us department of justice requesting documents and information relating to reimbursement advice offered by us relating to certain crm devices we are cooperating with the requeston march 22 2010 we received a subpoena from the us attorneys office for the district of massachusetts seeking documents relating to the former market development sales organization that operated within our crm business we are cooperating with the request on october 21 2011 the us district court for the district of massachusetts unsealed a qui tam complaint that relates to the subject matter of the us attorneys investigation after the federal government declined to intervene in the matter subsequently on january 30 2012 the relator filed an amended complaint on july 5 2012 the district court issued an opinion and order dismissing the amended complaint for lack of subject matter jurisdiction on july 12 2012 the relator appealed the judgment of dismissal to the us court of appeals for the first circuit and oral argument was held on february 7 2013on august 3 2012 we were served with a qui tam complaint that had previously been filed under seal against boston scientific neuromodulation corp in the us district court for the district of new jersey on march 2 2011 on august 8 2012 we learned that the federal government had previously declined to intervene in this matter the relators complaint now unsealed alleges that boston scientific neuromodulation corp violated the federal and various states false claims acts through submission of fraudulent bills for implanted devices underreporting of certain adverse events and offlabel promotions on september 10 2012 the relators filed an amended complaint revising and restating certain of the claims in the original complaint and on october 24 2012 we filed a motion to dismiss the amended complaintother proceedings on september 25 2006 johnson amp johnson filed a lawsuit against us guidant and abbott laboratories in the us district court for the southern district of new york the complaint alleges that guidant breached certain provisions of the amended merger agreement between johnson amp johnson and guidant merger agreement as well as the implied duty of good faith and fair dealing the complaint further alleges that abbott and we tortiously interfered with the merger agreement by inducing guidants breach the complaint seeks certain factual findings damages in an amount no less than 55 billion and attorneys fees and costs in august 2007 the judge dismissed the tortious interference claims against us and abbott and the implied duty of good faith and fair dealing claim against guidant on june 20 2011 guidant filed a motion for summary judgment and the hearing on this motion was held on july 25 2012on october 5 2007 dr tassilo bonzel filed a complaint against pfizer inc and our schneider subsidiaries and us in the district court in kassel germany alleging that a 1995 license agreement related to a catheter patent is invalid under german law and seeking monetary damages in june 2009 the district court dismissed all but one of dr bonzels claims and in october 2009 he added new claims we opposed the addition of the new claims the district court ordered dr bonzel to select the claims he would pursue and in january 2011 he made that selection a hearing is scheduled for july 26 2013on september 28 2011 we served a complaint against mirowski family ventures llc for a declaratory judgment that we have paid all royalties owed and did not breach any contractual or fiduciary obligations arising out of a license agreement mirowski answered and filed counterclaims requesting damages the case is pending in the us district court for the southern district of indianarefer to note j  income taxes for information regarding our tax litigation matters concluded since december 31 2011 on june 26 2008 the us attorneys office for the district of massachusetts issued a subpoena to us under the health insurance 116table of contentsportability amp accountability act of 1996 hipaa pursuant to which the us department of justice requested the production of certain documents and information related to our biliary stent business we cooperated with the subpoena request and related investigation on february 9 2012 the us attorneys office for the district of massachusetts advised us that it was discontinuing its investigationon august 19 2010 the iron workers district council southern ohio and vicinity pension trust filed a putative shareholder derivative class action lawsuit against us and our board of directors in the us district court for the district of delaware the allegations and remedies sought in the complaint were largely the same as those in the original complaint filed by the city of roseville employees retirement system on april 9 2010 and discussed below in october 2011 the district court granted our motion to dismiss this action without prejudice to refile an amended complaint and the plaintiffs filed a motion to stay the proceedings to allow them to make discovery demands before filing an amended complaint on june 14 2012 the district court dismissed this case with prejudiceguidant or its affiliates were defendants in five separate actions brought by private thirdparty providers of health benefits or health insurance tpps in these cases plaintiffs alleged various theories of recovery including derivative tort claims subrogation violation of consumer protection statutes and unjust enrichment for the cost of healthcare benefits they allegedly paid in connection with the devices that were the subject of guidants product communications one of the tpp actions was remanded by the multidistrict litigation judge to the us district court for the southern district of florida and has since been resolved and dismissed with prejudice two other tpp actions brought by blue cross amp blue shield plans and united healthcare and its affiliates were settled and dismissed with prejudice in june 2010 in 2011 we reached an agreement in principle to settle the other two tpp matters for approximately 3 million in the aggregate and in july 2012 we finalized the settlementon october 24 2008 we received a letter from the doj informing us of an investigation related to alleged offlabel promotion of surgical cardiac ablation system devices to treat atrial fibrillation in 2009 the us district court for the southern district of texas partially unsealed a qui tam complaint which was the basis for the doj investigation in august 2009 the federal government declined to intervene in this matter at that time after the district court dismissed the first amended complaint the relator filed a second amended complaint in april 2011 in which the relator dropped all of the false claims act allegations but continued to claim that the relator was discharged from guidant in retaliation for complaining about the alleged false claims on july 26 2012 the relator filed a stipulation to voluntarily dismiss the second amended complaint and on august 7 2012 the district court dismissed the second amended complainton april 9 2010 the city of roseville employees retirement system individually and on behalf of purchasers of our securities during the period from april 20 2009 to march 12 2010 filed a purported securities class action suit against us and certain of our current and former officers in the us district court for the district of massachusetts the suit alleged certain violations of the securities exchange act of 1934 as amended claiming that our stock price was artificially inflated because we failed to disclose certain matters with respect to our crm business and sought unspecified monetary damages in july 2010 the district court appointed kbc asset management nv and steelworkers pension trust as colead plaintiffs for the case in september 2010 the plaintiffs filed an amended class action complaint narrowing the alleged class period from october 20 2009 to february 10 2010 in september 2011 the district court granted our motion to dismiss the action and on july 12 2012 the us court of appeals for the first circuit issued its decision affirming the dismissalon may 27 2011 body science llc filed suit against us in the us district court for the northern district of illinois alleging that our latitude patient management system and latitude blood pressure monitor infringed two us patents the besson patents owned by them in july 2011 body science amended its complaint to add several cardiac resynchronization therapy defibrillator and implantable cardioverter defibrillator devices that are compatible with the latitude patient management system on august 6 2012 the united states judicial panel on multidistrict litigation transferred the case to the us district court for the district of massachusetts on september 26 2012 the parties settled this matter for an amount not significant to boston scientificlitigationrelated charges and creditsduring 2012 and 2011 we recorded net litigationrelated charges in the amount of 192 million and 48 million respectively in 2010 we recorded a litigationrelated credit of 104 million associated with a settlement of a dispute we had with medinol ltd we continue to assess certain litigation and claims to determine the amounts if any that management believes will be paid as a result of such claims and litigation and therefore additional losses may be accrued and paid in the future which could materially adversely impact our operating results cash flows andor our ability to comply with our debt covenants117table of contentsnote l  stockholders equitypreferred stockwe are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers designations preferences and relative participating option or other rights thereof including dividend rights conversion rights voting rights redemption terms liquidation preferences and the number of shares constituting any series without any further vote or action by our stockholders as of december 31 2012 and 2011 we had no shares of preferred stock issued or outstandingcommon stockwe are authorized to issue 20 billion shares of common stock 001 par value per share holders of common stock are entitled to one vote per share holders of common stock are entitled to receive dividends if and when declared by the board of directors and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation holders of common stock have no preemptive subscription redemption or conversion rights the holders of common stock do not have cumulative voting rights the holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairsin july 2011 our board of directors approved a share repurchase program authorizing the repurchase of up to 10 billion in shares of our common stock and reapproved approximately 37 million shares remaining under a previous share repurchase program throughout 2012 we repurchased approximately 105 million shares of our common stock for approximately 600 million during 2011 we repurchased approximately 82 million shares of our common stock for approximately 492 million and did not repurchase any shares of our common stock in 2010 as of december 31 2012 we had completed our share repurchase program authorized in 2011 and had remaining 21 million shares authorized under our previous share repurchase programs repurchased shares are available for reissuance under our equity incentive plans and for general corporate purposes including acquisitions there were approximately 187 million shares in treasury as of december 31 2012 and 82 million shares in treasury as of december 31 2011on january 25 2013 our board of directors approved a new stock repurchase program authorizing the repurchase of up to 10 billion of our common stocknote m  stock ownership plansemployee and director stock incentive plansin march and may 2011 our board of directors and stockholders respectively approved our 2011 longterm incentive plan the 2011 ltip authorizing up to 1456 million shares of our common stock the 2011 ltip provides for the grant of restricted or unrestricted common stock deferred stock units dsu options to acquire our common stock stock appreciation rights performance awards marketbased and performancebased dsus and other stock and nonstock awards shares reserved for future issuance under our current and former stock incentive plans totaled approximately 256 million as of december 31 2012 the 2011 ltip covers officers directors employees and consultants and provide for the grant of various incentives including qualified and nonqualified stock options deferred stock units stock grants share appreciation rights performancebased awards and marketbased awards the executive compensation and human resources committee of the board of directors consisting of independent nonemployee directors may authorize the issuance of common stock and authorize cash awards under the 2011 ltip in recognition of the achievement of longterm performance objectives established by the committeenonqualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date vest over a fouryear service period and have a tenyear contractual life in the case of qualified options if the recipient owns more than ten percent of the voting power of all classes of stock the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years nonvested stock awards including restricted stock awards and deferred stock units dsus issued to employees are generally granted with an exercise price of zero and typically vest in four to five equal annual installments these awards represent our commitment to issue shares to recipients after the vesting period upon each vesting date such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient118table of contentsthe following presents the impact of stockbased compensation on our consolidated statements of operations for the years ended december 31 2012 2011 and 2010  year ended december 31in millions except per share data 2012 2011 2010cost of products sold 15 25 25selling general and administrative expenses 69 74 93research and development expenses 24 29 32  108 128 150less income tax benefit 32 34 55  76 94 95       net impact per common share  basic 005 006 006net impact per common share  assuming dilution 005 006 006stock optionswe generally use the blackscholes optionpricing model to calculate the grantdate fair value of stock options granted to employees under our stock incentive plans we calculated the fair value for options granted during 2012 2011 and 2010 using the following estimated weightedaverage assumptions  year ended december 31  2012 2011 2010options granted in thousands 4726 16311 11008weightedaverage exercise price 623 711 726weightedaverage grantdate fair value 260 307 311blackscholes assumptions      expected volatility 43 42 42expected term in years weighted 59 61 55riskfree interest rate 095  115 116  261 152  293expected volatilitywe use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock optionsexpected termwe estimate the expected term of options using historical exercise and forfeiture data we believe that this historical data is the best estimate of the expected term of new option grantsriskfree interest ratewe use yield rates on us treasury securities for a period approximating the expected term of the award to estimate the riskfree interest rate in our grantdate fair value assessmentexpected dividend yieldwe have not historically paid dividends to our shareholders we currently do not intend to pay dividends and intend to retain all of our earnings to invest in the continued growth of our business and to repurchase shares therefore we have assumed an expected dividend yield of zero in our grantdate fair value assessment119table of contentsinformation related to stock options for 2012 2011 and 2010 under stock incentive plans is as follows  stock optionsin thousands weightedaverageexerciseprice weightedaverageremainingcontractuallife in years aggregateintrinsicvaluein millionsoutstanding as of december 31 2009 64712 15    granted 11008 7    exercised 719 7    cancelledforfeited 14627 13    outstanding as of december 31 2010 60374 14    granted 16311 7    exercised 18 7    cancelledforfeited 15746 12    outstanding as of december 31 2011 60921 13    granted 4726 6    exercised      cancelledforfeited 10766 15    outstanding as of december 31 2012 54881 12 57 exercisable as of december 31 2012 37111 14 46  expected to vest as of december 31 2012 16227 7 81  total vested and expected to vest as of december 31 2012 53338 12 57 the total intrinsic value of stock options exercised was less than 1 million in 2012 2011 and 2010nonvested stockwe value restricted stock awards and dsus based on the closing trading value of our shares on the date of grant information related to nonvested stock awards during 2012 2011 and 2010 is as follows  nonvestedstock awardunitsin thousands weightedaveragegrantdate fairvaluebalance as of december 31 2009 27890 12granted 17619 7vested 1 8431 14forfeited 3794 10balance as of december 31 2010 33284 9granted 14640 7vested 1 10344 10forfeited 4004 6balance as of december 31 2011 33576 8granted 17073 6vested 1 10158 9forfeited 3898 7balance as of december 31 2012 36593 71the number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements120table of contentsthe total vesting date fair value of stock award units that vested was approximately 60 million in 2012 71 million in 2011 and 62 million in 2010marketbased dsu awardsduring 2012 2011 and 2010 we granted marketbased dsu awards to certain members of our senior management team the attainment of these stock units is based on our total shareholder return tsr as compared to the tsr of the companies in the sampp 500 health care index and is measured in three annual performance cycles in addition award recipients must remain employed by us throughout the threeyear measurement period to attain the full awardwe determined the fair value of the 2012 marketbased awards to be approximately 8 million and the fair value of the 2011 marketbased awards to be approximately 8 million based on monte carlo simulations utilizing the following assumptions  2012 20112010  awards awardsawardsstock price on date of grant 628 716741measurement period in years 30 3030riskfree rate 038 110129we recognize the expense on these awards in our consolidated statements of operations on a straightline basis over the threeyear measurement periodfree cash flow performancebased dsu awardsduring 2012 we granted free cash flow performancebased dsu awards to certain members of our executive and operating teams the attainment of these stock units is based on our achievement of the 2012 annual financial plan performance for free cash flow fcf fcf is measured over a oneyear performance period beginning january 1 2012 and ending december 31 2012 the number of performance share units as to which the performance criteria under this program shall be determined to have been satisfied will be in a range of 0 to 150 of the target number of performance share units awarded to the participant in addition award recipients must remain employed by us throughout the threeyear measurement period to attain the full awardwe determined the fair value of the 2012 fcf awards to be approximately 7 million based on the closing stock price at december 31 2012 and an achievement of 130 of target payout which is subject to approval by the executive compensation and human resources committee of our board of directors the per unit fair value is 573 we recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grantexpense attributionexcept as discussed above we recognize compensation expense for our stock using a straightline method over the substantive vesting period most of our stock awards provide for immediate vesting upon death or disability of the participant in addition our stock grants to employees provide for accelerated vesting of our stockbased awards other than marketbased awards upon retirement in accordance with the terms of our stock grants for employees who will become retirement eligible prior to the vest date we expense stockbased awards other than marketbased awards over the greater of one year or the period between grant date and retirementeligibility the marketbased awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirementeligibilitywe recognize stockbased compensation expense for the value of the portion of awards that are ultimately expected to vest asc topic 718 compensation  stock compensation requires forfeitures to be estimated at the time of grant and revised if necessary in subsequent periods if actual forfeitures differ from those estimates the term forfeitures is distinct from cancellations or expirations and represents only the unvested portion of the surrendered option we have applied based on an analysis of our historical forfeitures a weightedaverage annual forfeiture rate of approximately 102 to all unvested stock awards as of december 31 2012 which represents the portion that we expect will be forfeited each year over the vesting period we reevaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary ultimately we will only recognize expense for those shares that vest121table of contentsunrecognized compensation costwe expect to recognize the following future expense for awards outstanding as of december 31 2012   unrecognized compensation costin millions1 weightedaverageremainingvestingperiodin yearsstock options 25  nonvested stock awards 128    153 151amounts presented represent compensation cost net of estimated forfeituresemployee stock purchase plansour global employee stock purchase plan provides for the granting of options to purchase up to 20 million shares of our common stock to all eligible employees under the global employee stock purchase plan we grant each eligible employee at the beginning of each sixmonth offering period an option to purchase shares of our common stock equal to not more than ten percent of the employees eligible compensation or the statutory limit under the us internal revenue code such options may be exercised generally only to the extent of accumulated payroll deductions at the end of the offering period at a purchase price equal to 90 percent of the fair market value of our common stock at the beginning or end of each offering period whichever is less as of december 31 2012 there were approximately 12 million shares available for future issuance under the employee stock purchase planinformation related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows shares in thousands 2012 2011 2010shares issued or to be issued 3979 3830 4358range of purchase prices 482  516 481  622 522  531we use the blackscholes optionpricing model to calculate the grantdate fair value of shares issued under the employee stock purchase plan we recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period we recognized 4 million in expense associated with our employee stock purchase plan in 2012 5 million in 2011 and 9 million in 2010note n  weighted average shares outstanding  year endeddecember 31in millions 201220112010weighted average shares outstanding  basic 140671509315178net effect of common stock equivalents 97weighted average shares outstanding  assuming dilution 140671519015178we generated net losses in 2012 and 2010 our weightedaverage shares outstanding for earnings per share calculations excluded common stock equivalents of 8 million for 2012 and 10 million for 2010 due to our net loss position in these yearsweightedaverage shares outstanding assuming dilution also excludes the impact of 59 million stock options for 2012 62 million for 2011 and 61 million for 2010 due to the exercise prices of these stock options being greater than the average fair market value of our common stock during the yearnote o  segment reportingeach of our reportable segments generates revenues from the sale of medical devices as of december 31 2012 we had four reportable segments based on geographic regions the united states emea consisting of europe the middle east and africa 122table of contentsjapan and intercontinental consisting of our asia pacific and the americas operating segments which include the emerging markets of brazil china and india the reportable segments represent an aggregate of all operating divisions within each segment we measure and evaluate our reportable segments based on segment net sales and operating income we exclude from segment operating income certain corporate and manufacturingrelated expenses as our corporate and manufacturing functions do not meet the definition of a segment as defined by asc topic 280 segment reporting in addition certain transactions or adjustments that our chief operating decision maker considers to be nonrecurring andor nonoperational such as amounts related to goodwill and other intangible asset impairment charges acquisition divestiture restructuring and litigationrelated charges and credits as well as amortization expense are excluded from segment operating income although we exclude these amounts from segment operating income they are included in reported consolidated operating income loss and are included in the reconciliation belowwe manage our international operating segments on a constant currency basis sales generated from reportable segments and divested businesses as well as operating results of reportable segments and expenses from manufacturing operations are based on internallyderived standard currency exchange rates which may differ from year to year and do not include intersegment profits we have restated the segment information for 2011 and 2010 net sales and operating results based on standard currency exchange rates used for 2012 in order to remove the impact of currency fluctuations because of the interdependence of the reportable segments the operating profit as presented may not be representative of the geographic distribution that would occur if the segments were not interdependent a reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows  year ended december 31in millions 2012 2011 2010net sales   restated restatedunited states 3756 4010 4215emea 1708 1756 1776japan 827 842 863intercontinental 836 751 687net sales allocated to reportable segments 7127 7359 7541sales generated from business divestitures 122 140 346impact of foreign currency fluctuations  123 81  7249 7622 7806  year ended december 31in millions 2012 2011 2010depreciation expense   restated restatedunited states 73 85 96emea 10 10 19japan 10 9 10intercontinental 7 7 8depreciation expense allocated to reportable segments 100 111 133manufacturing operations 126 123 119corporate expenses and currency exchange 62 62 51  288 296 303 we have restated prior year regional detail to conform to current year presentation123table of contents  year ended december 31in millions 2012 2011 2010income loss before income taxes   restated restatedunited states 541 616 729emea 669 740 756japan 403 367 400intercontinental 265 271 250operating income allocated to reportable segments 1878 1994 2135manufacturing operations 276 264 305corporate expenses and currency exchange 242 270 269goodwill and intangible asset impairment charges and acquisition divestiture litigation and restructuringrelated net charges 4833 135 1704amortization expense 395 421 513operating income loss 3868 904 656other expense net 239 262 407  4107 642 1063  as of december 31in millions 2012 2011total assets   restatedunited states 1716 1851emea 922 989japan 213 243intercontinental 543 477total assets allocated to reportable segments 3394 3560goodwill 5973 9761other intangible assets 6289 6473all other corporate and manufacturing operations assets 1498 1496  17154 21290enterprisewide information based on actual currency exchange rates124table of contents  year ended december 31in millions 2012 2011 2010net sales      interventional cardiology 2179 2495 2602cardiac rhythm management 1908 2087 2180endoscopy 1252 1187 1079peripheral interventions 774 731 669urologywomens health 500 498 481neuromodulation 367 336 304electrophysiology 147 147 147  7127 7481 7462sales generated from divested businesses 122 141 344  7249 7622 7806       united states 3756 4010 4215japan 931 951 886other foreign countries 2440 2520 2361  7127 7481 7462sales generated from divested businesses 122 141 344  7249 7622 7806  as of december 31in millions 2012 2011 2010longlived assets      united states 1065 1141 1188ireland 252 231 219other foreign countries 247 298 290property plant and equipment net 1564 1670 1697goodwill 5973 9761 10186other intangible assets 6289 6473 6343  13826 17904 18226note p  new accounting pronouncementsstandards implementedasc update no 201104in may 2011 the fasb issued asc update no 201104 fair value measurement topic 820 amendments to achieve common fair value measurement and disclosure requirements in us gaap and ifrss update no 201104 clarifies the fasbs intent about the application of certain existing fair value measurement and disclosure requirements and changes certain principles or requirements for measuring or disclosing information about fair value it requires for all level 3 fair value measurements new quantitative information about significant unobservable inputs used we adopted update no 201104 beginning in our first quarter ended march 31 2012 the adoption of update no 201104 did not impact our results of operations or financial position see note b  acquisitions and note d  goodwill and other intangible assets for relevant disclosuresasc update no 201105in may 2011 the fasb issued asc update no 201105 comprehensive income topic 220 presentation of comprehensive income update no 201105 requires that net income items of other comprehensive income and total comprehensive income be presented in one continuous statement or two separate consecutive statements the amendments in this update also require that reclassifications from other comprehensive income to net income be presented on the face of the financial statements we adopted update no 201105 beginning in our first quarter ended march 31 2012 update no 201105 is related to presentation only and its adoption did not impact our results of operations or financial position see our consolidated statements of comprehensive income for relevant presentation for additional information125table of contentsasc update no 201202in july 2012 the fasb issued asc update no 201202 intangibles  goodwill and other topic 350 testing indefinitelived intangible assets for impairment update no 201202 provides companies with the option to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinitelived intangible asset is impaired if the company concludes that it is more likely than not that the asset is impaired it is required to determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with topic 350 if the company concludes otherwise no further quantitative assessment is required we adopted update no 201202 beginning in our third quarter ended september 30 2012 the adoption of update no 201202 did not impact our results of operations or financial position see note b  acquisitions and note d  goodwill and other intangible assets for relevant disclosuresstandards to be implementedin december 2011 the fasb issued asc update no 201111 disclosures about offsetting assets and liabilities topic 210 requiring enhanced disclosures about certain financial instruments and derivative instruments that are offset in the statement of financial position or that are subject to enforceable master netting arrangements or similar agreements this accounting standard update will be effective for us beginning in the first quarter of 2013 at which time we will include the required applicable disclosures update no 201111 disclosures about offsetting assets and liabilities topic 210 will not impact our future results of operations or financial position126table of contentsquarterly results of operationsin millions except per share dataunaudited  three months ended  march 31 june 30 sept 30 dec 312012        net sales 1866 1828 1735 1821gross profit 1235 1250 1177 1238operating income loss 196 3587 594 115net income loss 113 3578 664 60net income loss per common share  basic 008 251 048 004net income loss per common share  assuming dilution 008 251 048 0042011        net sales 1925 1975 1874 1848gross profit 1294 1287 1194 1188operating income 322 237 174 170net income 46 146 142 107net income per common share  basic 003 010 009 007net income per common share  assuming dilution 003 010 009 007our reported results for 2012 included goodwill and intangible asset impairment charges acquisition divestiture litigation and restructuringrelated net charges discrete tax items and amortization expense after tax of 107 million in the first quarter 3817 billion in the second quarter 885 million in the third quarter and 192 million in the fourth quarter these charges consisted primarily of goodwill impairment charges attributable to our europe middle east and africa emea and us cardiac rhythm management crm reporting units and writedowns of certain intangible asset balances net acquisitionrelated gains primarily associated with previouslyheld equity interests and contingent consideration fair value adjustments gains associated with the divestiture of the neurovascular business restructuring and restructuringrelated costs attributable to our 2011 restructuring plan 2010 restructuring plan and plant network optimization program litigationrelated charges and discrete tax benefits related to certain tax positions taken in a prior periodour reported results for 2011 included goodwill and intangible asset impairment charges acquisition divestiture litigation and restructuringrelated net charges discrete tax items and amortization expense after tax of 290 million in the first quarter 116 million in the second quarter 81 million in the third quarter and 90 million in the fourth quarter these charges consisted primarily of a goodwill impairment charge attributable to our us cardiac rhythm management crm reporting unit and writedowns of certain intangible asset balances net acquisitionrelated gains associated with previouslyheld equity interests and contingent consideration fair value adjustments a gain associated with the divestiture of the neurovascular business in january 2011 restructuring and restructuringrelated costs attributable to our 2011 restructuring plan 2010 restructuring plan and plant network optimization program litigationrelated charges and discrete tax benefits related to certain tax positions taken in a prior period127table of contentsitem 9 changes in and disagreements with accountants on accounting and financial disclosurenone